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Abstract 
 
Chronic pain is estimated to affect 1 in 5 Australians.  The condition is debilitating for 
patients and remains a costly burden on the healthcare system.  Analgesics currently in 
clinical use lack efficacy, have low tolerability and are hampered with wide side-effect 
profiles.  Therefore, the underlying molecular mechanisms of pain sensing must be elucidated 
with a view to the development of improved therapeutics.  Peripheral sensory neurons are the 
site of pain signal initiation and are critical for the detection of painful stimuli.  Neuronal 
excitability relies on integral membrane bound proteins such as voltage-gated sodium 
channels (NaV), which allow the influx of sodium and action potential propagation in these 
cells.  Nine different NaV subtypes have been identified (NaV1.1-1.9) of which a subset are 
expressed in peripheral sensory neurons.  The exact role that each NaV isoform plays in the 
excitability of different fibre types remains unclear.  This thesis uses a multidisciplinary 
approach to assess the role of the NaV subtype NaV1.6 in peripheral sensory neurons. 
NaV1.6 channels share high sequence homology with other NaV isoforms expressed in 
peripheral sensory neurons.  Scorpion venom is a rich source of bioactive compounds, many 
of which act on mammalian NaV channels.  One such peptide, Cn2, is reported to be a 
selective NaV1.6 activator. Chapter 2 describes the chemical synthesis of Cn2 using a strategy 
of native chemical ligation.  The pharmacology of the synthetically derived Cn2 is in line 
with that of the venom derived peptide.  This approach allows the development of a number 
of probes, including a novel NaV1.6 antagonist Cn2[E15R], that retain selectivity for NaV1.6.  
Therefore, this chapter characterises novel NaV1.6 selective compounds and provides insight 
into NaV1.6-toxin interactions.   
Peripheral sensory neurons express a range of different ion channels that are critical for their 
function.  Chapter 3 aimed to assess the contribution of NaV1.6 to Na
+ currents in mouse 
isolated dorsal root ganglion cells.  High-content calcium imaging and whole-cell patch 
clamp electrophysiology was performed using the selective Cn2 peptide as a probe for 
NaV1.6 function.  Corresponding to expression of NaV1.6, Cn2 induces early Na
+ currents in 
large but not small diameter DRG neurons.  The Cn2 effect is absent in NaV1.6
-/- neurons 
confirming the selectivity of the peptide in a neuronal environment.  Furthermore, Cn2 
enhances excitability of large diameter neurons in vitro.  
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Isolated DRG cell bodies act as a robust approximation of the membrane protein composition 
of peripheral sensory neurons and allow characterisation of NaV channel kinetics in their 
native environment.  However, action potential initiation and sensory transduction begins at 
the peripheral nerve terminals in the skin and viscera.  To address this discrepancy, the effect 
of NaV1.6 activation in the skin was explored using the ex vivo rodent skin saphenous nerve 
preparation. In Chapter 4, the role of NaV1.6 in peripheral sensory terminals is explored using 
both selective and non-selective NaV agonists and antagonists.  Ciguatoxin along with a suite 
of NaV selective antagonists reveal crucial role for NaV1.6 in peripheral sensory neurons.  
Activation of NaV1.6 leads to profound enhancement of responses to mechanical stimuli, 
supporting the role of NaV1.6 in mechanosensitive A fibres.  C fibres display minor responses 
to selective NaV1.6 activation ex vivo.  
In Chapter 5 the role of NaV1.6 in peripheral sensory neurons in vivo is investigated using 
various animal models of nociception and the NaV1.6 selective tools defined in Chapters 2-4.  
The novel NaV1.6 antagonist Cn2[E15R] (introduced in Chapter 2) is analgesic in murine 
models of pathological pain, this includes the formalin model.  Furthermore, the integral role 
of A fibres in ciguatoxin-induced spontaneous pain is confirmed.  In agreement with findings 
from Chapter 4, NaV1.6 activation in vivo induces mechanical but not thermal allodynia.  A 
method for Aβ fibre blockade is explored and the overall effect of NaV1.6 agonists and 
antagonists on nociception in vivo is discussed. 
In summary, the function of the NaV1.6 channel is systematically explored using different 
methodologies to improve our understanding of the channel biophysics and the implications 
for particular peripheral sensory neuron populations.  NaV1.6 is an isoform that plays a 
critical role in a subset of neurons of the peripheral nervous system.  Insight from channel-
toxin interactions may aid development of molecules with potency and selectivity similar to 
these large peptides.   
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LCMS  liquid chromatography-mass spectrometry 
MALDI-TOF Matrix-Assisted Laser-Desorption Ionization-Time of Flight 
MEM Minimum Essential Medium Eagle 
MPAA  4-mercaptophenylacetic acid 
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Na+  sodium ion  
NaV  voltage-gated sodium channel 
NMR nuclear magnetic resonance 
NOESY Nuclear Overhauser effect spectroscopy  
PBS phosphate buffered saline 
PEPD  paroxysmal extreme pain disorder 
PNS  peripheral nervous system 
PSS  physiological salt solution 
RMP  resting membrane potential 
RP-HPLC  reverse-phase high-performance liquid chromatography  
SEM  standard error of the mean 
SIF synthetic interstitial fluid 
SNI  spared nerve injury  
SNT  spinal nerve transection 
SPPS solid-phase peptide synthesis 
TCA  tricyclic antidepressant 
TFA  trifluoroacetic acid 
TRP  transient receptor potential  
TTX  tetrodotoxin 
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Chapter 1 – Literature review  
 
 
1.1 Introduction 
Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant 
sensory and emotional experience, associated with actual or potential tissue damage”.  Chronic 
and neuropathic pain disorders remain debilitating for patients and a large economic burden on 
the healthcare system.  One in five Australians will experience some form of chronic pain in 
their lifetime (1).  The most recent assessment estimates the cost of chronic pain to be in the 
region of $34 billion per annum (2).  Current therapeutics are often ineffective, for example 50 
per cent of post-surgical and cancer patients report no relief from pain (3).  Common analgesic 
therapeutics, such as opioids, are hampered by wide side-effect profiles (4).  Furthermore, pain 
states such as complex region pain syndrome (CRPS), fibromyalgia and chemotherapy-
induced neuropathy respond poorly, if at all, to current therapeutic regimes (5-8).  These 
findings drive the need to understand the molecular basis of different pain modalities, in order 
to find more effective therapeutics for the treatment of pain.  
1.2 Nerve excitability: an historical perspective 
The nervous system’s ability to carry electrical currents was discovered in 1780, by Luigi 
Galvani.  His work showed that the muscles of a dead frog’s leg could be made to twitch upon 
stimulation by an electrical spark.  Further experiments, without the presence of electrical 
sparks, demonstrated that nerve cells possessed an intrinsic electrical force which he coined 
“animal electricity” (9).  However, the precise mechanism of neuronal conduction was not 
understood until the 20th century, when experiments on squid giant axons – published in a 
series of highly influential papers by Hodgkin and Huxley (10-13) – revealed the crucial 
contribution of the inward sodium (Na+) current to action potential generation. 
Hodgkin and Huxley’s quantitative description of the kinetics and ion movement during an 
action potential laid the ground work for further study on the mechanism by which the ion flux 
occurs.  Hodgkin and Keynes suggested that potassium (K+) and Na+ permeability could be 
explained by “narrow tubes or channels” in the membrane (14).  However, it was Hille, 
Armstrong and Benzanilla who went on to characterise many functional and structural aspects 
of these proposed channels including the gating kinetics and ion selectivity (15, 16).  It is now 
understood that large transmembrane channels that open and close in response to changes in 
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the electrical membrane potential – the voltage-gated sodium channels or NaV – mediate this 
selective influx of Na+ ions. 
1.3 Voltage-gated sodium channels  
 
1.3.1 Structure 
Early studies on the structure and function of NaV channels were greatly facilitated by toxins, 
leading to the purification of the 260 kDa pore-forming α subunit from electrical tissue of 
Electrophorus electricus and later different mammalian NaV channels (17-22).  Later it was 
found that the pore-forming α subunit associates with one or more 30-40 kDa auxiliary β 
subunits (β1- β4), which can modulate cell surface expression and functional properties of the 
α subunit (23, 24).  Structurally, the NaV channel α subunit protein contains four homologous 
domains (I-IV) each consisting of six alpha helical transmembrane spanning segments (S1-S6) 
connected by large intra- and extracellular loops (21, 22) (Figure 1.1).  In functional channels, 
the four domains are arranged in a concentric manner surrounding the ion-conducting pore of 
the channel which in turn is formed by the S5-S6 helices as well as their connecting, 
membrane re-entrant pore loop (25).  Notably, the arrangement of the voltage-sensing (S1-S4) 
and pore-forming (S5-S6) segments are offset so that in functional channels, the voltage 
sensor of each domain is closest to the pore-forming segment of the following domain (26).  
The β-subunit structure includes a small intracellular domain, a single transmembrane 
spanning region and a large extracellular portion (27). 
 
Figure 1.1 2D Schematic of the structure of the voltage-gated sodium channel α subunit  
The four homologous domains of the NaV channel are denoted as DI-DIV.  Transmembrane 
spanning segments (S1-S6) represented as cylinders.  S4 subunits act as the voltage sensor for 
the channel.  The extracellular region between S5-S6 forms the channel pore. 
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The selectivity filter consists of a four-glutamate-residue motif in the pore of the channel 
which allows the passage of Na+, but not K+ and Ca2+ ions and thus imparts the high Na+ 
selectivity of these channels (28).  This structural arrangement was recently confirmed by 
crystal structures of the homotetrameric bacterial NaV channel which have provided a better 
understanding of ion selectivity, channel gating, and drug interactions (26, 29).  
In recent years, the crystal structure of mammalian NaV including NaV1.2, NaV1.4 and channel 
NaV1.7 channel isoforms have been resolved (30-33).  This includes the structure of the NaV α 
subunit alongside the auxiliary β subunit (30). Notably, some of these studies of NaV structure 
made use of selective toxin-channel interactions to achieve high resolution NaV crystal 
structures (32-34). These structural advances also include details of the voltage sensor in 
activated, resting states and deactivated states, these states are discussed in more detail below. 
 
1.3.2 Gating  
 
NaV channels exist, at a minimum, in three discrete states: resting (closed), open (active) and 
inactive.  In both the closed and inactive state, the channels are impermeable to Na+ ions, with 
ion conduction only possible in the open state.  In a simplified model of NaV gating, 
depolarisation of the membrane causes the channel to transition from the resting to the active 
state, allowing the flow of Na+ ions along their concentration gradient (13, 35).  Following 
depolarisation and subsequent ion influx, channel inactivation halts ion conductance, a 
necessary pre-requisite for return of the membrane potential to resting levels.  Recovery from 
inactivation describes the – relatively poorly understood – process of returning inactivated 
channels to the resting state, and completes channel gating transitions (35).  
1.3.3 NaV channel activation 
The voltage-dependent activation of NaV channels depends crucially on the S4 transmembrane 
segments of domains I-III, which each contain a repeated motif consisting of positively 
charged amino acid residues uniformly separated by non-polar amino acids (22, 36-38).  
During membrane depolarisation, these “gating charges” move towards the extracellular 
surface as ion pair interactions between the positive charges of the S4 segment and negative 
charges of adjacent transmembrane regions are released (39, 40).  
How exactly the S4 domain, with its positive charges, can be stable but also translocate its 
positive charges to the extracellular surface is hypothesized in the “sliding helix-helical screw” 
model of voltage sensor function (36, 37).  The resultant conformational rearrangement leads 
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to opening of the pore and subsequent influx of Na+ ions.  During repolarisation of the 
membrane, the activation gate is released in a process known as deactivation that is separate 
from, and not to be confused with, the process of inactivation described below. 
1.3.4 NaV channel inactivation 
The process of inactivation ultimately results in the channel no longer conducting ions and can 
occur from the open state (fast inactivation) or from the closed state (closed state inactivation) 
(41).  Fast inactivation is the result of the occlusion of the pore by the cytosolic inactivation 
particle, which consists of the intracellular loop linking domains III and IV (42, 43).  During 
the activation process, movement of the voltage sensors, in particular of domain IV, exposes 
the inactivation particle binding site and leads to a physical block of the movement of ions into 
the cell (42).  As the voltage sensors of domains I-III respond more rapidly to membrane 
depolarisation than the domain IV voltage sensors (44), inactivation typically occurs 
subsequent to channel activation.  Accordingly, the process of inactivation is intrinsically 
linked to activation; albeit the experimentally observed membrane-potential dependent 
characteristics of inactivation are likely to be largely derived from the intrinsic coupling to 
activation, with movement of the DIV VSD a necessary pre-requisite for inactivation. The 
structural basis of NaV channel inactivation was explored in an elegant set of experiments by 
Clairfeuille et al. (33). The α scorpion toxin AaH2 was used to track movement of the DIV 
VSD during NaV channel gating in high resolution. AaH2 traps the DIV VSD in a deactivated 
state, visualised in detail by single-particle cryo-EM (Cryogenic Electron-Microscopy) (33). 
Crucially, these findings provide a framework for the molecular events surrounding previously 
enigmatic NaV channel fast inactivation gating movements (33).  
However, as movement of two of the voltage sensing domains may be sufficient for the 
inactivation particle to bind (45), it is possible for NaV channels to proceed directly from the 
closed (in these studies often called pre-open) to the inactivated state (46, 47) under conditions 
that kinetically favour the development of inactivation.  In this way, the channel does not have 
to fully open before being blocked by the inactivation particle leading to a closed state channel 
block.  
In contrast to fast inactivation, “slow inactivation” is a distinct type of inactivation that does 
not involve movement of the inactivation particle (48).  Slow inactivation occurs after 
prolonged depolarisation of the membrane or a long period of high frequency firing (49).  
Unlike fast inactivation, channels that are in the slow inactivation state require longer periods 
(100 ms – 10 s) of time to recover.  Slow inactivation is thought to arise from a 
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conformational change in the channel, most likely associated with the domain IV S4 region 
and S6 pore forming segments, whereby the pore is not fully blocked (29, 49, 50). 
1.3.5 NaV isoforms 
At present, nine mammalian NaV subtypes (isoforms) have been identified, which can be 
distinguished according to their expression pattern, biophysical characteristics and 
pharmacology. To eliminate confusion arising from the inconsistent naming conventions for 
these isoforms (Table 1.1), a standardized nomenclature based on a numerical system to define 
subtypes was introduced (51). According to their highly selective permeability to Na+ ions, 
gating by membrane voltage, and similar sequence and functional characteristics, the accepted 
naming convention for these α subunits is NaV1.1 – 1.9 (51).  
Early functional classification based on the sensitivity to tetrodotoxin (TTX), a neurotoxin 
isolated from puffer-fish, has been retained (52, 53).  Specifically, NaV isoforms that respond 
to low nano-molar concentrations of TTX (NaV1.1, 1.2, 1.3, 1.4, 1.6 and 1.7) are characterized 
as TTX-sensitive (TTX-S), while those that require micro-molar concentrations of TTX for 
significant inhibition (NaV1.5, 1.8 and 1.9) are classified as TTX-resistant (TTX-R) (54, 55) 
(Table 1.1).  Importantly, NaV isoforms are present in distinct populations across different 
tissues, including both excitable and non-excitable cells (Table 1.1), where they perform 
critical roles in mammalian physiology. In non-excitable cells and tissue that are not capable 
of producing an action potential, such as astrocytes (56-59), microglia (60-62), islet β-cells 
(63-65), Müller glia (66, 67), osteoblasts (68), Schwann cells (69, 70), cancer cells (71, 72), 
macrophages (73, 74), dendritic cells (75) and keratinocytes (76), NaVs play a role in cell 
migration, proliferation (77), and metastasis (78, 79). In contrast, in excitable cells, NaVs are 
crucial for regulating excitability and action potential firing. Accordingly, gain- and loss-of-
function mutations in individual NaV isoforms are causally associated with a number of 
diseases or “channelopathies”, including epilepsy, migraine, myotonia, periodic paralysis, 
cardiac arrhythmias, and altered pain sensitivity.  
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Table 2.1 Distribution of NaV subtypes in primary and non-excitable cell 
Type TTX 
sensitivity 
Gene Symbol – Chromosome 
location (human) 
Primary Tissue Non-excitable 
tissue 
Nav1.1 S IC50<30nM SCN1A – 2q24  CNS neurons Microglia  
Nav1.2 S IC50<30nM SCN2A – 2q23-24  CNS neurons Islet β-cells 
Osteoblasts  
Schwann cells  
Nav1.3 S IC50<30nM SCN3A – 2q24  CNS neurons Islet β-cells   
Nav1.4 S IC50<30nM SCN4A – 17q23-25 Skeletal muscle Cancer cells 
Nav1.5 I IC50 >1µM SCN5A – 3p21  Uninnervated 
skeletal muscle, 
Heart 
Macrophages  
Microglia 
Astrocytes 
Cancer cells 
Nav1.6 S IC50<30nM SCN8A – 12q13  CNS neurons Macrophages  
Astrocytes 
Cancer cells 
Nav1.7 S IC50<30nM SCN9A – 2q24 PNS neurons Dendritic cell  
Cancer cells 
Nav1.8 R IC50 >1µM SCN10A – 3p22-24  DRG neurons Keratinocytes 
Nav1.9 R IC50 >1µM SCN11A – 3p21-24 DRG neurons Mϋller glia  
Nax  SCN6A and SCN7A – 2q21-23  Astrocytes 
 
1.4 Toxins as NaV subtype selective probes 
 
The critical contribution of NaV channels to cellular excitability underpins their role in many 
essential physiological processes including neuromuscular and cardiac function.  As NaV 
channels are conserved across many phyla, it is not surprising that evolution of NaV-targeting 
venom peptides has occurred in many species, including scorpions, cone snails, spiders, 
anemones and snakes.  Venom-derived peptides exert diverse effects on NaV channel function, 
including inhibitory effects that are mediated via physical occlusion of the pore or impairing 
the movement of voltage sensors; as well as excitatory effects resulting from enhanced 
activation or impaired inactivation (52, 53, 80, 81).  NaV binding sites and examples of toxin 
modulators are summarized in Table 1.2. 
TTX and the related non-peptidic saxitoxin (STX) interact with the well-defined site-1 of the 
NaV channel which is located within the pore (82, 83).  These toxins block sodium 
conductance by physically occluding the ion permeability region of the NaV channel. μ-
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Conotoxins are able to inhibit the binding of TTX, suggesting that they also bind to site 1 and 
act as pore blockers (84).  Site 2 toxins such as veratridine and batrachotoxin bind at the pore 
region and cause persistent current by inhibiting inactivation of the NaV channel and by 
enhancing activation (83, 85).  Gating modifier toxins are those that bind to S1-S4 regions of 
any domain of the NaV and are so named for their effect on NaV channel gating.  Some spider 
toxins (86), sea-anemone toxins (17) and α-scorpion toxins (87) occupy site 3 of the sodium 
channel and delay inactivation of the channel increasing persistent current (88).  Similar to site 
3 toxins, the δ-conotoxin family that bind to site 6 of the NaV channel, delay inactivation (89).  
The δ-conotoxin are difficult to synthesize and are highly hydrophobic making their study 
difficult (90).  Toxins which interact with site 5 block channel inactivation and shift the 
voltage dependence of activation to more hyperpolarised potentials (91).  Neurotoxin binding 
site 5 is occupied by brevetoxins and ciguatoxin which are derived from dinoflagellates (92).  
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Table 1.2: NaV channel modulators, their binding site, structure and mechanism of action 
Molecule Source Site NaV 
domain 
Class Mechanism Reference 
Inhibitors  
Tetrodotoxin, 
saxitoxin 
Bacteria 1 pore Small 
molecule 
Pore blocker (82) 
Local 
anaesthetics 
Synthetic 9 pore Small 
molecule 
Pore blocker (93) 
µ-conotoxins Cone snails 1 pore Peptide 
(~20-25 aa) 
Pore blocker (84, 94) 
µ/β-therapho-
/cteni-
/thornitoxins 
toxins 
Spiders 3 
and/or 
4 
DIV S3-4 
DII S3-4 
Peptide 
(~30-35 aa) 
Trap channel in 
closed state. Some 
toxins also shift 
voltage-dependence 
of activation 
(95) 
µO-conotoxins Cone snails 4 DII S3-4 Peptide 
(31-32 aa) 
Trap channel in 
closed state 
(96) 
µO§ GVIIJ Cone snails 8 DII S5 Peptide (35 
aa) 
Inhibits peak current. 
Mechanism  
unknown. 
(97) 
Activators  
Veratridine, 
grayanotoxin, 
aconitine 
Plants 2 DIS6, 
DIIS6, 
DIIIS6, 
DIVS6 
Small 
molecule 
Delayed inactivation, 
hyperpolarising shift 
in voltage-
dependence of 
activation 
(98, 99) 
δ-conotoxins Cone snails 6 DIV S3–4 Peptide 
(~30-35 aa) 
Delayed inactivation (89) 
α-scorpion 
toxins 
Scorpions 3 DI S5-6, 
DIVS1-2, 
DIV S3-4 
Peptide 
(~60-70 aa) 
Delayed inactivation (100, 101) 
Anemone 
toxins 
Anemones 3 DIV S3-4 Peptide 
(~27-54 aa) 
Delayed inactivation (100) 
β-scorpion 
toxins 
Scorpions 4 DII S1-2, 
DII S3-4, 
DIII S5-6 
Peptide 
(~60-70 aa) 
Hyperpolarising shift 
in voltage-
dependence of 
activation 
(102, 103) 
δ-therapo-
/hexatoxins 
Spiders 3 DIV S1-2, 
DIV S3-4 
Peptide 
(~30-42 aa) 
Delayed inactivation (95, 104) 
brevetoxin, 
ciguatoxin 
Dinoflagellates 5 DI S6, DIV 
S5 
Polyethers Delayed inactivation, 
hyperpolarising shift 
in voltage-
dependence of 
activation 
(105, 106) 
pyrethroids Synthetic 7 DIIS6, 
DIIIS6 
Small 
molecule 
 
Delayed inactivation, 
hyperpolarising shift 
in voltage-
dependence of 
activation 
(107) 
Batracho-toxin Frog 2 DIS6, 
DIVS6 
Small 
molecule 
Delayed inactivation, 
hyperpolarising shift 
in voltage-
dependence of 
activation 
(108) 
δ-calliotoxin Snake ? ? 3-finger 
toxin (~80 
aa) 
Delayed inactivation, 
hyperpolarising shift 
in voltage-
dependence of 
activation 
(109) 
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1.4.1 β scorpion toxins 
Site 4 is the binding site of β-scorpion toxins (activators) and µO-conotoxins (blockers) (83, 
96).  The mechanism of β-scorpion action is described by a model of voltage-sensor trapping 
whereby activation of the channel and movement of the S4 regions facilitates toxin binding 
(80, 102, 110).  In effect, this traps the voltage-sensor in a position favouring NaV channel 
activation, increasing channel open probability.  Cn2 is a potent and selective β-scorpion toxin 
modulator for NaV1.6 that is purified from the crude venom of Centruroides noxius (111, 
112).  Following a conditioning pre-pulse to facilitate toxin binding, Cn2 causes NaV1.6 (and 
no other NaV isoform) to open at hyperpolarised potentials (112).  Interestingly, without the 
conditioning prepulse, Cn2 blocks sodium conductance (112), an effect shared by other β-
scorpion toxins (113).  Cn2 also induces resurgent current in cells that intrinsically cannot 
produce this current (112).  The structurally related scorpion β-toxin Css4 shares an 83% 
sequence homology with Cn2 (112, 114).  However, Css4 has no β-scorpion activity at 
NaV1.6, indeed it is selective for the CNS isoform NaV1.2.  A glutamic acid (E15) residue, 
conserved between Cn2 and Css4 is critical for Css4 NaV1.2 – voltage-sensor trapping (114).  
The mutant E15R-Css4 retains binding affinity for NaV1.2, yet no longer causes a 
hyperpolarising shift in voltage-dependence of activation.  The paralytic effects of the wild-
type toxin Css4 are lethal in vivo, yet co-administration with E15R-Css4 (at a 10-fold higher 
concentration) caused complete reversal of paralysis (114). 
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1.5 NaV channels and the peripheral nervous system   
 
1.5.1 Peripheral sensory neurons  
The ability to feel touch, temperature and pain is mediated by the somatosensory system and is 
critical for an organism’s survival.  This sensory pathway begins in primary sensory neurons 
that project into the skin, muscles and viscera.  The cell bodies of these pseudo-unipolar 
neurons reside in the dorsal root ganglion (DRG) (with the exception of parts of the head, neck 
and cranium) located outside of the spinal column (115, 116).  Specifically, axons of these 
neurons extend from the soma (in the DRG) in two directions; into the posterior column of the 
spinal cord and distally into the sensory nerve ending in the skin, viscera or muscles (116-
118).  Thus, these neurons relay sensory information from the periphery to the central nervous 
system where it may be processed and modulated by the brain.   
The aetiology of chronic neuropathic pain is multifaceted, which reflects the multitude of 
associated co-morbidities.  Clinically, neuropathic pain is classified as either stimulus-evoked 
pain or non-stimulus (spontaneous) evoked pain (116, 119, 120).  Spontaneous pain can 
manifest in a constant or intermittent manner; for example, a constant burning pain or an 
intermittent shooting pain respectively (121).  Stimulus evoked pain can be further categorised 
as allodynia or hyperalgesia.  Allodynia is pain arising from normally non-noxious stimuli for 
example, pain associated with the pressure of clothing or warm or cool stimulus (120).  These 
symptoms are termed mechanical or thermal allodynia depending on their origin.  On the other 
hand, hyperalgesia is an increased sensitivity to normally painful stimulus; this too is assessed 
clinically using mechanical and thermal stimuli (122, 123).  It is not uncommon for these 
alterations in pain sensing to be accompanied by non-painful paraesthesia including tingling or 
prickling sensations.  All of the described symptoms can be caused by irregularities in neurons 
of the peripheral nervous system.  
Peripheral sensory nerve fibres are classified by size and conduction velocity.  Three 
peripheral sensory nerve fibre types were originally identified based on compound action 
potential speed these are Aβ, Aδ and C fibres (120).  In mice, Aβ fibres are large myelinated 
sensory fibres with a conduction velocity in rodents of greater 16 m/s, smaller myelinated 
fibres are Aδ fibres (1.6-12 m/s) and finally the slowest are small unmyelinated C fibres (<1 
m/s) (124).  Peripheral sensory neurons are also characterised on the basis of their ability to 
sense noxious stimuli (nociceptive vs non-nociceptive).  Nociceptive neurons respond to 
noxious thermal, noxious mechanical and noxious chemical stimuli or a combination of 
stimuli.  While nociceptive neurons generally have conduction velocities in the Aδ or C fibre 
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range, there is evidence that Aβ fibres play a role in pain sensing (125, 126).  Generally, A 
fibres have a rapid conduction velocity and can therefore affect a fast withdrawal response 
(127, 128).  Specifically, Aδ mediate responses to mechanical stimulus such as a response to 
pinching or pricking (118).  Due to their slow conduction velocity and expression of specific 
transducer channels, C fibre activation is associated with constant burning pain (118, 120).  C 
fibres are also critical for sensing pain caused by noxious cold (129).  
Other than functional classification of sensory fibre types, different neuronal populations are 
identified by the presence of protein markers.  For example, tropomyosin receptor kinase A 
(TrkA) is the receptor for nerve growth factor (NGF).  It is selectively expressed in a sub-
population of peripheral C fibres called peptidergic based on their expression of substance P 
and calcitonin gene-related peptide (CGRP) (130, 131).  Non-peptidergic C fibre neurons are 
identified by their ability to bind isolectin IB4 (132).  More recently, single-cell RNA 
sequencing has mapped RNA expression in DRG neurons and allowed an un-biased 
classification approach (133).  
The peripheral nerve terminal expresses a number of transducer channels including transient 
receptor potential (TRP), acid-sensing ion channels (ASIC) and ligand-gated ion channels, all 
of which remain targets for novel analgesic molecules (117).  Activation of these channels and 
induction of an action potential at the terminal by thermal, mechanical or other nociceptive 
stimuli leads to transmission that relies critically on ion channels such as NaV.   Indeed, 
perturbation of NaV function in peripheral sensory neurons can catastrophically impair 
neuronal function leading to both painful and/or painless channelopathies (134, 135).  Only a 
subset of all the NaV subtypes are found in high levels in peripheral sensory neurons including 
NaV1.1, 1.6, 1.7, 1.8 and 1.9 (Table 1.1).  Of these gain- and loss- of-function mutations in the 
peripherally restricted isoforms the NaV1.7, 1.8 and NaV1.9 have been the most extensively 
studied (see section 1.5.2).  Finally, the action potential reaches the central terminal in specific 
laminae of the spinal cord, where synaptic transmission to the second order neurons occurs 
(Figure 1.2).  
After injury, peripheral sensitisation occurs, making the region of injury more sensitive to 
stimulation.  This process is protective as it allows uninterrupted healing of the damaged 
region.  However, the process can become damaging if it persists unabated and can give rise to 
molecular changes in the afferent neurons (136-138).  Ectopic discharges in primary sensory 
neurons might be responsible for spontaneous pain symptoms (139, 140).  After injury, 
peripheral sensory neurons can generate pacemaker-like potentials leading to constant or 
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irregular, non-stimulus evoked firing (139, 141).  However, ectopic firing may only be 
essential for the initiation of neuropathic pain, not its maintenance (142).  Changes in NaV 
distribution and kinetics can alter firing regularity in peripheral sensory neurons. 
 
 
Figure 1.2 Anatomy of the peripheral nervous system 
 
1.5.2 NaV of peripheral sensory neurons  
The expression of different NaV isoforms in discrete populations of sensory fibres and their 
differential kinetics drives the function of sensory neurons.  Mutations in the NaV channel 
subtypes that are largely restricted to peripheral sensory neurons (NaV1.7, NaV1.8 and NaV1.9) 
are all associated with painful and painless neuropathies.  The function of these subtypes (and 
others) in peripheral sensory neurons and the emerging evidence for a crucial role of NaV1.6 
channels are discussed below. 
The NaV1.7 channel is ubiquitously expressed in peripheral sensory neurons (133, 143, 144).  
This includes at the DRG soma, along the axons of C and A fibres and at the peripheral nerve 
terminal (145, 146).  Along with other TTX-S channels, this isoform rapidly activates in 
response to depolarisation.  Unlike other subtypes, the NaV1.7 isoform has a hyperpolarised 
voltage-dependence of inactivation and slow repriming kinetics and consequently it is unlikely 
able to sustain repetitive firing (147, 148).  Furthermore the development of closed state 
inactivation (or steady-state inactivation) is slower in NaV1.7 (148) and therefore NaV1.7 
remains available for activation during slow ramp depolarisations (147).  NaV1.7 is therefore 
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able to respond to sub-threshold generator potentials and might be involved in setting the 
sensitivity for action potential generation (146, 149).  
Crucially, loss-of-function mutations in NaV1.7 cause the rare clinical phenotype of congenital 
insensitivity to pain (CIP) (150).  Patients with CIP are unable to sense pain in the absence of 
any other major sensory abnormalities (the inability to sense smell has been reported in some 
patients) (150, 151).  NaV1.7 gain-of-function mutations are causal in hereditary pain disorders 
including inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD) 
(152, 153).  These disorders are characterised by bouts of extreme burning pain, swelling and 
redness of regions of the body such as the hands and feet.  Mechanistically, these gain-of-
function mutations shift the voltage-dependence of activation of NaV1.7, enhancing 
excitability of NaV1.7 expressing sensory neurons (154).  While some of the symptoms of CIP 
have been reliably recapitulated in a mouse model (155), NaV1.7 global knock-out mice and 
specific deletion of the isoform from sensory neurons has led to mixed phenotypes (156, 157). 
Interestingly, a range of small molecule and venom-derived NaV1.7 selective blockers have 
been developed that show variable efficacy in animal models of inflammatory and neuropathic 
pain (158-160).  
The apparent role of NaV1.7 in carrying sub-threshold generator potentials is contentious. A 
recent study of the isoform in induced pluripotent stem cells (iPSC) differentiated into 
humanized sensory neurons found no difference in the slope of sub-threshold depolarisations 
between WT NaV1.7 and an IEM (gain-of-function) mutant (161). However, the same study 
found NaV1.7 current crucial for defining the threshold of activation of action potentials in 
iPSC derived nociceptors (161). Concurrently, recording from iPSC nociceptors derived from 
CIP patients (NaV1.7 loss-of-function) were less responsive to slow ramp depolarisations than 
WT iPSC derived nociceptors (162).  
The NaV1.8 channel isoform is highly expressed in small diameter, nociceptive C fibres where 
it contributes to a sizeable TTX-R Na+ current (163, 164).  However, approximately 40-50% 
of myelinated A fibres also express NaV1.8, where its contribution to excitability is less well 
defined (165, 166).  The NaV1.8 channel voltage dependence of activation is deeply 
depolarised and its inactivation kinetics are slow compared with other subtypes (164).  NaV1.8 
channels are large contributors to the upstroke of the action potential in small diameter fibres 
(149).  Furthermore, a suite of gain-of-function mutations in NaV1.8 are associated with small-
fibre neuropathy and erythromelalgia (167-170).  NaV1.8 knock-out mice are viable, however 
the effect on basal nociception appears to be limited to noxious cold sensing (129).  In a range 
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of models, neuropathic pain develops normally in global NaV1.8 knock out animal (171, 172).  
Although, NaV1.8 appears to play a role in inflammatory pain as knock-out animals and 
selective inhibition of the isoform in vivo attenuates pain behaviours in inflammatory models 
(173-175). Loss-of-function mutations have also been associated with altered human pain 
perception in humans (176). 
The NaV1.9 is expressed preferentially in small diameter nociceptors and is thought to be 
involved in pain sensing (177).  NaV1.9 displays unique biophysical properties such as 
hyperpolarised voltage-dependence of activation, slow gating kinetics and large persistent 
current (178).  In neurons that express NaV1.9, the Na
+ current carried by this channel is 
crucial for setting the threshold potential for action potential generation (179).  Consequently, 
mutations in NaV1.9 are associated with painful and painless clinical phenotypes (180-183).  
Like NaV1.8, assessing the role of NaV1.9 in animal behavioural studies of nociception has led 
to mixed results. Global knock-out animals develop normal mechanical hypersensitivity but 
recover faster from thermal hypersensitivity induced in inflammatory models (171, 184).  
There are contrary reports of basal heat sensing in NaV1.9 knock-out animals however they are 
less sensitive to noxious cold (185-187).  Pharmacological isolation of NaV1.9 has been 
hampered by difficulties in heterologously expressing the channel (188) and while these have 
recently been overcome, no potent and selective modulator of NaV1.9 has been reported (189, 
190). 
The NaV1.3 subtype is expressed at low levels in adult rodents however up-regulation of the 
channel is reported after nerve injury (191, 192).  NaV1.3 conditional and global knock-out 
animals develop allodynia normally in a model of nerve injury, indicating that NaV1.3 is not 
crucial for the development of neuropathic pain (193).  Recently the NaV1.1 subtype was 
implicated in nociception and mechanical hypersensitivity in sensory afferents innervating the 
gut (104). NaV1.1 is widely expressed in the central nervous system and because of this, like 
NaV1.6 (see section 1.5.4), mutations are associated with epilepsy and ataxia (194-196).  
Peripherally NaV1.1 is expressed in medium diameter Aδ fibres (104, 197) and selective 
activation of NaV1.1 by the spider toxin Hm1a leads to mechanical hypersensitivity in and ex 
vivo. 
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1.5.3 The Nav1.6 subtype  
The NaV1.6 isoform, encoded by SCN8A gene, was originally discovered in the rat central and 
peripheral nervous systems where it is widely expressed in different cell types including 
Purkinje cells, motor neurons, pyramidal and granule neurons as well as glial and Schwann 
cells (69).  NaV1.6 is highly localized at the nodes of Ranvier, the gaps between the myelin 
sheath that allow for saltatory conduction of action potentials (35).  The low activation 
threshold and rapid repriming kinetics of NaV1.6, which allow sustained high frequency firing, 
are likely key to nodal function (198).  Several human conditions associated with NaV1.6 
mutations have been described, including cases presenting with cerebellar atrophy, ataxia, 
intellectual disability, dyskinesia, epileptic encephalopathy; as well as trigeminal neuralgia 
(199-203). In mice, a naturally occurring NaV1.6 splice variant leading to non-functional 
protein expression leads to a neurological disorder known as ‘motor endplate disease’ (204), 
which has provided crucial insights into the physiological role of NaV1.6. The phenotype of 
these animals, characterized by cerebellar ataxia and muscle atrophy due to the loss of 
excitatory innervation to the muscle, leads to juvenile death (205-207). Mutations in NaV1.6 
have highlighted an important contribution of this isoform to the resurgent current of Purkinje 
neurons (208).  In peripheral sensory neurons, NaV1.6 is highly expressed in medium-sized 
and large diameter A fibres (209).  In part, this is due to the association with the nodes of 
Ranvier and their presence only on myelinated fibres.  However, in situ hybridization 
demonstrates robust expression of NaV1.6 in peripherin-positive unmyelinated fibres (210).  
Accordingly, single-cell PCR from mouse DRG neurons shows transcripts in both myelinated 
and unmyelinated fibres (133).  
The NaV1.6 subtype has been identified as a contributor to nociception in animal models of 
inflammatory and neuropathic pain (211-214).  NaV1.6 is implicated in diabetes-induced 
neuropathy (211) and has been associated with post-herpetic neuralgia (PHN) (215).  An early 
study suggested NaV1.6 mRNA was down-regulated in DRG neurons after spinal nerve 
ligation (SNL) and spinal nerve injury (SNI) (216).  However, after infraorbital nerve injury 
NaV1.6 expression increased at the site of the lesion (217).  Furthermore, local knockdown of 
NaV1.6 via siRNA reduced mechanical allodynia after spinal nerve ligation (SNL), a result 
that was associated with a block of abnormal spontaneous activity in DRG neurons (218, 219).  
This suggests that NaV1.6-driven hyperexcitability underlies mechanical allodynia in 
neuropathic pain models.  However, siRNA approaches may lack sufficient selectivity for 
NaV1.6 in a particular sensory fibre type, and the level of decreased protein expression is often 
unclear.  To overcome these limitations, a conditional NaV1.6 knock-out mouse was developed 
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and used to assess the role of the NaV1.6 in NaV1.8 expressing neurons (NaV1.6
Nav1.8 
KO)(220).  Conditional knock-out of NaV1.6 had no effect on nociceptive baseline including 
response to mechanical or heat stimulus.  However, after spinal nerve injury (SNI) these 
animals developed less severe mechanical allodynia  (220).  Detailed electrophysiology from 
DRG neurons isolated from NaV1.6
Nav1.8 KO animals showed that NaV1.6 only accounts for 
~34% of the TTX-S current in small diameter neurons, and 80% of the TTX-S current in 
NaV1.8 expressing large diameter neurons (220).  However, not all large diameter DRG 
neurons express NaV1.8 (approximately 40% do express the isoform) therefore the 
contribution of NaV1.6 to pain signalling in these neurons remains unknown.  Taken together, 
the high NaV1.6 expression in large myelinated A fibres and evidence from in vivo models of 
allodynia supports a critical role in mechanosensing (120). 
Through the use of selective pharmacological tools, NaV1.6 was shown to be the mediator of 
oxaliplatin and cisplatin mechanical allodynia (212, 213, 221).  Chemotherapy treatment is a 
major cause of peripheral neuropathy and current analgesics are ineffective at reducing painful 
symptoms (222).  The most commonly reported peripheral neuropathy in cancer patients is A 
fibre neuropathy (223).  NaV1.6 resurgent and persistent currents drive enhanced response to 
cooling in oxaliplatin treated cells, hinting at the importance of these particular currents in 
aetiology of neuropathic pain (212).  The role of NaV1.6 in the development of cold pain was 
further studied in a model of ciguatoxin-induced cold allodynia.  Aided by the use of selective 
antagonists, ciguatoxin-induced cold allodynia was found to be mediated by both NaV1.6 and 
NaV1.8 (214, 224).  The selective NaV1.6 / 1.1 antagonist GIIIA alone blocked approximately 
50% of the phenotype, however when co-administered with NaV1.8 blocker A803467, 
approximately 90% of cold pain was abolished (214). 
Finally, the identification of a gain-of-function mutation in NaV1.6 associated with a human 
case of trigeminal neuralgia provided additional evidence for the crucial contribution of this 
isoform to peripheral neuronal excitability (201).  The mutation in DI/SI (Met136Val) of 
NaV1.6 causes enhanced current density and increased resurgent current in trigeminal neurons 
transfected with the mutant channel (201).  Consequently, the mutation increased both the 
number of evoked action potentials and the propensity for neurons to fire spontaneous action 
potentials in sensory neurons.  However, NaV1.6 mutations are more commonly linked to 
epilepsy and ataxia (225, 226) and these patients are not routinely screened for sensory 
aberration or enhanced pain sensing.  Alternatively, the severe symptoms seen in these 
patients may make identifying small changes in somatosensation challenging.  On the whole, 
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the function of NaV1.6 expressing sensory neurons in normal and pathological pain states 
remains to be elucidated. 
1.6 Summary 
In summary, NaV channels are transmembrane proteins that allow the influx of Na
+ into the 
cell allowing the generation and propagation of action potentials in neurons.  NaV channel 
subtypes are distributed in tissues where their variable kinetics play diverse roles in 
electrogenesis.  Peripheral sensory neurons, the first order neuron in the pain pathway, convert 
external stimuli such as touch, hot and cold into action potentials.  These neurons express 
different NaV subtypes and the role of particular peripheral NaV isoforms has been studied 
extensively.  NaV1.6 is expressed in peripheral sensory neurons and has been linked to pain in 
vivo.  NaV subtypes share high (>50%) sequence homology making pharmacological targeting 
of a particular isoform challenging.  This is the case for NaV1.6 for which there is a lack of 
potent and selective molecules.  However, these channels are the target of many venom-
derived toxins which are often potent and highly selective for ion channels.  Pharmacological 
isolation of NaV1.6 could expand our understanding of which NaV channels are critical for the 
development and maintenance of pain. 
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1.7 Hypothesis and Aims  
1.7.1 Hypothesis 
1) NaV1.6 is a novel pain target that is crucial for excitability of peripheral sensory 
neurons in pain states. 
2) Subtype-selective toxins are useful tools to delineate the role of NaV1.6 in pain 
pathways. 
1.7.2 Aims 
Aim 1: Characterise the effect of novel NaV1.6-selective tool compounds in vitro. 
Aim 2: Characterise the functional contribution of NaV1.6 to excitability of peripheral 
sensory nerve fibres using the ex vivo rat skin-saphenous nerve preparation. 
Aim 3: Define the contribution of NaV1.6 to pain pathways in vivo using pharmacological 
approaches. 
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Chapter 2 – Creating and assessing tools for the study of NaV1.6 
 
 
2.1 Foreword 
 
The aim of the following chapter is to develop novel modulators and characterise their effect 
on NaV1.6.  In order to achieve this, the NaV1.6 activator Cn2 and following this the analogs: 
Cn2[E15R]; Cn2-488; and, Bodipy-Cn2; were generated by synthetic chemistry.  These 
molecules were then assessed for activity at NaV1.6 and other NaV subtypes using high-
throughput fluorescent and electrophysiology assays.  Chapter 2 is based on a paper published 
in Journal of Medicinal Chemistry (227), edited and formatted for the style and flow of this 
thesis.  Contributions made by others are stated in body of this chapter along with the thesis 
preliminary pages. 
 
2.2 Introduction 
 
The generation and propagation of action potentials in neurons is realized through a well-
orchestrated interplay of ion channels in which the family of voltage-gated sodium channels 
(NaV) plays a central role (228, 229).  Humans have at least nine functional NaV α subunits 
(NaV1.1–NaV1.9) that mediate specialized physiological processes in different tissues and 
electrically excitable cell types.  Dissecting the physiological roles of individual subtypes has 
been hampered in the past because multiple individual NaV subtypes often co-localize and 
their central α subunits are structurally similar.  The latter aspect in particular has also made it 
difficult to develop highly NaV-specific and subtype-selective modulators that could be used 
as molecular probes or as potential therapeutics in NaV-related diseases. 
Molecules modulating the activity of NaVs are abundant in the venoms of cone snails, spiders 
and scorpions and are noteworthy for their high potency and selectivity for individual NaV 
isoform (230).  These small disulfide-rich peptides bind to NaVs with high affinity and can 
interfere with specific steps of the NaV gating mechanism; for example, by occluding the 
central pore or by interacting with one or more of the four voltage-sensing domains (VSDs) 
that control channel opening and closing. 
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Using a range of NaV modulators and knock-out animals, an important role for NaV1.6 in 
multiple peripheral pain pathways was demonstrated, particularly those involved in mediating 
cold and mechanical allodynia (213).  Further exploration of the role of NaV1.6 in pain 
pathways and evaluation of NaV1.6 as a potential therapeutic target hinge on the availability of 
advanced molecular tools or model systems such as NaV1.6 knock-out animals (that are not 
viable) and/or NaV1.6-selective molecular probes.  In the above-mentioned studies, the long-
chain scorpion β-toxin Cn2 from Centruroides noxious proved especially useful in dissecting 
the roles of the individual NaV isoforms in vivo because of its potent (213) and highly selective 
activation of NaV1.6 (112).   
These pharmacological properties make Cn2 a promising candidate for development of 
advanced NaV1.6-selective molecular probes, particularly fluorescent analogues (for 
cell/animal-based localization experiments or biophysical receptor studies) as well as variants 
with altered mechanism of action to explore their effect on NaV1.6 physiology.  For example, 
Gurevitz and co-workers reported mutant scorpion β-toxin analogues of Css4 and Bj-xtrIT that 
showed complete or partial loss of activity on NaV gating, but retained channel binding 
activity (231, 232).  This was achieved by substituting glutamate 15, which is highly 
conserved across scorpion β-toxins (including Cn2), with arginine (E15R). Furthermore, β-
scorpion toxins have been successfully tagged to fluorescent molecules such as the boron-
dipyrromethene molecule (Bodipy) (233). Bodidy fluorophores are relatively inert molecules 
that have a narrow emission spectra making them ideal for physiological studies (234). 
Manipulating selective peptides for reduced or altered activity at their targets is a pathway for 
creating selective antagonists.  This is an important aim, as there are few NaV1.6 selective 
inhibitors currently reported.  The tetrodotoxin metabolite 4,9-anhydro-TTX is reported to 
inhibit NaV1.6 selectively with an IC50 = 7.8 nM compared with the next most potent, NaV1.3 
IC50 = 314 nM (235).  However, others have failed to reproduce this result and equipotent 
interactions with NaV1.4 and NaV1.5 have been described (236).  The µ-conotoxin GIIIA 
(isolated from Conus geographus) has been used to isolate NaV1.6 pharmacologically in vivo 
(213, 214).  In rank order potency, GIIIA inhibits NaV1.1, NaV1.4, NaV1.6 and NaV1.2 (237).  
However, when tested in vivo in conjunction with the µ-conotoxin TIIIA (NaV1.4/1.1/1.2) the 
relative effect of NaV1.6 block can be assessed (214).  This method highlights the need for 
potent and selective antagonists of NaV1.6, however in their absence, this approach remains 
valuable. 
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To realize the envisioned NaV1.6 selective analogues, we developed a total chemical synthesis 
approach that permits multi–milligram scale production of the relatively complex (66 amino 
acid residues) wild-type Cn2 as well as variants thereof.  One fluorescently labelled Cn2 
molecule resulting from this work retained the exquisite NaV1.6 selectivity of the wild-type 
toxin and is superior in fluorescence imaging studies when compared to commercially 
available monoclonal antibodies.  Detailed pharmacological analysis of Cn2[E15R] 
demonstrate the absence of characteristic -scorpion like effects on NaV1.6-modulation in 
vitro.  I expect these probes and the developed methodologies to be powerful tools for probing 
the structure, function and underlying physiology of NaV1.6. 
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2.3 Methods 
 
2.3.1 Materials  
Cn2 reference material, isolated from the venom of C. noxius Hoffmann, was a generous gift 
from Lourival Possani (Institute of Biotechnology, National Autonomous University of 
Mexico). 4,9-anhydro-TTX and veratridine were purchased from Focus Biomolecules (USA) 
and Alomone labs (Jerusalem, Israel) respectively. Peptides were routinely diluted in 
physiological salt solutions with 0.1% bovine serum albumin in order to avoid adsorption to 
plastic. Unless otherwise specified, other reagents were purchased from Sigma Aldrich, 
Australia. 
2.3.2 Peptide synthesis 
The follow peptides were synthesized by Dr Thomas Durek and Panumart Thongyoo.  
Peptides were synthesized by solid-phase peptide synthesis (SPPS). Peptide α-thioalkylesters 
corresponding to Cn2[1−28]-α-thioester (KEGYLVDKNTGCKYECLKLGDND-YCLRE-[S-
CH2-CH2-CO]F), Cn2[1−28,E15R]-α-thioester (KEGYL-
VDKNTGCKYRCLKLGDNDYCLRE-[S-CH2-CH2-CO]L) were assembled by manual in situ 
neutralization Boc SPPS on pre-loaded PAM polystyrene resins as described recently (238).  
Cn2[29-66] (CKQQYGKGAGGYCYAFACW-CTHLYEQAIVWPLPNKRCS-NH2) was 
assembled by automated Boc SPPS on a CSBio peptide synthesizer using MBHA polystyrene 
resin and standard protocols.  The following side chain protecting groups were employed: 
Arg(Tos), Asp(OcHex), Asn(Xan), Cys(4-MeBzl), Glu(OcHex), Gln(Xan), His(Bom), 
Lys(2Cl-Z), Ser(Bzl), Thr(Bzl), Trp(Hoc) and Tyr(2Br-Z).  After chain assembly, peptides 
were side chain-deprotected and simultaneously cleaved from the resin by treatment with 
anhydrous HF containing 10% (v/v) p-cresol and 5 eq. of Cys-OEt (per equivalent of 
His(Bom) residues) for 1 h at 0ºC. HF was evaporated under reduced pressure.  The crude 
product was precipitated and washed with chilled diethylether, then dissolved in 50 % (v/v) 
aqueous acetonitrile containing 0.1 % trifluoroacetic acid (TFA) (v/v) and lyophilized.   
Peptides were purified by reversed-phase high-performance liquid chromatography (RP-
HPLC) using preparative Vydac C8 (22 × 250 mm), semi-preparative Zorbax C3 (10 × 250 
mm) and analytical Zorbax C18 (4.6 × 50 mm) columns.  Preparative and semi-preparative 
peptide purifications were performed on Shimadzu Prominence LC-30AT HPLC system using 
Phenomenex C18 RP-HPLC (21.2×250 mm, 15 μm, 300 Å) or Agilent C18 RP-HPLC 
(9.4×250, 5 μm, 300 Å) columns.  Crude peptides were dissolved in a 10 % (v/v) 
acetonitrile/water mixture containing 0.05 % (v/v) TFA, before being loaded onto the column 
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pre-equilibrated with 10 % of solvent B (90:10:0.1 – acetonitrile:water:TFA) in solvent A (0.1 
% (v/v) TFA in water).  Peptides were eluted using linear gradients of solvent B in solvent A, 
and fractions were collected across the expected elution time.  
Peptide purity and identity were assessed by HPLC on a Shimadzu Nexera LC-30AD uHPLC 
system equipped with an Agilent 300SB-C18 column (2.1×50 mm, 1.8 µm, 300 Å) by using a 
linear gradient of 15-45% of buffer B in buffer A over 12 min at 50C.  Electrospray ionization 
mass spectrometry (ESI-MS) was performed on Shimadzu LCMS-2020 system or on a 
Shimadzu Nexera uHPLC coupled with an AB SCIEX 5600 mass spectrometer equipped with 
a Turbo V ion source.  Matrix-Assisted Laser-Desorption Ionization-Time of Flight (MALDI)-
TOF was conducted on an Applied Biosystems 4700 TOF/TOF Proteomics Analyzer using α-
cyano-4-hydroxycinnamic acid (CHCA) as a matrix (8 mg/mL in 75% (v/v) acetonitrile, 
0.05% (v/v) formic acid in water.  Cn2[1−28]-α-thioester observed mass 3505.6 ± 0.4 Da, 
calculated mass (average isotope composition) 3505.9 Da; Cn2[1−28, E15R]-α-thioester 
observed mass 3498.8 ± 0.4 Da, calculated mass 3498.9 Da; Cn2[29-66] observed mass 
4343.4 ± 0.5 Da, calculated mass 4344.0 Da.  Fractions containing the desired product were 
pooled, lyophilized and stored at –20ºC. 
2.3.3 Peptide ligation and folding 
We dissolved 25 mg of Cn2[29-66] MW: 4344.0, 5.8 μmol) and 22.9 mg of Cn2[1-28]-α-
thioester, MW: 3505.9, 6.9 μmol) in 4 mL of ligation buffer (6M guanidinium HCL 
(GdmHCl), 200 mM Na-phosphate, 50 mM 4-mercaptophenylacetic acid (MPAA), 50 mM 
TCEP, pH 7.1).  After dissolution, the pH was re-adjusted to 6.9–7.0 and the mixture stirred 
under an argon atmosphere for 18 h.  The reaction was quenched by adding TFA to a final 
concentration of 2% (v/v) and the product isolated by preparative HPLC (isolated yield: 20.0 
mg, 2.6 μmol (44.8%); Cn2[1-66] observed mass 7596.0 ± 1.0 Da, calculated mass 7596.7 Da 
(average isotope composition, ESI-MS).  
20 mg (2.6 μmol) of reduced Cn2 was dissolved in 5 mL of 6 M GdmHCl (pH ~ 5) to give a 
final peptide concentration of 4 mg/mL.  The peptide solution was then added to 100 mL of 
oxidation buffer consisting of 100 mM Tris, 1.5 M GdmHCl, 10 mM reduced L-glutathione 
(GSH), 1 mM oxidized L-glutathione (GSSG), pH 8.1.  Oxidation was performed at 22°C, 
monitored by HPLC and found to reach equilibrium after 72 hours.  2 mL of TFA was added 
to the oxidation mixture and the folded Cn2 purified by semi-preparative HPLC.  Isolated 
yield: 6.5 mg, 0.8 μmol (30.8%).  Cn2 observed mass 7588.3 ± 1.0 Da, calculated mass 7588.7 
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Da (average isotope composition).  High-resolution MALDI-MS: Cn2 observed MW: 7584.41 
± 0.2 Da (M+H+); calculated MW: 7584.49 Da (M+H+, most abundant isotope composition). 
Cn2 (E15R) and Cn2 (Q54Pra) were prepared via the same protocol used for wild type toxin 
and afforded the analogs in similar yields (30-40% isolated yield for final folding step).  High 
resolution ESI-MS: Cn2 [E15R] observed MW: 7610.62 ± 0.2 Da; calculated MW: 7610.55 
Da (most abundant isotope composition); Cn2 (Q54Pra) observed MW: 7555.5 ± 0.2 Da; 
calculated MW: 7555.7 Da (average isotope composition). 
2.3.4 NMR spectroscopy 
Lyophilized Cn2 samples were dissolved in 90% H2O/10% D2O at a concentration of 0.2 mM 
and a pH of 3.6. Spectra were recorded at 303 K on a Bruker Avance 600 MHz spectrometer 
equipped with a cryogenically-cooled probe.  Phase-sensitive mode using time-proportional 
phase incrementation for quadrature detection in the t1 dimension was used for all two-
dimensional spectra.  Excitation sculpting with gradients was used to achieve water 
suppression.  NMR experiments included TOCSY using a MLEV-17 spin lock sequence with a 
80 ms mixing time, and NOESY with a 200 ms mixing time.  Spectra were recorded with 4096 
data points in the F2 dimension and 512 increments in the F1 dimension.  The t1 dimension was 
zero-filled to 1024 real data points, and the F1 and F2 dimensions were multiplied by a sine-
squared function prior to Fourier transformation.  The spectra were referenced to water at 
4.715 ppm (303 K).  All spectra were processed using TopSpin (Bruker) and manually 
assigned with CCPNMR using the sequential assignment protocol (239, 240). 
2.3.5 Amine-labeling of Cn2 with Alexa488 
Labeling of synthetic Cn2 with the amine-reactive Alexa Fluor 488 sulfodichlorophenyl ester 
dye (Life Technologies, Australia) was performed in 100 mM sodium bicarbonate, pH 8.5-9.0 
at a peptide concentration of 60 M.  Two equivalents of dye dissolved in DMSO were added 
and the reaction was allowed to proceed for 2 hrs at room temperature.  The reaction was 
quenched by adding TFA to a final concentration of 10% (v/v), and the mixture was purified 
by RP-HPLC.  Fractions containing mono-acylated product, as identified by MALDI-MS, 
were lyophilized and used in all future experiments.  
2.3.6 Click-chemistry labeling of Cn2 [Q54Pra] with Bodipy 
Labelling of Cn2 [Q54Pra] was carried out via a slightly modified procedure, published 
previously(241).  Freshly prepared reaction buffer (1.0 M GdmHCl, 0.2 M Tris, 40 mM 
TCEP, 75 mM Cu(II)SO4) was heated at 80 °C for 10 minutes.  The mixture was cooled to 
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room temperature and the pH was adjusted to 8.5 resulting in a colour change from blue to 
purple.  Subsequently, 1mL of this buffer was mixed with 24.8 µl of a 2 mM Cn2 [Q54Pra] 
solution (in 50% acetonitrile/water, 0.375 mg, 49.63 nmol) and 2.3 µl of a 54 mM BODIPY 
FL azide (Lumiprobe, Germany) solution (in acetonitrile, 0.046 mg, 124 nmol).  The mixture 
was left at room temperature for 3 hrs and then purified via preparative HPLC.  Collected 
fractions were analysed by uHPLC-MS, and fractions containing the desired product were 
pooled and lyophilized (Yield: 0.35 mg (44.13 nmol; 88.9%). Cn2[Q54Pra-Bodipy] observed 
MW: 7928.9 ± 0.5 Da; calculated MW: 7929.8 Da (average isotope composition). 
2.3.7 Cell culture 
Human embryonic kidney (HEK) cells with constitutive expression of NaV isoforms 1.1-1.8 
were purchased from Scottish Biomedical (Glasgow, Scotland).  Cells were maintained in 
minimal essential media (MEM) (Sigma-Aldrich, Australia) supplemented with 2mM L-
glutamine and 10 % foetal bovine serum (FBS) (Assay Matrix, Ivanhoe, Australia).  Cell lines 
were cultured with appropriate selection antibiotics; blasticidin and G418 for NaV1.1, 1.2, 1.3, 
1.5, 1.6, 1.7 and 1.8; blasticidin, G418 and zeocin for NaV1.4.  Each cell line was grown in 
37°C in a humidified 5% CO2 incubator to 70-80% confluence, passaged every 3-4 days with 
TrypLE Express (Invitrogen).  
2.3.8 High-throughput fluorescent assay 
The activity of Cn2 at NaV1.1-NaV1.8 was assessed using a FLIPRTetra fluorescent membrane 
potential assay as previously described (242, 243).  In brief, HEK293 cells stably expressing 
human NaV isoforms NaV1.1-NaV1.8 were plated on 384-well plates at a density of 10,000 – 
15,000 cells per well in normal growth medium (Minimal Essential Medium (MEM; Sigma-
Aldrich, Australia).  After 48 h culture at 37oC/5 % CO2, growth medium was replaced with 
20 µL of red membrane potential dye prepared in physiological salt solution (composition (in 
mM): NaCl (140), glucose (11.5), KCl (5.9), MgCl2 (1.4), NaH2PO4 (1.2), NaHCO3 (5), CaCl2 
(1.8), 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid (10), pH 7.4) according to the 
manufacturer’s instructions and cells were incubated for 30 minutes at 37oC.  Changes in 
fluorescence (excitation: 510-545 nm, emission: 565-625 nm) after addition of native and 
synthetic Cn2 were measured every second for 300 s using a FLIPRTetra fluorescent plate 
reader (Molecular Devices, Sunnyvale, CA) and analysed using ScreenWorks 3.1.1.4 
(Molecular Devices).  Inhibition of NaV responses by 4,9-anhydro-TTX was assessed by 
incubating the cells with 4,9-anhydro-TTX for 5 minutes before addition of the NaV activator 
veratridine (60 µM). Fluorescent responses measured as above. 
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To assess the selectivity of Cn2 [E15R] a no wash sodium dye assay was developed.  Briefly, 
cells were plated as above and growth media was replaced with Asante NaTRIUM Green-2 
(ANG-2, 20µL, 10 µM, Abcam) and the food dye Ponceau-4R (1 mM) acting as a quencher. 
Cells were then incubated in the dark at 37oC for at least 30 minutes. Following this the 
FLIPRTetra was used to measure change in fluorescence (excitation 470–495 nm, emission 
515–575 nm) every 1 s post compound addition, and analysed using Screenworks. 
2.3.9 Electrophysiology 
The effect of Cn2 and analogues was assessed in whole-cell recordings under voltage-clamp 
conditions using a QPatch 16-well automated electrophysiology platform (Sophion 
Bioscience, Ballerup, Denmark) and 16-well planar chip plates (Qplates, Sophion) with 
resistance of 2 ± 0.02 MΩ and diameter of 1 μm.  HEK293 cells expressing human NaV1.6 
were expanded in normal growth media into a T175 flask 48hrs prior to experiment and 
maintained at 37°C in humidified 5% CO2.  At 70-80% confluence, cells were washed twice 
with Dulbecco’s phosphate-buffered saline prior to harvesting with 1 mL DetachinTM.  Finally, 
cells were resuspended in 3 ml Ex-Cell ACF CHO media supplemented with 25 mM HEPES 
(Sigma-Aldrich, NSW, Australia) and placed on the Qpatch’s Qstirrer for 30 minutes prior to 
the assay.  Positioning pressure was set at -60 mBar, holding potential -100 mV, minimum seal 
resistance 0.1 GΩ, holding pressure -20 mBar and currents were filtered at 25 kHz (8th order 
Bessel, cut off 5 kHz).  
Extracellular solution contained (in mM): NaCl 145, KCl 4, CaCl2 2, MgCl2 1, HEPES 10 and 
glucose 10; pH 7.4; osmolarity 305 mOsm.  The intracellular solution contained (in mM): CsF 
140, EGTA/CsOH 1/5, HEPES 10 and NaCl 10; pH 7.3 with CsOH; osmolarity 320 mOsm.  
Cells were incubated for 5 minutes before voltage protocols with working concentrations of 
peptides which were diluted in ECS containing 0.1% bovine serum albumin (BSA).   
All protocols contained a pre-pulse to 0 mV and 120 ms recovery at the holding potential to 
allow toxin binding and voltage sensor trapping consistent with previously described protocols 
(102).  Current (I) – voltage (V) relationship before and after toxin application was assessed as 
follows, cells were held at -100 mV, (50 ms recovery) test pulses were recorded for 50 ms 
between -90 mV and +55 mV in 5 mV increments followed by depolarisation to -10mV to 
assess the voltage dependence of fast inactivation. 
2.3.10 Immunohistochemistry 
NaV.1.1-1.8 expressing HEK293 cells were plated in normal growth media on 12 mm glass 
coverslips previously coated with poly-D-lysine (PDL) and allowed to grow for 24 hours in 12 
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well plates.  Cells were then washed 5 times with Dulbecco’s Phosphate-buffered saline 
(DPBS) before being fixed with 50:50 methanol/acetone for 20 minutes at -20 °C.  Cells were 
incubated in blocking solution containing 3% Donkey serum (Sigma Aldrich, Australia) 3% 
BSA and 0.1% Triton x100 in PBS for 1 hr at RT.  Cells were then incubated overnight at 4 
°C with polyclonal rabbit anti-NaV1.6 (1:500 in blocking solution; Abcam, Australia).  Cells 
were washed 5 times in DPBS.  Secondary antibody Alexa-fluor donkey anti-rabbit 488 
(1:1000 in blocking solution) and coverslips were incubated for 2 hours at RT.  Cells were 
prepared as above for staining with Cn2-488.  Cn2-488 was diluted in blocking solution (100 
nM) and incubated with fixed cells for 1 hr at room temperature.  All cells were co-stained 
with DAPI (1 ug/mL, Sigma Aldrich, Australia).  Coverslips were mounted onto slides and 
imaged with an Olympus BX51 upright fluorescent microscope. 
2.3.11 Data analysis and statistics 
Values from the fluorescence-based assay were corrected to a negative control and normalised 
to a response over baseline (10s prior to addition of compound) using ScreenWorks 3.2.1.14.  
Agonist concentration-response curves were assessed by area under the curve after addition 
plotted against log concentration.  For antagonists, the maximum antagonist response after the 
addition of an agonist was plotted against the log concentration.  GraphPad Prism (Version 
7.00, San Diego, California) was used to fit a 4-parameter Hill equation with variable Hill 
slope to the data.  All data, unless otherwise stated, are expressed as the mean ± standard error 
of the mean (SEM). 
For electrophysiology experiments, the conductance-voltage relationships were obtained for 
voltage sweeps using G = I/(V-Vrev), Vrev being the reversal potential.  Resulting data was 
fitted using a Boltzmann equation: GNa = GNa,max/1 + exp [(Vm – V1/2) / k] in GraphPad Prism; 
GNa is the voltage dependent sodium conductance, GNa,max is the maximal sodium 
conductance, Vm the membrane potential and k is the slope factor.  Voltage dependence of fast 
inactivation was calculated by dividing the test current (I) by the peak current (Io).  Statistical 
analysis was performed using GraphPad Prism (Version 7.00, San Diego, California) and 
significance was defined as p < 0.05 and was determined using unpaired and paired Students t-
tests.  
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2.4 Results  
 
2.4.1 Synthesis of putative NaV1.6 selective molecules 
Scorpion β-toxin Cn2 is a polypeptide of 66 amino acid residues that is C-terminally 
carboxamidated and adopts a cysteine-stabilized  fold that is stabilized by four disulfide 
bonds (111, 244).  Although heterologous expression is a viable option for obtaining such 
molecules on a preparative scale, the range of modifications envisioned, including abiotic 
fluorophores, prompted us to pursue a total chemical synthesis strategy which permits full 
control over the Cn2 structure (245). 
We initially attempted chemical synthesis of the full-length wild-type Cn2 polypeptide by 
optimized Fmoc solid-phase peptide synthesis.  A trial TFA deprotection with concomitant 
peptide cleavage from the resin was conducted after coupling of Cys29 to evaluate peptide 
assembly.  HPLC-MS analysis of the crude cleavage product indicated significant amounts of 
truncation and deletion side products, which prompted us to revise our initial plan to a 
fragment-based ligation strategy.  Thus, the full-length sequence was initially divided into two 
polypeptide segments, Cn2(1-28) and Cn2(29-66), which were joined by native chemical 
ligation (NCL) at Glu28 and Cys29 (246, 247).  Chemical synthesis of the required Cn2(1-28)-
α-thioester fragment via optimized Boc-SPPS was straightforward and the chemical ligation 
with Cn2(29-66) proceeded smoothly, producing the full-length polypeptide in good overall 
yield (44.8%) (Figure S1-S4).  Folding and disulfide formation of the polypeptide required 
extensive optimization.  We found that guanidinium HCl at relatively high concentrations (1.5 
M) was essential during folding to prevent toxin from aggregating and precipitating, and 
relatively long folding times (72 h) were necessary to favour the native disulfide isomer and 
improve yields (Figure S7).  The synthetic toxin was isolated by RP-HPLC in acceptable 
yields (30.8 %) and its molecular weight, determined by high resolution MALDI-MS (7584.41 
± 0.3 Da, Fig. 1B), was found to be in excellent agreement with the theoretical value (7584.49 
Da; considering C-terminal amidation and formation of four disulfide bonds).  HPLC 
comparison of the purified synthetic Cn2 toxin with Cn2 toxin isolated from C. noxious 
venom under identical conditions revealed excellent agreement, suggesting that the correct 
disulfide isomer had been obtained (Figure S11).  Interestingly, HPLC analysis of both 
synthetic and native Cn2 samples at room temperature (23°C) indicated the presence of two 
slowly interconverting conformers, which coexist in a ratio of approximately 4:1.  As 
expected, this chemical exchange process is accelerated at higher temperatures (40°C, 50°C) 
leading to coalescence of the two conformer peaks (Figure S11).  The structural integrity of 
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synthetic Cn2 was further confirmed by 2D TOCSY and NOESY NMR spectroscopy, which 
allowed near complete assignment of backbone proton resonances.  Comparison of the 
determined Hα-chemical shift of each residue to the published values for venom-derived Cn2 
indicated excellent agreement, suggesting that the synthetic and venom-derived Cn2 
molecules are structurally identical (Figure 2.1C) (111). 
The corresponding Cn2 (E15R) mutant (hereafter Cn2[E15R]) was prepared using the same 
synthetic strategy used for wild-type toxin by replacing the N-terminal ligation fragment with 
Cn2(1-28, E15R)-thioester.  To equip Cn2 with fluorescent reporter groups, we explored two 
strategies: a) ‘random’ acylation of wild-type Cn2 using amine-reactive Alexa488 
sulfodichlorophenyl ester dye, and b) site-specific labelling using click chemistry as reported 
previously for scorpion toxin Ts1 (241).  As can be expected, the former strategy yielded a 
mixture of mono-acylated Cn2 together with small amounts of products carrying multiple 
acylation products. Tandem mass spectrometry (MS/MS) sequencing of tryptic peptide 
segments derived from the singly labelled fraction (hereafter referred to as Cn2-488) indicated 
further heterogeneity with fluorophore attachment sites at lysines 1, 8 and 13 of Cn2, which 
could not be individually resolved by RP-HPLC.  
For site-specific labelling of Cn2 we chose residue Gln54 as the conjugation site, because 
replacement of the structurally equivalent Trp50 in the related scorpion toxin Ts1 has 
previously been shown to not significantly affect its sodium channel activity (241).  To this 
end, Gln54 was replaced by Propargylglycine (Pra) to allow site-specific labelling with azide-
modified fluorophores via 1,3-dipolar cycloaddition (‘click’) chemistry in the final synthetic 
step (241).  Full length Cn2(Q54Pra) was prepared via a three-segment NCL strategy in an 
attempt to optimize synthesis of the challenging Cn2[29-66] fragment, by further splitting it up 
into two smaller segments (Cn2[29-45]-α-thioester and Cn2[46-66, Q54Pra], (see Figure S5, 
S6, S12 and Optimized Conditions).  The oxidized Cn2(Q54Pra) was obtained using the same 
folding protocol established for wild-type toxin and its correct 3D structure confirmed via 
NMR spectroscopy (Figure 2.1 C).  Subsequent labelling with BODIPY-azide in the presence 
of Cu(I) afforded Cn2-BODIPY in excellent isolated yield after HPLC purification (90%).  
With the designed Cn2 analogues in hand, we next set out to evaluate their pharmacological 
properties at human (h) NaV1.6.  
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Figure 2.1 Chemical synthesis of Cn2 by native chemical ligation.  
A) Synthetic scheme: i) native chemical ligation (6 M GdmHCl, 0.2 M sodium phosphate, 50 
mM 4-mercaptophenylacetic acid (MPAA), 50 mM TCEP, pH 7.1); ii) folding and disulfide 
formation (100 mM Tris, 1.5 M GdmHCl, 10 mM reduced L-glutathione (GSH), 1 mM 
oxidized L-glutathione (GSSG), pH 8.1). The inset shows the primary structure of Cn2, with 
cysteines in bold and the ligation site (Glu28-Cys29) underlined. B) uHPLC and MALDI-MS of 
the folded, synthetic wild-type toxin. C) NMR Hα-chemical shift analysis indicates correct 
folding of all synthetic analogs when compared to native, venom derived Cn2 (111). 
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2.4.2 Synthetic Cn2 is a selective activator of NaV1.6 
To assess the effect of synthetically produced Cn2 on NaV isoforms NaV1.1-1.8, the high-
throughput fluorescence imaging plate reader (FLIPR) was used as previously described (243).  
Native and synthetic Cn2 concentration-dependently activated NaV1.6-expressing HEK293 
cells with EC50s of 72 nM (pEC50 7.14 ± 0.91) and 15.8 nM (pEC50 7.81 ± 0.20) respectively 
(Figure 2.2 A).  In line with the native Cn2 peptide previously reported, synthetic Cn2 
(henceforth termed Cn2) at a concentration of up to 100 nM had no significant effect on 
sodium channel isoforms NaV1.1, NaV1.2, NaV1.3, NaV1.5, NaV1.7 and NaV1.8 (Figure 2.2 B).  
Activity at the muscle specific NaV subtype, NaV1.4 has not been reported for native Cn2 at 
concentrations of 300 nM (112).  However, our data show that the synthetic Cn2 is a weak 
agonist for NaV1.4 in the FLIPR assay (pEC50 = 7.4 ± 0.1).  However, at concentrations that 
alter the kinetics of NaV1.6 channels in vitro (see Figure 2.4 B), Cn2 has no effect on NaV1.4 
(Figure S13).  Collectively, these data suggest that synthetic and venom-derived wild-type 
Cn2 are structurally identical and retain pharmacological selectivity.  
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Figure 2.2 Native and synthetic Cn2 activate NaV1.6 in membrane potential assay  
A) Synthetic or venom-derived Cn2 elicited Nav1.6-mediated responses with EC50s of 15.8 
nM and 72 nM, respectively. B) Cn2 had little effect on sodium channel isoforms NaV1.1–1.5, 
1.7 and 1.8 at concentrations up to 100 nM but only elicited concentration-dependent changes 
in membrane potential in HEK293 cells expressing NaV1.6 (mean ± SEM from 2-3 
independent experiments). 
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2.4.3 Cn2[E15R] is a novel NaV1.6 partial blocker 
There are many selective blockers of NaV subtypes such as NaV1.7 and NaV1.8 reported, 
including small molecule inhibitors and those derived from animal venoms (160, 173).  
However, only one NaV1.6 selective inhibitor, 4,9-anhydroTTX, has been described (235).  
The metabolite of TTX was reportedly 40x more potent at NaV1.6 than the closest subtype 
(NaV1.3) assessed in Xenopus oocytes.  Thus, I sought to test 4,9-anhydro-TTX in our high-
throughput NaV membrane potential assay. 4,9-anhydro-TTX was slightly more potent at 
NaV1.6 compared to other TTX-S subtypes however, it was not selective for NaV1.6 (Figure 
2.3 B, C) in this assay. 
In the absence of a selective antagonist of NaV1.6 we turned our attention to the design of Cn2 
analogues with altered activity.  Gurevitz and colleagues have shown that substituting a 
conserved glutamate in -scorpion toxins Css4 or Bj-xtrIT with arginine (E15R) results in 
uncoupling of NaV-binding and NaV-activation (114, 231).  Specifically, Css4[E15R]
 retains a 
similar binding affinity to the native Css4 but without causing a hyperpolarising shift in 
activation (114, 248).  Thus, we generated Cn2[E15R] and verified the selectivity of this 
analogue for NaV1.6. Cn2[E15R] had no effect on NaV1.1, 1.2, 1.3, 1.5, 1.7 up to 2 µM while 
partially blocking NaV1.6 responses IC50 120 nM (pIC50 = 6.9 ±0.18) (Figure 2.3 A).  
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Figure 2.3 Cn2[E15R] but not 4,9-anhydro-TTX is a selective NaV1.6 inhibitor 
A) Cn2[E15R] has no effect of NaV1.1, 1.2, 1.3, 1.5, 1.7 but concentration-dependently blocks 
NaV1.6 responses with an IC50 of 120 nM (mean ± SEM from 2-3 independent experiments). 
B) 4,9-anhydro-TTX is a non-selective NaV blocker in the membrane potential assay. C) 
Tabulated pIC50 values for 4,9-anhydro-TTX demonstrate small increase in potency at NaV1.6 
over other TTX-S isoforms (mean ± SEM from 2-3 independent experiments).  
 
  
A B C 
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2.4.4 Cn2 retains β-scorpion mechanism of action  
Although synthetically produced Cn2 retains the selectivity of the native toxin, the FLIPR 
assay cannot provide mechanistic insight.  Thus, I sought to test the electrophysiological 
properties of NaV1.6 in the presence of Cn2.  β-Scorpion toxins bind to site-4 on NaVs, which 
has been mapped to the S3-S4 linker of domain II of the NaV -subunit (229).  Binding causes 
a hyperpolarising shift in the voltage dependence of channel activation (80, 102, 112, 113).  To 
assess whether synthetically produced Cn2 retains these properties, we made whole-cell patch 
clamp recordings from HEK293 cells expressing hNaV1.6.  Cn2 causes a concentration-
dependent decrease in peak current (obtained by recording resultant currents at pulses to -10 
mV) with an EC50 of 61 nM (pEC50 7.2 ± 0.1) (Figure 2.4 A, Figure S14).  This value is in 
agreement with the predicted EC50 from Schiavon et al., 39.2 ± 3.7 nM (112).  To test for the 
typical shift in the voltage dependence of activation associated with β scorpion toxins, current-
voltage (I-V) curves were generated.  This protocol includes a depolarising prepulse to 0 mV 
in order to facilitate channel opening and toxin binding as described by the voltage sensor 
trapping model (102).  Indeed, in the presence of 10 nM Cn2, sodium current was observed at 
previously prohibitive potentials (Figure 2.4 B, inset, D), with significantly increased current 
at pulses between -60 to -40 mV (p < 0.05; paired t-test).  In contrast, Cn2 (10 nM) decreased 
current between potentials -10 mV and +50 mV, with peak whole cell current elicited by a 
pulse of 0 mV decreased by 47.3 ± 0.1%.  The V1/2 of NaV1.6 activation for Cn2 treated cells 
(-24.1 ± 0.8 mV) was not significantly different from control (-24.4 ± 0.3 mV) (Figure 2.4 C).  
However, Cn2 significantly increased the slope factor at NaV1.6 (control: 4.8 ± 0.3; Cn2: 8.2 ± 
0.8, p < 0.05) leading to a higher conductance at more hyperpolarised membrane potentials. 
Cn2 (10 nM) also caused a depolarising shift in the V1/2 of NaV1.6 steady-state fast 
inactivation (ΔV1/2: +10.2 mV) (Figure 2.4 C), which in combination with a shallower 
activation slope, led to an increase in window current.  In effect, there was a ~20% increase in 
channel availability at -35 mV in the presence of Cn2 compared with control.  This excitatory 
(activating) Cn2 effect is coupled to a depressant activity as evidenced by the concomitant 
reduction in peak sodium conductance.  
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Figure 2.4 Effect of synthetic Cn2 on the electrophysiological properties of hNaV1.6. 
A) Cn2 elicits a concentration-dependent increase in current elicited at -50 mV and subsequent 
concentration-dependent decrease in peak current in HEK293 cells expressing NaV1.6/β1. 
B) Current-voltage relationship in the absence (black) and presence of 10 nM Cn2 (grey). 
Protocol includes depolarising prepulse to 0mV to allow toxin binding from -100 mV holding 
potential followed by 120ms recovery before 50ms test pulse. All data normalized to peak 
current amplitude of control.  Inset, Cn2 causes a significant shift of the voltage dependence of 
activation (*= p < 0.05, paired t-test) (n = 5). C) Voltage dependence of activation (G/V) and 
steady-state fast inactivation (I/Imax) of hNaV1.6 in the absence (black) and presence of 10 nM 
Cn2 (grey) derived data obtained from (B), fitted with single Boltzmann relationship (solid 
line). Control V1/2 activation of hNaV1.6 was in the absence -24.3 ± 0.3 mV and presence -24.5 
± 0.8 of 10 nM Cn2 (n = 5). Cn2 shifts the V1/2 inactivation ( +10.2 mV). D) Representative 
trace of the effect of Cn2 on whole cell current in hNaV1.6 expressing cells depicting 
concentration dependent current at previously prohibitive potentials. Inset voltage protocol as 
described above.  
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2.4.5 Cn2[E15R] no longer alters activation kinetics 
The electrophysiological effects of Cn2[E15R] on hNaV1.6 were evaluated at a toxin 
concentration of 200 nM because preliminary studies indicated that at this concentration 
hNaV1.6 sodium current is inhibited by approximately 50%.  In contrast to Cn2, 200 nM 
Cn2[E15R] did not elicit current at previously prohibitive potentials, but led to a depolarising 
shift in the voltage-dependence of activation (Figure 2.5 A, B, C) (V1/2: control -17.4 ± 0.2 
mV; 200 nM Cn2[E15R], -11.4 ± 0.6 mV).  In addition, Cn2[E15R] significantly increased the 
slope factor at NaV1.6 (control: 5.0 ± 0.2; Cn2 7.9 ± 0.6, p < 0.05), reducing conductance at 
more depolarised membrane potentials without changing conductance at hyperpolarised 
potentials.  In line with these observations, Cn2[E15R] at 200 nM decreased peak current by 
42.4 ± 1.5%.  The V1/2 of steady-state fast inactivation of NaV1.6 was not significantly 
changed in the presence of 200 nM Cn2[E15R], but a proportion (~25%) of the Cn2[E15R] 
treated channels resisted inactivation altogether as evidenced by the current elicited at pulses 
between -40 and 0 mV (Figure 2.5 B). 
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Figure 2.5 Cn2[E15R] does not negatively shift the voltage-dependence of activation of 
NaV1.6 
A) Current - voltage relationship hNaV1.6, control (black) and 200 nM Cn2[E15R] (grey).  
Unlike wild type toxin, Cn2[E15R] does not induce current at –40 mV test pulse (inset). 
B) Voltage dependence of activation and steady-state fast inactivation of hNaV1.6 in the 
absence (black) and presence of 200 nM Cn2[E15R] (grey).  V1/2 activation of hNaV1.6 was -
17.4 ± 0.2 mV in the absence and -11 ± 0.7 mV in the presence of 200 nM Cn2[E15R] (each n 
= 6). V1/2 inactivation control -56.8 ± 0.8 mV and Cn2[E15R] and -60.2 ± 1.4 mV. 
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2.4.6 Electrophysiology properties of NaV1.6 fluorescent probes 
The fluorescently labelled analogue Cn2-488 displays kinetics similar to Cn2; including a shift 
in the voltage-dependence of activation, allowing current at hyperpolarised potentials (-55 
mV) (Figure 2.6 A).  Like Cn2, V1/2 activation was not significantly altered -24.17 mV in 
control and -22.96 mV in the presence of EC50 concentration of Cn2-488 (50 nM) (Figure, 2.6 
B).  Conversely, at 50 nM Cn2-488 did not significantly decrease peak NaV1.6 current. At this 
concentration the slope factor was also not significantly altered; control 5.0 ± 0.4 and Cn2-488 
5.8 ± 0.7. However, at 300 nM, Cn2-488 peak current was decreased by approximately 35% 
and the slope factor was significantly increased (Figure S16, 5.0 ± 0.3 control, Cn2-488 10.4 ± 
0.9) 
The activity of Cn2-Bodipy (100 nM) was similar to the wild-type toxin.  This includes early 
channel opening in the presence of Cn2-Bodipy at pulses to -50 mV.  Cn2-Bodipy did not shift 
the V1/2 activation -26.6 ± 0.6 mV control; -27.3 ± 0.9 mV Cn2-Bodipy.  In addition, although 
the slope factor of Cn2-Bodipy treated cells trended towards increasing (4.6 ± 0.5 control and 
6.7 ± 0.8 Cn2-Bodipy) it did not reach significance (Figure 2.6 E).  In spite of this, NaV1.6 peak 
current was decreased by 49 ± 6.1 % (Figure 2.6 D). This decrease in peak current is line with 
the wild-type Cn2 peptide (55 ± 5.6%).  
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Figure 2.6 Effect of Cn2-488 and Cn2-Bodipy on the electrophysiological properties of 
NaV1.6  
A) Current - voltage relationship in the absence (black) and presence of 50 nM Cn2-488 
(grey). Protocol as previously described (Section 2.4.4). All data normalized to peak current 
amplitude of control. Inset, Cn2-488 causes a significant shift in the voltage dependence of 
activation (* = p < 0.05, paired t- test) (n = 4). B) Voltage dependence of activation of 
hNaV1.6 in the absence (black) and presence of 50 nM Cn2-488 (grey). V1/2 activation of 
hNaV1.6 was -24.2 ± 0.4 mV in the absence and -23 ± 0.7 in the presence of 50 nM Cn2-488 
(each n = 5). D) Current - voltage relationship in the absence (black) and presence of 100 nM 
Cn2-Bodipy (grey) with small current observed at hyperpolarised potentials. V1/2 activation of 
hNaV1.6 control, and 100 nM Cn2-Bodipy (n = 5-7). E) Voltage-conductance curve, control; 
V1/2 activation 26.6 ± 0.6 mV and Cn2-Bodipy; 27.3 ± 0.8 mV. C and F) Representative traces 
of early NaV1.6 channel opening caused by Cn2 elicited by pulses to -40 mV.  
A 
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2.4.7 Fluorescently labelled Cn2 as a NaV1.6 specific probe 
Fluorescently labelled probes have proved useful as tools for investigating receptor – ligand 
interactions (233, 249).  To assess whether the fluorescent Cn2 probe had maintained 
selectivity for NaV1.6, and to compare their performance to a commercially available 
polyclonal antibody directed against NaV1.6, immunohistochemistry of HEK293 cells with 
stable NaV expression was performed.  Commercial antibodies often require lengthy 
optimization steps.  In this study, the concentrations of primary antibody chosen were obtained 
from recommended range values given by the manufacturer. Abcam anti-NaV1.6 (1:500) and 
anti-rabbit AB (1:1000) conjugated to Alexa-488 stained all NaV subtypes excluding NaV1.5 
(Figure 2.7, top panel).  In contrast, application of 100 nM Cn2-488 for 1 hour at room 
temperature produced robust staining of NaV1.6 expressing cells, without appreciably staining 
other subtypes (Figure 2.7, lower panel).  NaV1.6 labelling with Cn2-488 was confirmed with 
confocal imaging (Figure S16).  Therefore, Cn2-488 retains selectivity and functional activity 
for NaV1.6.  Furthermore, the rapid protocol for staining with Cn2-488 presents a convenient 
alternative to traditional immunohistochemistry.  Interestingly, unlike Cn2-488, Cn2-Bodipy 
did not selective stain NaV1.6 expressed in HEK293 cells (Figure S17).  
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 1 
Figure 2.7 Cn2-488 is a selective fluorescent probe for NaV1.6 2 
Top panel, non-selective binding of Abcam anti-NaV1.6 (1:500) and Alexa-fluor anti-rabbit 3 
488 (1:1000) to hNaV1.1-1.8 stably expressed in HEK293 cells (60X objective). Bottom panel, 4 
selective binding of 100 nM Cn2-488 to NaV1.6 (100X objective). All nuclei stained with 5 
DAPI (1 ug/mL).6 
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2.5 Discussion  
 
The history of NaV channels has shown that scorpion  and  toxins are valuable molecular 
probes for studying the complex gating mechanisms of these ion channels.  Traditionally, 
these toxins have been obtained by isolation from crude animal venom or through 
heterologous protein expression systems, but neither of these strategies permit extensive 
structural modifications to the toxin.  Native chemical ligation-based chemical synthesis of 
these relatively large polypeptide toxins (~60 AA) is an elegant and efficient way to produce 
homogenous material for structural and pharmacological studies and allows introduction of 
site-specific mutations and abiotic functionalities that, more recently, have permitted advanced 
biophysical studies of NaV channels (233, 250). 
The synthesis of Cn2 and its analogues Cn2[E15R] and Cn2(Q54Pra) by either a 2-segment or 
3-segment ligation strategy afforded good overall yields and high purity of the molecules.  
NMR analysis of all analogues and comparison to published chemical shifts for Cn2 isolated 
from scorpion venom (Figure 2.1 C) indicated that all molecules adopt the native cysteine-
stabilized  fold characteristic for toxins of this class.  Although minor chemical shift 
differences are observed in the vicinity of the introduced mutations (E15R and Q54Pra), this 
analysis demonstrates that these amino acid substitutions do not cause a significant change in 
the overall structure of the toxin.  Interestingly, evidence for a slow conformational exchange 
process was detected in folded synthetic and venom-derived Cn2 by HPLC analysis.  The 
molecular basis for this exchange process, which was not evident in NMR spectra presumably 
due to the low abundance of the minor conformer, has not been established.  However, it is 
traditionally ascribed to slow proline cis/trans isomerization, aromatic ring-flipping, or pro-
S/pro-R disulfide bond isomerization. 
Pharmacologically, synthetic Cn2 recapitulated the activity of venom-derived Cn2 in the 
FLIPR membrane potential assay, demonstrating potent and highly selective modulation of 
hNav1.6. Side-by-side comparison revealed a slightly higher potency of the synthetic toxin, 
possibly reflecting a higher purity of the chemically-synthesised material. Electrophysiology 
on HEK cells stably transfected with hNaV1.6/β1 demonstrated potent -toxin activity as 
evidenced by the observation of currents at otherwise prohibitive membrane potentials as well 
as by a significant increase in the slope factor of the steady state activation curves.  However, 
in our hands and contrary to previous reports, Cn2 did not induce a significant shift in V1/2 for 
hNaV1.6 activation (112).  Cn2 also caused a substantial reduction in peak sodium current and 
a significant rightward shift in the steady state fast inactivation curves.  The -toxin effects on 
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NaV gating have been explained by the voltage sensor trapping model, in which these toxins 
are believed to stabilize the activated state of the voltage-sensing domain II (VSDII) (102).  In 
contrast, the molecular basis for the reduction in macroscopic peak current (a hallmark feature 
of scorpion -toxins) has, to our knowledge, never been satisfactorily explained.  Tytgat and 
colleagues using -scorpion toxin Ts1 as an example, recently argued that this effect may be 
explained by a toxin-induced hyperpolarising (leftward) shift in the steady-state fast 
inactivation curve, indicating that channels fast inactivate at more negative potentials and 
effectively results in fewer channels being available for generating sodium currents (251).  
However, Cn2 causes a rightward shift in the fast inactivation curve (indicating increased 
resistance of Cn2-modulated NaV1.6 to fast inactivation) suggesting that other mechanisms 
may be responsible for the reduction in peak sodium current.  
Initially reported as a selective NaV1.6 antagonist (235), the tetrodotoxin analog, 4,9-anhydro-
TTX, was however not found to be a selective modulator in the high-throughput fluorescent 
assay (FLIPR).  Equipotent effects have been observed at NaV1.4 and NaV1.5 (236). The lack 
of selectivity may reflect that the binding site (site 1, within the pore region) is relatively 
conserved between the NaV isoforms.  Therefore, I envisaged the generation of a NaV1.6 
specific antagonist that binds to the more diverse voltage sensor region of the channel.  Some 
of the effects seen in wild-type Cn2 are significantly altered in the Cn2[E15R] mutant. In 
agreement with Gurevitz’s work, this mutation causes loss of some (but not all) of the -toxin 
effects observed in the wild type toxin: First, Cn2[E15R] does not activate NaV1.6 at 
otherwise prohibitive membrane potentials whereas wild-type Cn2 does (Figure 2.4 B and 
2.5 A).  Secondly, Cn2[E15R] causes a significant polarising (rightward) shift in the steady 
state activation curves, indicating that channels are more difficult to open (Figure 2.5 B).  
Thirdly, Cn2[E15R] does not shift the V1/2 of NaV1.6 channel inactivation (whereas wild-type 
Cn2 does), but a fraction (control 9.9% and Cn2[E15R] 26%) of Cn2[E15R]-modulated 
channels are refractory to fast inactivation.  In contrast, both Cn2 and Cn2[E15R] significantly 
reduce NaV1.6 peak current at nM concentrations (Figure 2.4 B, 2.5 A) indicating that some of 
the functional effects have been effectively uncoupled as a result of the single amino acid 
substitution.  Similar mechanistic uncoupling was previously observed for Css4/Css4[E15R], 
although the exact physiological effects of the Cn2/hNav1.6 and Css4/rNav1.2 systems are 
different (231). 
Although the excitatory -toxin effects on NaV gating have been satisfactorily explained by 
the voltage sensor trapping model (102), our findings are better rationalized by a ‘two-state 
voltage sensor trapping’ model proposed recently by Heinemann and colleagues to take into 
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account the depressant effects observed for many of these toxins (252).  In this model, Cn2 
binds with similar affinities to both the deactivated and activated conformations of VSDII, 
macroscopically giving rise to the observed excitatory and depressant effects. Our data for 
Cn2[E15R] demonstrate uncoupling of these activities, suggesting that at the molecular level 
the mutation destabilizes the activated VSDII:toxin complex while not significantly affecting 
the deactivated VSDII:toxin complex. 
Fluorescent analogues of Cn2 (Cn2-488 and Cn2-Bodipy) qualitatively retained the 
electrophysiological properties of the wild-type toxin, including hyperpolarising shifts in 
hNav1.6 steady-state activation curves and reduction of peak sodium conductance. Cn2-488 
showed slightly diminished potency in electrophysiological studies when compared to Cn2 
and Cn2-Bodipy.  This finding is perhaps not surprising given the heterogeneity caused by 
‘random’ acylation of surface exposed lysine residues, some of which may be in proximity to 
functionally important residues.  In this respect, site-specific conjugation as exemplified by 
total chemical synthesis of Cn2-Bodipy should be the strategy of choice to obtain a chemically 
well-defined product with minimal effects on activity.  Nevertheless, Cn2-488 retained the 
exquisite hNav1.6 selectivity of Cn2 in fluorescence imaging studies.  The toxin 
concentrations used in these studies (100 nM) are comparable to those used for commercially 
available anti-NaV1.6 antibodies (approximately 20 nM), however, in our hands the latter 
displayed substantial cross reactivity with other NaV subtypes.  While this could perhaps be 
further improved with extensive optimisation, poor performance of NaV antibodies has been 
observed previously (S. Waxman, personal communications, 2017).  Compared to antibodies, 
the rapid protocol for direct staining with Cn2-488 presents a convenient alternative to 
traditional immunohistochemistry. In addition, Cn2-488 may be suitable for live-cell imaging 
as the extracellular binding epitope could negate the need for cell permeabilisation.  However, 
this application would need to be explored in more detail in future studies.   
In spite of the site-specific conjugation strategy, Cn2-Bodipy failed to produce a reproducible 
selective fluorescent signal in HEK293 cells.  This might be due to the lipophilicity of the 
Bodipy tag which could result in non-selective binding to lipid membranes (253).  Peptide-
Bodipy conjugates have been used successfully to examine molecular details of NaV1.4 
channel gating by lanthanide-based resonance energy transfer (233).  Given the selectivity of 
Cn2 for NaV1.6 and the unique effects reported on resurgent current (112); Cn2-Bodipy might 
prove a more useful resource for mapping the structural changes associated with resurgent 
current gating.  
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In summary, we have successfully applied a native chemical ligation based synthetic strategy 
to gain access to uniquely modified analogues of the highly NaV1.6-selective scorpion toxin 
Cn2. Our data demonstrate that the excitatory and depressant activities can be uncoupled, 
suggesting that these effects are governed by distinct toxin pharmacophore residues. 
Furthermore, fluorescent peptides may be used to probe the distribution and gating of NaV1.6. 
This work paves the way for rational design of NaV inhibitors based on β-scorpion toxins, 
which so far have mainly been limited to a role as ‘molecular tools’ due to their potent NaV-
excitatory activity. We expect these molecules to be powerful probes for studying the 
physiological roles of NaV1.6 in health and disease. 
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Chapter 3 – Exploring the role of NaV1.6 in isolated dorsal root ganglion 
neurons 
 
 
3.1 Foreword 
 
This chapter aims to use the tool compound synthesised in Chapter 2 to assess the functional 
effects of NaV1.6 activation in isolated DRG neurons. This includes preliminary study using 
high-content Ca2+ imaging followed by in-depth exploration by whole-cell patch clamp 
electrophysiology of DRG neurons. In particular, I sought to confirm the selectivity of the Cn2 
peptide in a native neuronal environment.  Additionally, current clamp experiments provide 
the first observations of the effect of NaV1.6 activation in cultured sensory neurons.  The 
following results are based on a paper that has been accepted for publication in the Journal of 
Physiology. The structure has been edited and formatted to fit the style and flow of this thesis.  
Contributions made by other authors are stated in body of this chapter along with the thesis 
preliminary pages. 
 
 
3.2 Introduction 
 
Heterologous expression systems, such as those used in Chapter 2, are useful for the basic 
assessment of ion channel kinetics and allow the use of high-throughput platforms.  However, 
to determine the biophysical properties and physiological roles of NaV channels, it is important 
to consider function in a native context, as intracellular auxiliary proteins can modulate NaV 
channel kinetics (254).   
NaV1.6 is known to be expressed in several classes of DRG neurons, including large diameter 
peripheral sensory neurons where it is thought to be responsible for the fast upstroke of the 
action potential.  There is also direct evidence for the expression and activity of NaV1.6 in 
small diameter DRG neurons (133, 210).  However, as small diameter neurons express a range 
of TTX-S and TTX-R NaV isoforms, dissecting the relative functional contribution of each 
isoform to their signal transduction has been challenging.  Conditional knock-out of NaV1.6 
from NaV1.8 expressing small diameter neurons revealed a ~34% decrease in the current 
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density (220).  Corresponding to higher expression, in large diameter neurons the reduction in 
current density increases to > 50% (220).  Current clamp experiments from isolated small 
diameter DRG neurons confirm that a TTX-R isoform is responsible for the rising phase of the 
action potential (255, 256).  Contrastingly, compound action potential recordings from sciatic 
nerves of NaV1.6
-/- mice displayed 30% reduction in peak to peak amplitude (210). 
Additionally, NaV1.6 has many known binding proteins that change the channel’s kinetics, 
some of which are expressed in peripheral sensory neurons and that may alter the functional 
properties of the pore-forming α subunit (257-259).  For example, NaV beta (β) subunits which 
are differentially expressed in distinct sensory neuron populations affect α subunit gating (133, 
197, 260).  The NaVβ4 subunit is highly expressed in large diameter neurons (261) and there is 
conflicting evidence on its regulatory role on the NaV1.6 resurgent current (262, 263).  
Coexpressing NaVβ4 in HEK293 cells with NaV1.6 does not lead to the appearance of the 
resurgent current (212).  However, loss of NaVβ4 attenuates but does not completely abolish 
the resurgent current in Purkinje neurons (264).  
Thus, the proportional role of NaV1.6 in isolated, cultured peripheral sensory neurons remains 
inconclusive. The chemical synthesis of the β-scorpion toxin Cn2, a highly potent and 
selective activator of NaV1.6 channels allows further study of this isoform without the time 
consuming step of milking the animal for venom and fractionation (Chapter 2 and (112)).  
Therefore, equipped with Cn2 I sought to explore the effect of NaV1.6 channel activation in 
peripheral sensory neurons using high-content calcium imaging and whole-cell patch clamp 
electrophysiology. I confirmed that NaV1.6 activation by Cn2 caused premature channel 
opening in large diameter isolated mouse DRG neurons, an effect that was absent in NaV1.6 
-/- 
(SCN8Amed/med) DRG neurons.  Cn2 also enhanced persistent and resurgent current in these 
neurons, leading to a distinct repetitive action potential firing pattern.  The repetitive firing 
was absent in large diameter neurons from NaV1.6
-/- mice. Interestingly, early channel opening 
was absent in small diameter neurons. Furthermore, action potential characteristics were 
unchanged after Cn2 application, unequivocally confirming the selectivity of the toxin.  In 
summary, pharmacological isolation of NaV1.6 in peripheral sensory neurons confirms the 
functional expression of NaV1.6 in large diameter neurons and suggests that NaV1.6 plays a 
minimal role in the soma of small diameter DRG neurons. 
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3.3 Methods 
 
3.3.1 Materials  
Cn2 was synthesized as described in Chapter 2. Peptides were routinely diluted in 
physiological salt solutions with 0.1% bovine serum albumin in order to avoid adsorption to 
plastic. Unless otherwise specified, other reagents were purchased from Sigma Aldrich.  
3.3.2 Primary mouse DRG neuron isolation 
Mouse DRG isolation and culture was performed by Peng Zhao (Yale University).  DRG 
neurons from thoracic and lumbar regions were isolated from Nav1.6
-/- (SCN8Amed/med) mice 
(P11 - P17, both male and female) or C57BL/6 mice (4-8 wks old, both male and female) as 
previously reported (265). Brieﬂy, DRGs were harvested from homozygous mice, incubated 
at 37°C for 20 min in complete saline solution (CSS) [in mM: 137 NaCl, 5.3 KCl, 1 
MgCl2, 25 sorbitol,  3 CaCl2, and 10 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic  
acid (HEPES), adjusted to pH 7.2 with NaOH] containing 0.5 U/mL Liberase TM (Sigma) 
and 0.6 mM EDTA, followed by a 15-min incubation at 37°C in CSS containing 
0.5 U/mL Liberase TL (Sigma), 0.6 mM EDTA,  and 30 U/mL papain (Worthington 
Biochemical).  DRGs were then centrifuged and triturated in 0.5 mL of DRG media: 
Dulbecco's modified Eagle's medium-F12 (1:1) with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin (Invitrogen), and 10% fetal bovine serum (Hyclone), containing 1.5 mg/ml BSA 
(low endotoxin; Sigma) and 1.5 mg/ml trypsin inhibitor (Sigma).  After trituration, the cells 
were then diluted with DRG media containing 1.5 mg/mL BSA and 1.5 mg/mL trypsin 
inhibitor, seeded onto poly-D-lysine/laminin-coated coverslips (BD), and incubated at 37°C 
in a 95% air/5% CO2 (vol/vol) incubator for 45 min for neurons to attach to the coverslips.  
After 45 min, DRG media was added into each well to a final volume of 1.0 ml and the DRG 
neurons were maintained at 37°C in a 95% air/5% CO2 (vol/vol) incubator for 18-30 hrs 
before current-clamp or voltage-clamp recording.  For current-clamp recording culture, 
medium was supplemented with 50 ng/ml mouse nerve growth factor (mNGF) (Alomone 
Labs) and 50 ng/ml recombinant human glial cell line-derived neurotrophic factor (hGDNF) 
(PeproTech).  
Protocol for DRG isolation for calcium imaging was as follows: DRG neurons; at all spinal 
levels; from 4–8 week old male C57BL/6 mice were dissociated with collagenase; (1mg/ml 
for 90 minutes) and plated in DMEM (Gibco, MD, USA) containing 10% fetal bovine serum 
(FBS) (Assaymatrix, VIC, Australia) and penicillin/streptomycin (Gibco, MD, USA) on a 96-
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well poly-D-lysine-coated culture plate (Corning, ME, USA) and maintained for 20-24 hrs 
before assay. 
3.3.3 Calcium imaging of sensory neurons 
A Ca2+ imaging assay was performed by Dr Samuel Robinson (Institute for Molecular 
Bioscience).  DRG neurons were loaded with Fluo-4 AM calcium indicator and incubated for 
1 hour at 37oC (ThermoFisher Scientific, MA, USA). After loading (1 h), the dye-containing 
solution was replaced with assay solution (1x Hanks’ balanced salt solution, 20 mM HEPES).  
Fluorescence corresponding to [Ca2+]i of typically 100–150 DRG cells per experiment were 
monitored in parallel using an Nikon Ti-E Deconvolution inverted microscope, equipped with 
a Lumencor Spectra LED light source. Images were acquired at 20x objective at 1 frame per 
second (excitation 485 nm, emission 521 nm). For each experiment, baseline fluorescence was 
monitored for 30 s.  At 30, 60, 90 and 150 s, assay solution was replaced with assay solution 
(negative control), Cn2 (500 nM in assay solution), assay solution (wash) and KCl (30 mM in 
assay solution), respectively.  Cells responding to KCl and/or Cn2 were considered neuronal 
and grouped according to size: large (> 600 µm2), medium (300-600 µm2) and small diameter 
(< 300 µm2). 
3.3.4 Whole-cell patch clamp electrophysiology: voltage clamp  
Whole-cell electrophysiology recordings were obtained from mouse DRG neurons using an 
EPC-10 double amplifier and Patchmaster (HEKA Elektronik) software.  Voltage-clamp 
recordings were undertaken at room temperature 20oC ± 1 using extracellular solution 
composition (mM): NaCl 30, Choline-Cl 110, KCl 3, MgCl2 1, CaCl2 1, HEPES 10, CsCl 5, 
TEA-Cl 20, CdCl2 0.1, 4-AP 1, pH 7.3 adjusted with NaOH, osmolarity 315 - 320 mOsm 
adjusted with dextrose.  Intracellular recording solution contained (mM): CsMeSO4 130, NaCl 
20, EGTA 0.2, HEPES 10, Mg-ATP 4, Na-GTP 0.3, Dextrose 10, pH 7.3 adjusted with CsOH, 
osmolarity 300 – 305 mOsm adjusted with dextrose.  Patch pipettes were pulled from 
borosilicate glass (1.65/1.1, OD/ID, World Precision Instruments) by Sutter Instruments P - 97 
puller and polished (Microforge MF830, Narashige) to have a resistance between 0.7 - 1.3 
MΩ. Whole cell configuration was achieved and DRG cells were held at -80mV, for medium 
and large diameter DRG neurons voltage error was kept below ± 10mV, small diameter DRG 
neurons voltage error ± 5mV, by 70 - 90% series resistance compensation.  Recordings were 
acquired at 50 kHz and filtered with a low-pass Bessel filter at 10 kHz, further linear leak was 
filtered by P/6 subtraction. Data was analyzed offline with Fitmaster (HEKA Electronik), 
Excel (Microsoft) and plotted using GraphPad Prism software (Version 7, La Jolla, CA). 
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Protocols contained a prepulse to 0 mV to allow toxin binding as per the voltage-sensor 
trapping model, and repolarisation to -100 mV for 100 ms to allow recovery from fast 
inactivation (102, 112).  This was followed by measurement of current-voltage (I/V) 
relationships obtained from sweeps between -80 mV and + 20 mV for 100 ms at 5 s intervals. 
Following control recording, ECS containing toxins (in 0.1% BSA) was perfused for 2 - 3 
minutes through a pressure driven perfusion system with perfusion pencil (Automate 
Scientific) to allow sufficient fluid exchange and toxin binding.  Recordings were then 
obtained with continuous perfusion.  
3.3.5 Whole-cell patch clamp electrophysiology: current clamp  
Current-clamp recordings were also obtained using HEKA EPC-10 - double amplifier 
(acquired at 50 Hz and filtered at 10 Hz with a low-pass Bessel filter).  Extracellular solution 
contained (mM): 140 NaCl, 3 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES, 10 dextrose (pH and 
osmolarity adjusted as above).  Intracellular solution contained (mM): 140 KCl, 0.5 EGTA, 5 
HEPES, 10 dextrose (pH adjusted to 7.3 with KOH, osmolarity adjusted to 310 with sucrose).  
Patch pipettes were pulled, using a Sutter Instruments P-97, from borosilicate glass (1.65/1.1, 
OD/ID; World Precision Instruments) and fire polished (Microforge MF830, Narashige) to a 
resistance of 1 - 2 MΩ.  Whole cell configuration of large diameter DRG neurons (> 35 
micron) were obtained in voltage-clamp prior to proceeding to current-clamp mode. Due to 
instability in resting membrane potential (RMP), cells were continuously perfused with ECS 
(in 0.1% BSA) in control recordings. Cells with a stable RMP (over 30 s) and found to be than 
less than or equal to -55 mV, were recorded.  Input resistance was determined by 
hyperpolarising current steps at 10 pA increments between -10 to -60 pA and fitted to linear 
regression.  Current threshold was determined to be the first action potential elicited after 
serial depolarising current injections in 10 pA increments.  Repetitive firing was assessed by 
increasing current injection up to two times current threshold in 100 pA increments.  Action 
potential amplitude was measured from the action potential peak to RMP.  All current-clamp 
parameters were tested post perfusion (2 - 3 minutes) with Cn2 in ECS (0.1% BSA). 
3.3.6 Data analysis and statistical analysis  
The data and statistical analysis in this study comply with the recommendations on 
experimental design and analysis in pharmacology (266).  Unless otherwise noted, statistical 
significance was determined using paired Student’s t-test. Results are presented as mean ± 
SEM, and p < 0.05 was considered a statistically significant difference between control and 
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Cn2 treated conditions.  Statistical analysis was carried out using GraphPad Prism (Version 7, 
La Jolla, CA).  
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3.4 Results  
 
3.4.1 NaV1.6 activation induces Ca2+ influx in large diameter DRG neurons 
Although the β-scorpion toxin Cn2 was previously reported to display exquisite selectivity for 
NaV1.6 channels over other NaV isoforms in HEK293 over-expression systems (Chapter 2 and 
(227)), neurons express a number of different voltage-gated ion channels subtypes including 
those belonging to the KV, CaV and Cl
- families (35).  Furthermore, it is well understood that 
auxiliary proteins such as sodium channel beta (β) subunits, calmodulin (CaM) and fibroblast 
growth factor homologous factors (FHFs) play an important role in modulating NaV1.6 
channel function (258, 260, 267).  The highest expression of the NaV1.6 channel is reported in 
large and some small diameter DRG neurons (144, 210).  I therefore utilised a high-content 
calcium imaging assay to assess the effect of Cn2 on small, medium and large diameter DRG 
neurons.  Application of Cn2 (500 nM) to dissociated mouse DRG neurons caused an 
immediate sharp and sustained increase in intracellular calcium concentration ([Ca2+]) in a 
large proportion (45%) of large diameter neurons (Figure 3.1).  A small population of medium 
and small diameter neurons also responded to Cn2, consistent with the reported expression 
profile of NaV1.6 channels (144, 210).  
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Figure 3.1 Calcium imaging showing effect of Cn2 in mouse DRG neurons  
A) DRG neurons before (background) and after addition of Cn2 (500 nM). Cn2 caused rapid, 
strong and sustained calcium influx in a subset of large diameter (white arrows) neurons. 
Small diameter neurons that responded with calcium influx are labelled with a red arrow. 
B) Traces from all neurons (defined as cells responding to KCl (30 mM) and/or Cn2) of one 
representative experiment. C) Percentage of large (> 600 µm2), medium (300-600 µm2) and 
small diameter (< 300 µm2) neurons responsive to application of Cn2 (500 nM). Total number 
of neurons from 3 independent experiments is indicated. l.d., large diameter, m.d., medium 
diameter; s.d., small diameter. 
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3.4.2 NaV1.6 activation in large diameter neurons  
To further confirm that Cn2 is selective for NaV1.6 channels in a neuronal environment with 
heterogeneous and endogenous sodium channel expression, we utilized isolated DRG neurons 
from wild-type (WT) mice.  Since Cn2 preferentially activated large diameter DRG neurons 
(Figure 3.1) in the Ca2+ assay, these cells were initially chosen for voltage-clamp recordings.  
The voltage protocol contains a depolarising prepulse to allow β-scorpion toxin binding and 
excitatory action (102) (Figure 3.2 B).  
In accord with previous findings (Chapter 2, (112)), Cn2 (50 nM) caused sodium current 
influx at previously prohibitive potentials between (-70 mV and -40 mV) in large diameter 
DRG neurons (Figure 3.2 A, inset). Concurrently, Cn2 caused a significant (p < 0.001, n = 9) 
increase in NaV persistent current (Figure 3.2 D, E) that peaked at –35 mV compared to 
control percent peak current (Control: -0.7 ± 0.14 %; (-306 ± 77 pA) and Cn2: -2.7 ± 0.5%, (-
893.4 ± 224.1 pA)).  The rate of channel opening, measured as time to peak, was assessed 
from the time of test pulse onset to the peak of inward sodium current.  Time to peak showed 
early channel opening after Cn2 application, but a similar rate of activation at potentials 
ranging from -40 mV to +5 mV (Figure 3.2 F). Cn2 did not shift the V1/2 activation or 
significantly alter the slope (Figure 3.2 C).   
  
80 
 
 
Figure 3.2 Cn2 enhances early sodium current large diameter DRG neurons 
 A) Normalized sodium current-voltage relationship of large diameter (> 35 microns) DRG 
neurons before (black) and after (red) Cn2 (50 nM) perfusion. Cn2 causes early sodium 
channel opening (inset) (n = 10). B) Voltage protocol adapted from Schiavon et al., 2006 
including brief (120 ms) depolarising prepulse to 0 mV  C) Activation curve for WT large 
diameter (neurons before (black) and after (red) Cn2 treatment show similar V1/2 activation 
(Control: -25.6 ± 0.6 mV; Cn2: -25.2 ± 0.7 mV) and slope (Control: 4.8 ± 0.5; Cn2: 5.8 ± 0.6) 
p >  0.05, paired sample t-test, n=10  D) Representative trace (pulse to -50 mV) in the 
presence and absence of Cn2 50nM. E) Cn2 significantly increases persistent current in large 
diameter DRG (peak persistent -35 mV; % peak current Control -0.7 +- 0.14 and Cn2 -2.7 +- 
0.5). F) Time to peak current analysis reveals early channel opening (-60 mV to -45 mV) after 
Cn2 application. 
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3.4.3 NaV1.6 activation in small diameter neurons  
Small diameter DRG neurons express the most diverse range of NaV subtypes of any neuron, 
including NaV1.7, NaV1.8 and NaV1.9 (133, 197).  Some of these isoforms, such as NaV1.9, 
are not expressed in the large diameter DRG neurons tested (268).  While Cn2 does not 
modulate these isoforms in HEK293 overexpression systems, the effect of the peptide on the 
native channels has yet to been assessed.  To examine whether our NaV1.6 selective probe is 
activating these off-target NaV channels, small diameter DRG neurons (< 30 microns) were 
preferentially chosen for voltage-clamp experiments.  Furthermore, NaV1.6 protein is reported 
to be expressed along small diameter fibres and contribute to excitability (210) however, 
pharmacological assessment of NaV1.6 in these neurons is lacking.  At the concentration (50 
nM) that robustly caused early NaV channel opening in large diameter neurons (Figure 3.2), 
Cn2 failed to induce current between -70 mV and -40mV in the small diameter neurons 
(Figure 3.3 A).  The voltage-dependence of activation of NaV current was also unchanged after 
Cn2 application (Figure 3.3 B).  Finally, the appreciable increase in persistent current 
observed in large diameter DRG neurons was absent in small diameter (Figure 3.3 C).  
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Figure 3.3 NaV1.6 activation in small diameter DRG neurons  
A) Cn2 (50 nM, red) did not cause early channel opening in small diameter neurons or alter 
the current-voltage relationship (n = 7). B) Activation curve for WT small diameter (<30 
micron) V1/2 activation (Control: -18.4 ± 1.1; Cn2: 18.5 ± 0.9) and slope (Control: 8.8 ± 1; 
Cn2: 8.2 ± 0.8) p > 0.05, paired sample t-test, n = 7. C) Persistent current before and after Cn2 
was also unchanged in small diameter DRG neurons. 
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3.4.4 Cn2 does not induce early opening in large diameter DRG neurons from NaV1.6-/- 
mice 
Small diameter DRG neurons did not respond to Cn2 (50nM), suggesting that Cn2 does not 
modulate the activity of other NaV isoforms expressed in these cells.  However, in order to 
unequivocally test the selectivity of the NaV1.6 probe, I used NaV1.6
-/- large diameter DRGs 
isolated from SCN8Amed/med mice.  Like the small diameter DRGs, Cn2 (50 nM) did not 
induce early opening in large diameter neurons (Fig 3.4 A). The voltage-conductance 
relationship was also not significantly shifted by Cn2 (Figure 3.4 B). Finally, Cn2 induced a 
small (0.1% ±0.2 control vs Cn2 0.4% ± 0.07) but significant increase (p < 0.05) in persistent 
current at pulses between -55 and -45 (Figure 3.4 C).  
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Figure 3.4 Cn2 is selective for NaV1.6 in heterologous expression of NaV channels  
A) Cn2 does not alter current-voltage relationship of large diameter DRGs from NaV1.6 
-/- 
mice. Cn2 does not induce early opening in NaV1.6 
-/- large diameter neurons n = 11. 
B) Voltage-conductance curve for large diameter neurons isolated from NaV1.6
-/- animals V1/2 
activation (Control: -16.8 ± 0.8; Cn2: -21.2 ± 1.1) and slope (Control: 6.7 ± 0.7; Cn2, 6.2 ± 
1.0) p > 0.05, paired sample t-test, n = 11. C) Persistent current between -55 and -45 is 
significantly increased 0.1% ±0.2 control and Cn2 0.4% ± 0.07, p<0.05, paired student t-test, 
n = 7 
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3.4.5 NaV1.6 resurgent current is enhanced by Cn2 
The native Cn2 toxin enhances resurgent current in Purkinje neurons that exhibit high 
frequency firing and have high expression of NaV1.6 channels (112).  DRG neurons are also 
known to generate resurgent currents through NaV1.6 (263).  Therefore, I considered whether 
Cn2 could enhance the endogenous resurgent current in large diameter DRG neurons.  Figure 
3.5 A shows an increase in sodium current amplitude by Cn2 (50 nM), and partial recovery 
following a 5 min washout period.  Indeed, Cn2 increased the endogenous resurgent current 
amplitude in large diameter neurons by 3-fold (Control: -3.1 ± 0.7 nA, Cn2 -9.9 ± 1.0 nA, n = 
7, p < 0.05) (Figure 3.5 B, D). Cn2 (50 nM) dramatically shifted the voltage-dependence of 
resurgent current approximately 40 mV in a hyperpolarising direction (Control: -27.1 ± 3.2 
mV; Cn2 -68.6 ± 2.1 mV, n = 7, p < 0.05) (Figure 3.5C, E). Increased resurgent current 
amplitude and the shift in current-voltage relationship was not observed in buffer-treated cells 
(Figure S18).  
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Figure 3.5 Cn2 enhances resurgent current in large diameter DRG neurons.  
A) Representative trace of resurgent current from large DRG neurons in the presence and 
absence of 50 nM Cn2. DRG neurons were held at -100 mV and depolarised to +30 mV for 
20 ms, followed by repolarisation to a range of pulses (-10 to -80 mV) to elicit resurgent 
current. B) Average resurgent current amplitude before and after Cn2 application show a 3-
fold increase in peak amplitude (n = 7). C) Current-voltage relationship showing a 
hyperpolarised shift (~40 mV) in peak resurgent current amplitude after Cn2 (50 nM), and 
partial recovery following a 5 min washout period (n = 7). D) Peak resurgent current measured 
before and after Cn2. E) Peak voltage shifted ~40 mV after Cn2 application.   
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3.4.6 NaV1.6 activation dramatically alters firing properties of large diameter DRG 
neurons 
Toxins that enhance persistent (such as ATX-II) and resurgent current (Cn2) affect firing 
properties of cortical neurons (112, 269), therefore I chose to assess the effect of Cn2 on 
excitability of large diameter DRG neurons.  I found that in control conditions large diameter 
mouse DRG neurons had high current threshold and resisted repetitive firing (Table 1). 
Application of Cn2 to large diameter DRG neurons caused a significant increase in the number 
of evoked action potentials at respective current thresholds (Figure 3.6).  Cn2 caused large 
diameter DRG neurons to transition from phasic to tonic firing.  Increasing the current input to 
1.5 times the threshold reduced the number of action potentials (Figure 3.6 A, blue).  The 
overall increase in activity was not associated with changes in input resistance, current 
threshold or action potential amplitude (Table 3.1).  Interestingly, Cn2 altered the shape of the 
second action potential; essentially removing the threshold entirely (Figure 3.6 B).  
Previously, native Cn2 significantly depolarised the membrane potential of Purkinje neurons 
(112), however we observed no significant overall difference in resting membrane potential 
during or after Cn2 application (Table 3.1).  This is consistent with evidence that NaV1.6 
channels are critical for the fast upstroke of an action potential but do not contribute to the 
maintenance of the resting membrane potential (198, 218). 
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Figure 3.6 Cn2 increases evoked action potential firing in large diameter DRG neurons.  
A) Representative trace from current clamp recording of isolated large diameter DRG neurons 
before and after Cn2 (50 nM) application. Cn2 caused an increase in number of action 
potentials evoked by current injection at current threshold (red). Decrease in action evoked 
action potentials following an injection of current 1.5 times threshold (blue). B) First and 
second action potential after Cn2 (red) showing the lack of sub-threshold depolarisation after 
first depolarisation (arrows). C) Number of action potentials at threshold before and after Cn2 
(50 nM), four large diameter neurons did not fire more than one action potential after Cn2 
application. 
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Table 3.1 Current clamp parameters WT large diameter DRG neurons  
 Resting 
membrane 
potential 
(mV) 
Repetitive 
firing cells 
(%) 
Number 
of action 
potentials 
at 
threshold 
Input 
resistance 
(MΩ) 
Current 
threshold 
(pA) 
Action 
potential 
amplitude 
(mV) 
Control -67.2 ± 0.9 
(n = 15) 
0/15, 0% 1 ± 0 
(n=11) 
54.8 ± 8.9 
(n = 10) 
1985 ± 236 
(n = 10) 
118.9 ± 2.7 
(n = 10) 
Cn2 50 nM -65.68 ± 1.3 
(n = 15) 
11/15, 74%  
 
 
25 ± 8 
(n=11) 
41.6 ± 9.8 
(n = 10) 
1860 ± 234 
(n = 10) 
117.2 ± 4.1 
(n = 10) 
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3.4.7 Cn2 does not cause repetitive firing in large diameter neurons from NaV1.6 -/- mice  
Promiscuous modulators of NaV and KV channels can modify action potential characteristics 
including after hyperpolarisation duration (270).  To assess whether the repetitive firing 
observed in large diameter WT DRGs neurons was caused by NaV1.6 activation, excitability 
of NaV1.6
-/- large diameter DRGs were tested.  Cn2 did not induce repetitive firing patterns in 
NaV1.6 
-/- large diameter neurons (Figure 3.7 A).  The RMP became slightly hyperpolarised in 
this example trace, however the changes in RMP in NaV1.6
-/- large diameter neurons were not 
significant (Figure 3.7 B). Furthermore, slight increases and decrease in RMP were also 
observed in buffer control cells (Figure 3.7 C). Finally, the action potential characteristics of 
NaV1.6
-/- DRG neurons were unchanged from buffer control (Table S11). 
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Figure 3.7 Cn2 does not cause repetitive firing NaV1.6-/- large DRG neurons  
A) Representative trace of the effect of Cn2 (red, 50 nM) on the action potential characteristics 
of large diameter DRG neurons isolated from NaV1.6
-/- mice (P14) B) Resting membrane 
potential of large diameter neurons from NaV1.6
-/- mice before (black) and after (red) 
application of Cn2 (50nM) (n = 6). C) Resting membrane potential of large diameter neurons 
from NaV1.6
-/- mice before (black) and after (red) application of buffer (0.1 % BSA in ECS) 
(n = 7). 
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3.5 Discussion  
 
Cn2 is a canonical β-scorpion toxin, previously shown to induce current at prohibitively 
hyperpolarised potentials in HEK293 cells expressing NaV1.6 channels (Chapter 2 and (112)).  
In the current study, I confirm this mechanism of action at NaV1.6 channels in peripheral 
sensory neurons and delineate the contribution of NaV1.6 to sensory neuron excitability in 
culture using pharmacological approaches.  Interestingly, along with early channel opening, 
Cn2 application to large diameter DRG neurons also led to a robust persistent current not 
reported in HEK293-NaV1.6 cells (Chapter 2 and (112)).  This is likely due to differential 
expression of key interacting proteins such as NaVβ subunits which are known to regulate 
persistent sodium currents (such as β4) (271, 272).  NaVβ4 is highly expressed in 
neurofilament-positive neurons that correspond to the heavily myelinated, large diameter A 
fibres, those affected by Cn2 in this study (133, 273).  Furthermore, the electrophysiological 
analysis confirms Cn2 activity on mouse NaV1.6 channels which will be critical for future 
animal studies (see Chapter 5).   
Specific deletion of NaV1.6 channels from NaV1.8-expressing small diameter neurons 
decreased current density by approximately 30% (220).  However, NaV1.6 channel activation 
by Cn2 does not alter sodium currents in small diameter DRG neurons (Figure 3.3).  Chen 
et al found that the decrease in current density carried by NaV1.6 in large diameter neurons 
correlates well with neurons from NaV1.6 
-/- (med/med) mice.  However, the authors do not 
report what (if any) percentage decrease in current density is present in small diameter DRG 
neurons from NaV1.6 
-/- mice.  An elegant study of electrogenesis in DRG soma (255) and 
projections (256) of small diameter neurons confirms that NaV1.8 is the major driver of the 
action potential upstroke in these neurons.  In addition, TTX-S currents are responsible for 
modest changes in the current threshold and voltage thresholds in small diameter neurons 
(256).  My data supports an overall minor role for NaV1.6 in small diameter sensory neurons.  
Indeed, the conditional knock-out of NaV1.6 in small diameter DRG neurons did not 
significantly change any action potential characteristics including current threshold (220).  
However, in my study design, neurons were not selected based on evidence of expression of 
NaV1.6 channels, therefore I cannot rule out a functional contribution of NaV1.6 channels to a 
subset of small diameter soma. Certainly, a small but distinct number of small diameter 
neurons responded to Cn2 in high-throughput calcium imaging (Figure 3.1).  
Enhanced resurgent currents in sensory neurons are thought to contribute to excitability in 
various pain disorders including paroxysmal extreme pain disorder (PEPD) and oxaliplatin-
93 
 
induced cold allodynia (212, 274).  I show for the first-time enhanced resurgent current in 
peripheral sensory neurons by Cn2.  The hyperpolarising shift in activation (-40mV shift) and 
substantial increase in peak resurgent current is consistent with results from Purkinje neurons 
(40 nM, -30mV shift) (112).  This is perhaps unexpected as, unlike sensory neurons, Purkinje 
neurons express 5 to 8-fold more NaV1.6 than other NaV isoforms (1.1 and 1.2) (275).  The 
presence of a β-scorpion toxin, such as Cn2, can trap the DIIS4 segment in the outward 
position and delay channel closing resulting in premature release of the inactivation gate and 
resurgent current upon repolarisation (102, 112).  Thus, I cannot exclude the possibility that 
the 3-fold increase in resurgent current is solely due to release of the inactivation particle upon 
deactivation, and not at least partially a cooperative action with the β4 subunit in large 
diameter sensory neurons.   
Consistent with findings from mouse Purkinje neurons (112), large diameter DRG neurons 
were also capable of repetitive firing (followed by gradual adaption) in the presence of Cn2.  
Interestingly, the characteristics of the first action potential remain unchanged while 
subsequent action potentials lose their sub-threshold “hump” and decrease in amplitude likely 
due to inactivation block by resurgent current.  Unlike Purkinje neurons, large diameter DRG 
neurons resist repetitive firing in control conditions making comparison of affected action 
potential characteristics impossible.  Exactly why the first action potential in the volley is 
unaffected by Cn2 remains unclear.  One explanation comes from the mechanism of action of 
β-scorpion toxins.  The voltage sensor must move outward, which requires an initial 
depolarisation, allowing toxin binding that ultimately facilitates early channel opening. 
Indeed, without this depolarising step, other β-toxins cause only a decrease in peak current 
(102, 252).  In this way, the opening of NaV1.6 channels during the first action potential 
allows the Cn2 toxin to bind and trap the voltage sensor, favouring channel activation and as a 
result action potential firing.  Current clamp experiments from sensory neurons (this study) 
and Purkinje neurons (112) support this hypothesis.  Further examination with peptide 
analogues that have a reduced capacity for voltage-sensor trapping, such as the E15R mutant 
(Chapter 2), may help elucidate this mechanism.  Unlike Purkinje neurons, NaV1.6 activation 
by Cn2 did not gradually depolarise the resting membrane potential of large diameter neurons.  
This might be due to the higher expression of NaV1.6 in these neurons or the expression of 
different ion channels.  
It is worth noting that a proportion of large diameter neurons (4/15) did not respond to Cn2 
with increased evoked action potential firing. It is conceivable that a proportion of large 
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diameter sensory neurons express only NaV1.8 and other TTX-S isoforms and proportionally 
fewer (or no) NaV1.6 channels.  This is supported by single cell RNA sequencing data (133).   
Although hyperpolarised NaV activation was absent in large diameter DRG neurons from 
NaV1.6
-/- mice, some animal-derived toxins may also modulate other ion channels that alter 
firing properties in neurons, such as voltage-gated potassium channels (276-278). However, 
Cn2 did not alter firing patterns of DRG neurons from NaV1.6
-/- mice, confirming that the 
distinct firing pattern is driven by NaV1.6 channel activation alone. Furthermore, unlike 
modulators of voltage-gated potassium channels, Cn2 did not significantly change the resting 
membrane potential, rheobase, after-hyperpolarisation amplitude or action potential width in 
wild-type DRG neurons.  Although the opening at hyperpolarised potentials caused by Cn2 is 
the canonical β-scorpion effect, it remains small compared to the substantial increase in 
persistent current, peak resurgent current and the strong hyperpolarising shift in resurgent 
current.  Therefore, I posit that the Cn2-induced changes in resurgent current kinetics and 
amplitude seen in large diameter DRG neurons (> 50% increase, 40 mV hyperpolarising shift) 
underlie the repetitive firing induced in large diameter sensory neurons.   
In conclusion, Cn2 causes changes to the kinetics of NaV1.6 alone in the presence of native 
intracellular proteins and other ion channels.  The effect of Cn2 on NaV1.6 in large diameter 
neurons is comparable to the effects observed in HEK293 cells (Chapter 2).  Cn2 does not 
change NaV current in small diameter DRG neurons suggesting a minor functional role for this 
isoform in these neurons.  Finally, NaV1.6 activation in large diameter DRG neurons leads to 
enhanced excitability.  
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Chapter 4 – NaV1.6 in the distal terminals of the skin    
 
  
4.1 Foreword 
 
This chapter aims to assess the contribution of NaV1.6 to the initiation and conduction of 
action potentials in the distal terminals of the skin.  The previous chapters utilised whole-cell 
electrophysiology to confirm mechanism of action of the NaV1.6 selective probe and began to 
explore the effects of NaV1.6 activation in sensory neurons.  Here, ex vivo skin saphenous 
nerve recordings were used to bridge the gap between previous in vitro work and in vivo 
studies of NaV1.6 function (Chapter 5).  In this way, the contribution of particular fibre types 
to pain can be better understood.  Non-selective and selective activators and blockers of NaV 
channels are used to investigate NaV1.6 function in A and C fibres.  Parts of this chapter were 
accepted for publication in Scientific Reports (243).  Following on from Chapter 3 these 
results are also based on a paper that has been accepted for publication in the Journal of 
Physiology.  The structure has been edited and formatted to for the style and flow of this 
thesis.  Contributions made by other authors are stated in body of this chapter along with the 
thesis preliminary pages. 
 
 
4.2 Introduction 
 
Peripheral sensory neurons are pseudo-unipolar with two projections emanating from the cell 
body, located in the dorsal root ganglia.  One projection terminates in the dorsal horn of the 
spinal cord, the other in the skin, muscles and viscera.  Sensory fibres are broadly classified 
based on their cell body size, degree of myelination and conduction velocity; from fastest to 
slowest these are Aβ, Aδ and C fibres.  They can be further divided by their adaption speed, 
mechanical threshold and response to temperature or noxious chemicals such as capsaicin or 
menthol (Table 4.1) 
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Table 4.1: Classes of rodent peripheral sensory neurons  
Fibre Subtype Sensory modality Class Sensation 
  
cold hot  mechanical 
  
C CMCH X X X Polymodal nociceptor Pain 
 
CMH 
 
X X Polymodal nociceptor Pain 
 
CC X 
  
Cold receptor thermosensing 
 
CMC X 
 
X Cold nociceptor Pain 
 
CH 
 
X 
 
heat sensor thermosensing 
 
CMW 
 
X X Warm sensors thermosensing 
 
CMiHi 
   
Silent nociceptor Pain 
 
C tactile 
  
X 
 
Pleasure/touch 
Aδ AMH 
 
X X mechanonociceptors Pain 
 
AMC X 
 
X mechanonociceptors Pain 
 
A(LT)M 
RA 
  
X D-hair mechanoreceptor Touch 
 
A(LT)M 
SA 
  
X Low threshold slowly 
adapting 
Touch/pain 
 
A(HT)M 
SA 
  
X High threshold slowly 
adapting 
Touch/pain 
Aβ ? 
  
X Nociceptors? Pain? 
 
SA type I mechanoreceptors Merkel disc touch 
 
SA type II mechanoreceptors Ruffini corpuscle Stretch/pressure 
 
RA type I mechanoreceptors Meissner corpuscle touch 
 
RA type II mechanoreceptors Pacinian corpuscle pressure 
 
The distal terminal in the skin is the point of sensory transduction and initiation of action 
potential.  The composition of the ion channels and transducer channels at the distal terminal 
directly influences the role that the fibre plays in somatosensation. 
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Canonical nociceptors, or pain sensing neurons, are small diameter non-myelinated C fibres.  
C fibres express both TTX-S and TTX-R Na subtypes including NaV1.7, NaV1.8 and NaV1.9 
(133).  Recently, pharmacological assessment of the distribution of TTX-S and TTX-R 
isoforms in C fibres highlighted TTX-S isoforms at the proximal but not distal terminal (279).  
In primate C fibres, the distal ending in the skin is enriched with NaV1.8 where it underlies the 
TTX-R conduction (279).  Aδ fibres are thinly myelinated and convey signals of noxious heat 
and mechanical stimuli (124).  Aβ fibres are often classified as non-noxious low threshold 
mechanoreceptors, however evidence suggests they too may be involved in transmitting 
noxious information (280-283) and these fibres clearly contribute to many pathological pain 
states.  Both Aδ and Aβ fibres express TTX-S isoforms, such as NaV1.1, NaV1.6 and NaV1.7.  
Altered expression and function of NaV isoforms is well known to contribute to neuronal 
hyperexcitability and pain, and this crucial contribution is particularly poignantly illustrated by 
acquired painful neuropathies such as the food-borne illness ciguatera fish poisoning. 
Ciguatera is the most common non-bacterial form of fish-borne illness and is caused by the 
consumption of fish contaminated with ciguatoxins (284).  These polycyclic ethers are 
lipophilic, heat stable itchthyotoxins that originate from benthic dinoflagellates of the genus 
Gambierdiscus that bloom in tropical and sub-tropical oceans around the world.  Consumption 
of coral and seaweed contaminated with Gambierdiscus by herbivorous fish leads to 
bioaccumulation of the ciguatoxins through the food chain via larger carnivorous fish that in 
turn are consumed by humans and cause ciguatera.  The communities most affected by 
ciguatera are those that rely on fish as a major part of their diet such as the island nations of 
the Pacific and Indian oceans and the Caribbean Sea (285-287).  However, as the world’s 
oceans warm and algal blooms become more frequent, ciguatera is now emerging as a 
significant issue in Asia, America and parts of Europe (288-290).  
The presenting symptoms of ciguatera are predominantly neurotoxic in the majority of cases 
and include post-ingestion paraesthesiae, dysaesthesiae and heightened nociception, including 
the pathognomonic symptom of cold allodynia, which is associated with intense discomfort on 
exposure to cool temperatures (224, 284, 291, 292).  In addition, early signs of ciguatera 
include gastrointestinal symptoms such as diarrhoea, vomiting and abdominal pain as well as 
musculoskeletal symptoms, in particular weakness and fatigue (284).  Cardiovascular 
symptoms such as bradycardia occur more rarely and often in more severe cases of poisoning 
(293-295).  This diverse symptomatology is believed to be caused by the interaction of the 
ciguatoxins with site 5 of the NaV channel (292, 296-298).  Pacific ciguatoxin-1 (P-CTX-1), 
the most potent ciguatoxin congener thought to be responsible for the majority of symptoms 
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associated with ciguatera in the Pacific (299), elicits varied effects on the electrophysiological 
properties of NaV channels and as a consequence enhances neuronal excitability.  In DRG 
neurons, P-CTX-1 shifts the voltage of activation of TTX-S NaV channels to more 
hyperpolarised potentials and decreases peak TTX-R Na+ current (105).  Similarly, in 
parasympathetic neurons P-CTX-1 enhances the open probability of single TTX-sensitive NaV 
channels without altering the unitary conductance or reversal potential (300).  However, while 
it is known that the ciguatoxins modulate activity of TTX-S and TTX-R NaV isoforms, the 
relative selectivity for and pharmacological effects on individual NaV isoforms and their 
association with diverse pathophysiological consequences have not been assessed to-date.  
A previous study reported that (105, 294) co-administration of GIIIA (NaV1.6/1.1) and 
A803467 (NaV1.8) abolished P-CTX-1 induced cold pain in an animal model (224).  However, 
the contribution of NaV channels isoforms to the non-stimulus evoked pain reported, or the 
identities of the NaV isoforms mediating ciguatoxin-induced effects on sensory neurons, have 
not been assessed.  To address these questions, I used the high-throughput fluorescent 
membrane potential assay (used previously in Chapter 2) to assess the relatively potency P-
CTX-1 at NaV1.1-1.8 channels.  Although P-CTX-1 non-selectively activated all NaV 
isoforms, spontaneous firing of C fibres was significantly reduced by a NaV1.8 antagonist.  In 
contrast, A fibre activation by P-CTX-1 was abolished by either NaV1.6 or NaV1.7 blockers.  
These initial results suggested an important contribution of NaV1.6 at peripheral terminals to 
excitability of A fibres, but not C fibres.  Compound action potentials from NaV1.6
-/- mouse 
sciatic nerves found that the isoform was responsible for 30 % of the C fibre activity (210), 
this observation warranted further investigation.  Unfortunately, NaV1.6 
-/- mice are juvenile 
lethal, making skin-saphenous nerve recordings from them technically challenging.  To this 
end, the selective NaV1.6 probe (Cn2) described in Chapter 3 was used to delineate the 
contribution of NaV1.6 to excitability of the distal terminal of peripheral sensory neurons using 
the rat skin-saphenous preparation.  Consistent with data presented in Chapter 3, as well as 
findings from experiments with P-CTX-1, the results presented in this Chapter demonstrate 
that activation of NaV1.6 has a varied and comparatively small effects on C fibre firing in the 
distal terminals in the skin; while NaV1.6 activation in A fibres dramatically increased their 
response to mechanical stimuli, resulting in bursting or mechanically hypersensitive fibres.   
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4.3 Methods 
 
4.3.1 Materials 
P-CTX-1 (> 90% purity) was isolated from moray eel (Gymnothorax javanicus) viscera as 
previously described (301) and was generously donated by Professor Richard J Lewis 
(Institute for Molecular Biosciences, University of Queensland).  Pn3a,  originally isolated 
from the venom of Pamphobeteus nigricolor, was synthesised by Zoltan Dekan (Institute for 
Molecular Biosciences, University of Queensland) previously described (160).  P-CTX-1 and 
peptides such as Pn3a and GIIIA were routinely diluted in physiological salt solutions with 
0.1% bovine serum albumin in order to avoid adsorption to plastic.  Unless otherwise 
specified, other reagents were purchased from Sigma Aldrich, Australia.  
4.3.2 High-throughput fluorescent membrane potential assay 
To assess the relatively potency of the NaV modulator P-CTX-1, the high-throughput 
fluorescent membrane potential assay was used as previously described (242).  HEK293 cells 
that stably express NaV1.1-1.8 were purchased from SB Drug Discovery (Glasgow, Scotland).  
Cells were routinely cultured with minimal essential media (MEM, Sigma Aldrich, Australia) 
supplemented with 10% fetal bovine serum (FBS) and appropriate selection antibiotics 
(blasticidin and G418 for NaV1.1, 1.2, 1.3, 1.5, 1.6, 1.7 and 1.8; blasticidin, G418 and zeocin 
for NaV1.4).  Cells were plated 48 hours prior to assay in black-walled 384 well plates at a 
density of approximately 20,000 cells per well.  Media was replaced with 20 µL of Molecular 
Devices (Sunnyvale, CA) red membrane potential dye diluted in physiological salt solution 
(composition (in mM): NaCl 140, glucose 11.5, KCl 5.9, MgCl2 1.4, NaH2PO4 1.2, NaHCO3 
5, CaCl2 1.8, 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid 10, pH 7.4) 30 minutes 
prior to experiment.  Cells were incubated (5 minutes) with a subthreshold concentration of 
the NaV channel activator veratridine (NaV1.1-1.7, 5-10 uM) or deltamethrin (NaV1.8, 30 µM) 
and potentiation of fluorescence (excitation: 510-545 nm, emission: 565-625 nm) after 
addition of P-CTX-1 was measured every second for 300 s using a FLIPRTetra fluorescent plate 
reader (Molecular Devices, Sunnyvale, CA).  
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4.3.3 Single fibre experiments from skin-saphenous nerves 
To assess the pharmacology of toxins on sensory, A and C fibre afferents, I utilized the skin-
saphenous nerve preparation as previously described (302).  Juvenile male Wistar rats (200 - 
250g) or C57Bl/6 mice (6-8 weeks) were sacrificed by CO2 inhalation and the hairy skin of 
each pair of hind paws were dissected with the saphenous nerve attached.  The first skin of 
each pair was placed in a recording chamber and secured hairy side down with petroleum jelly 
and continuously perfused with carbogenated synthetic interstitial fluid (SIF) composed of 
(mM), NaCl 107.8, KCl 3.5, MgSO4 2H2O 0.69, NaHCO3 26.2, NaH2PO4 2H20 1.67, gluconic 
acid 9.64, glucose 5.55, sucrose 7.6, CaCl2, 2H2O 1.53; pH 7.3 the second skin of the animal 
was kept at 4OC until ready for experimentation (up to 6 hours post-dissection).  The 
saphenous nerve bundle of the first skin was then placed on a mirror in a separate recording 
chamber filled with paraffin oil, de-sheathed and teased to smaller filaments which were 
placed on a platinum recording electrode.  The corium of the skin was then manual probed 
with a blunt glass rod until single, mechanically sensitive receptive fields could be identified 
and subsequently classified by conduction velocity (C < 1 m/s, A > 1.6-16 m/s) after 
stimulation by bipolar Teflon coated steel microelectrode (impedance 1 MΩ).  Mechanical 
thresholds were determined by gravity-driven von Frey probe.  The receptive field was then 
isolated using a small plastic ring and baseline response to heat (>50°C) and cold (<10°C) 
stimulus was assessed by perfusion of temperature-controlled SIF.  Toxin was then perfused 
for 5 minutes. Subsequently, A and C fibres were subjected to temperature ramps and the pre-
determined threshold mechanical stimulus was applied.  For P-CTX-1 experiments, the NaV 
selective antagonists Pn3a (1 µM), GIIIA (10 µM) , TTX (1 µM) and A803467(10 µM) were 
sequentially added (in SIF) to the receptive field of the C fibres. Recording was sustained over 
this period.  Each compound was recorded for at least 10 minutes before the next compound 
was added.  As Pn3a blocked all A fibres that responded to P-CTX-1, a separate experimental 
group was included to add GIIIA after P-CTX-1 induced spontaneous firing. 
4.3.4 Data analysis and statistics 
Values from the fluorescence-based assay were corrected to veratridine alone and normalized 
to a response over baseline (10s prior to addition of compound) using ScreenWorks 3.2.1.14.  
Agonist concentration-response curves were assessed by area under the curve after addition 
plotted against log concentration.  GraphPad Prism (Version 7.00, San Diego, California) was 
used to fit a 4-parameter Hill equation with variable Hill slope to the data. 
For skin-saphenous nerve recordings, all data was recorded and analysed using DAPSYS 
(Brian Turnquist; www.dapsys.net) software.  Number of action potentials and peak firing 
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frequency were determined for the duration of the stimulus.  All data, unless otherwise stated, 
are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was 
performed using GraphPad Prism (Version 7.00, San Diego, California) and significance was 
defined as p < 0.05 and was determined using unpaired Students t-tests or ANOVA.   
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4.4 Results  
 
4.4.1 P-CTX-1 is a non-selective NaV activator 
P-CTX-1 elicited a concentration dependent potentiation of NaV1.1-1.8 responses in stably 
expressed in HEK293 cells in the FLIPR membrane potential assay (Figure 4.1 A; 
EC50 ± SEM: NaV1.1, 7.9 ± 3.1 nM; NaV1.2, 8.3 ± 3.9 nM; NaV1.3, 3.4 ± 1.6 nM; NaV1.4, 
18.4 ± 6.9 nM; NaV1.5, 10.8 ± 3.8 nM; NaV1.6, 18.1 ± 9.4 nM; NaV1.7, 13.0 ± 5.8 nM; NaV1.8, 
2.1 ± 0.7 nM).  P-CTX-1 most potently affected NaV1.3 and NaV1.8 however the relative 
selectivity was not statistically significant (ANOVA, p > 0.05). Therefore, P-CTX-1 is a non-
selective activator of NaV channels. 
Although not part of this thesis, this non-selective action was explored in further detail using 
electrophysiological recordings from NaV1.1-1.9, which demonstrated the differential effects 
of P-CTX-1 on NaV isoforms.  All subtypes were modulated by P-CTX-1, however activator-
like changes at different isoforms included shifting the voltage-dependence of activation to 
more hyperpolarised potentials (NaV1.1-1.9), increased peak currents (NaV1.6) and enhanced 
persistent current (NaV1.3 and NaV1.8) (243).  Therefore, in line with the high-throughput 
fluorescent assay, P-CTX-1 is not a selective NaV modulator. 
4.4.2 P-CTX-1 evokes action potential firing in dermal sensory afferents  
Despite the lack of selectivity of P-CTX-1, cold allodynia, the pathognomonic symptom of 
ciguatera, is mediated by an isoform dependent mechanism (214).  However, P-CTX-1 also 
causes a number of other paraesthesiae that are unrelated to changes in temperature including 
itching and tingling sensations (294).  These spontaneous pain phenotypes are likely due to 
direct effects of P-CTX-1 on peripheral sensory neurons. Thus, I sought to assess the effect of 
P-CTX-1 on A and C fibres using ex vivo murine skin-saphenous nerve recordings.  
P-CTX-1 (0.5 nM) induced action potential firing in all previously quiescent C fibres (12/12), 
with some fibres exhibiting a modest increase in activity (4/12 fibres; < 50 action potentials/5 
min) (Figure 4.1B).  Consistent with previous findings (224), action potential firing induced 
by P-CTX-1 in skin was mediated predominantly by TTX-R NaV isoforms in C fibres, as 
treatment with the selective NaV1.7 inhibitor Pn3a (1 µM, Figure 4.1 C), the NaV1.6 inhibitor 
GIIIA (10 µM), or TTX (1 µM) did not significantly decrease action potential firing overall (p 
> 0.05).  However, some individual fibres (4/12) were silenced after inhibition of TTX-S NaV 
isoforms (Figure 4.2 B, C).  Notably, the P-CTX-1-induced firing frequency of these fibres 
was modest (action potentials/5 min: 53.2 ± 40.6) in comparison with fibres that were 
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unaffected by TTX (action potentials/5 min: 166.1 ± 66.6).  Similar to previous findings using 
recordings from NaV1.8
-/- animals (224), where P-CTX-1-induced firing in C fibres was 
markedly decreased, the NaV1.8 inhibitor A803467 (10 µM; p < 0.05) significantly decreased 
action potential firing frequency (Figure 4.1 B, D).   
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Figure 4.1 P-CTX-1-induced activation of C fibres is significantly blocked by NaV1.8 
antagonist  
A) P-CTX-1 activates NaV1.1-1.8 in the FLIPR membrane potential assay (three independent 
experiments) B) P-CTX-1 (0.5 nM) on single C fibres recorded from a murine skin-saphenous 
nerve preparation. Selective inhibitors of NaV1.7 (Pn3a, 1 µM); NaV1.6 (GIIIA, 10 µM), TTX-
s NaV isoforms (TTX, 1 µM) and NaV1.8 (A803467, 10 µM) were sequentially perfused at the 
receptive field to assess cumulative effects of NaV inhibition on action potential firing. Each 
data point represents the number of action potentials/5 min from a single C fibre receptive 
field. C) Representative recording of a C fibre silenced by the selective NaV1.7 inhibitor Pn3a 
(1 µM). D) Representative recording of a C fibre unaffected by Pn3a (1 µM), GIIIA (10 µM) 
and TTX (1 µM) and silenced by the NaV1.8 inhibitor A803467 (10 µM). Each data point 
represents a single action potential and is plotted as a function of instantaneous frequency (1/s) 
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to represent the time elapsed since the previous action potential. Bars above indicate time 
points of superfusion with compounds.  
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4.4.2 NaV1.6 antagonist blocks P-CTX-1 induced firing in A fibres 
In contrast, P-CTX-1 elicited action potential firing in only 44.8% (13/29) of A fibres, with 
responding fibres displaying significantly (p < 0.05) slower conduction velocities (6.28 ± 0.95 
m/s, n = 6) than non-responders (10.64 ± 1.50 m/s, n = 5).  Inhibition of the TTX-S isoforms 
NaV1.6 or NaV1.7 had a profound effect on action potential firing in A fibres, with both Pn3a 
and GIIIA almost completely silencing P-CTX-1-induced activity (Figure 4.2 A). 
Interestingly, inhibition of either NaV1.7 (Figure 4.2 B) or NaV1.6 (Figure 4.2 C) appeared to 
be sufficient to virtually abolish spontaneous action potential firing, suggesting that both 
channels act in concert to maintain P-CTX-1-induced ongoing activity.  Thus, both TTX-S and 
TTX-R isoforms contribute to the enhanced excitability of peripheral sensory neurons caused 
by P-CTX-1, albeit with their relative contributions differing between fibre types.   
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Figure 4.2 A fibres that spontaneously fire after P-CTX-1 application are blocked by 
NaV1.6 and NaV1.7 antagonism.  
A) Selective inhibitors of either NaV1.7 (Pn3a, 1 µM) or NaV1.6 (GIIIA, 10 µM) almost 
completely silenced P-CTX-1-induced action potential firing in A fibres. Each data point 
represents the number of action potentials/5 min from a single A fibre receptive field. 
B) Representative recording of an A fibre silenced by Pn3a (1 µM) and C) (GIIIA, 10 µM). 
Each data point represents a single action potential and is plotted as a function of 
instantaneous frequency (1/s) to represent the time elapsed since the previous action potential. 
Bars above indicate time points of superfusion with compound.   
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4.4.3 Selective activation of NaV1.6 in C fibres 
The non-selective activation of A and C fibres by P-CTX-1 provides key insight into which 
isoforms are functionally important at the distal terminals in the skin.  The selective activator 
of NaV1.7, OD1, has been used to further demonstrate the contribution of this isoform to both 
A and C fibre function (303).  However, the contribution of the NaV1.6 isoform at the distal 
terminal to C fibre firing remains unclear.  Therefore, armed with the selective and potent 
NaV1.6 activator Cn2, I assessed NaV1.6 mediated changes in excitability. 
Unlike P-CTX-1, C fibres did not spontaneously fire after Cn2 application (n = 16). NaV1.6 
activation in C fibres did not change the mechanical threshold, or fire more action potentials in 
response to mechanical stimulus (Figure 4.3 E).  NaV1.6 activation by Cn2 caused a decrease 
in the number of action potentials (before 51.9 ± 1.6; after 31.5 ± 5.8, p < 0.05, Student’s 
paired t-test) in response to cold stimulation in cold-mechanosensitive C fibres (13/16).  Heat 
sensitive C fibres (CMH) fired at higher peak frequency after Cn2 application, however this 
effect did not reach statistical significance (Figure 4.3 A, B).  Recordings from a polymodal 
cold/heat sensitive (CMCH) fibre demonstrate the decrease in action potentials in response to 
cold and increase in peak frequency in response to heat (Figure S19).  
109 
 
 
110 
 
Figure 4.3 NaV1.6 channel activation in temperature and mechanosensitive C fibres 
A) Representative trace of a C mechano-heat fibre (CMH) demonstrating increased peak 
frequency after Cn2 application (10 nM). Shown above is the temperature at the receptive 
field. B) Summary data of heat sensitive C fibres (n = 6/16). C) Representative trace of a C 
mechano-cold (CMC) fibre showing decreased action potential discharge to cold stimulation 
after exposure to Cn2. D)  Cold sensitive C fibres display a decrease in number of action 
potentials after Cn2 (10 nM) before 51.9 ± 1.6; after 31.5 ± 5.8 application. E) Representative 
response to mechanical stimulus after Cn2 (10 nM) showing no increase in peak frequency or 
number of action potentials.  
111 
 
4.4.4 NaV1.6 in A fibres leads to increased mechanosensitivity 
Application of Cn2 at the distal terminals innervating the skin caused increased responses to 
mechanical stimulation in A fibres.  Unlike the NaV1.7 selective OD1 or indeed P-CTX-1 
(Figure 4.2), Cn2 (10nM) did not cause spontaneous firing in any A fibre (Figure 4.4 A, 
n = 25) (243, 303).  Isolated mechanosensitive A fibres responded in two distinct groups, one 
characterized by repetitive (tonic) sustained firing in response to a single mechanical stimulus 
at threshold (n = 11), and the other with an enhanced but recoverable response to increasing 
mechanical stimuli (n = 14); here-on referred to as bursting and mechanically sensitive, 
respectively (Figure 4.4 A, E, F).  However, at higher concentrations (>100 nM) Cn2 induced 
spontaneous firing followed by loss of excitability (data not shown).  Application of Cn2 to 
so-called mechanically sensitive A fibres leads to an increase in the number of action 
potentials per stimulus (Figure 4.4 A, C) and significantly increased peak firing frequency 
(Control: 47.8 ± 16.5, Cn2: 210 ± 29.5, p < 0.0001, n = 12) (Figure 4.4 D).  Conduction 
velocity between the two identified groups was not significantly different, albeit non-bursting 
(mechanically sensitive) fibres tended to have faster conduction velocities than bursting fibres 
(Figure 4.4 B).  
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Figure 4.4 NaV1.6 channel activation at distal terminals in the skin dramatically alters 
firing of A fibres.  
A) Cn2 altered excitability in all 25 A fibres recorded, with 10 developing a bursting 
phenotype, and 15 becoming mechanically sensitive. B) Conduction velocity does not differ 
significantly (unpaired t-test, p > 0.05) between the A fibres that display burst firing pattern 
(3.5 ± 0.5 m/s; n = 5) and those which have increased response to mechanical stimulus (7.3 ± 
1.3 m/s, n=12). C) Increase in number of action potentials of a subset of mechanically 
sensitive A fibres after Cn2 application. D) Peak firing frequency of mechanically sensitive A 
fibres before (47.8 ± 16.5, n = 12) and after Cn2 (210.8 ± 29.3) application. E, F) 
Representative traces of mechanosensitive A fibre before and after Cn2 (10 nM, 5 minutes 
perfusion) using increasing von Frey filaments (grams force, gf) applied to the receptive field 
in the skin. Each point represents a single action potential. E) A fibre with continuous burst 
firing after removal of stimulus or F) recoverable increase number of action potentials and 
peak firing frequency after Cn2 application  
113 
 
4.5 Discussion 
 
Sensory neural transduction begins at the distal terminals in the skin, where a range of ion 
channels and transducer channels “sense” external stimuli.  Understanding the contribution of 
different ion channels to the initiation and transduction of sensory signals in the periphery may 
help the pursuit of novel therapeutics.  Canonical nociceptors are unmyelinated, small 
diameter C fibres that preferentially express TTX-R NaV (197).  In-situ hybridization confirms 
robust NaV1.6 channel expression in these C fibre terminals in the skin and compound action 
potential recordings from isolated sciatic nerves show it contributes to excitability (304).  
Whole-cell electrophysiology from the cultured cell bodies of these neurons small diameter 
neurons suggest that NaV1.6 is responsible for ~34% of the NaV currents (220).  However, 
evidence from this Chapter (and Chapter 3) paint a more complex picture of NaV1.6 channel 
function in peripheral sensory neurons.  
Non-selective activation of C fibres by P-CTX-1 leads to robust induction of action potential 
firing (Figure 4.1).  This induced action potential firing was sustained over long periods of 
time (>30 min) without activity-induced adaption or silencing of these fibres.  Despite the 
crucial role of NaV1.7 in pain sensing discovered in part from patients who do not experience 
pain (congenital insensitivity to pain, CIP); selective block of NaV1.7 currents failed to 
significantly abolish firing of C fibres.  Furthermore, iPSC nociceptors humanized from 
patients with CIP are capable of firing action potentials suggesting that NaV1.7 is not critical 
for firing (162). NaV1.7 channels which are also TTX-S and have kinetic properties more 
comparable to NaV1.6, were found to play a minimal role in C fibres activation (305).  
Interestingly, the NaV1.7 channel agonist OD1 in the same experimental set up caused 
spontaneous firing of C fibres suggesting that the NaV1.7 channel is indeed present and 
functional in these terminals (303). 
In this study, the NaV1.6 blocker GIIIA was perfused (on C fibre receptive fields) after Pn3a 
and had no effect of the average number of action potentials induced by P-CTX-1 (Figure 4.1 
B).  Indeed, selective activation of NaV1.6 in C fibres in the skin by Cn2 did not induce action 
potential firing or alter mechanical thresholds (Figure 4.3).  However, subtle changes in 
temperature sensitivity were observed in C fibres after NaV1.6 activation; of particular note, a 
surprising decrease in excitability in response to cooling.  NaV1.6 has been implicated in 
aberrant cold sensing including P-CTX-1-induced cold allodynia and oxaliplatin-induced cold 
pain (212-214).  Specifically, that these behavioural phenotypes in vivo are reversed by 
NaV1.6 inhibitors.  However, NaV1.6 activation by Cn2 alone does not cause cold allodynia.  
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The potassium channel blocker 4-AP in conjunction with Cn2 causes enhanced responses cold 
in vivo (213).  Indeed, a decrease in response to cold in C fibres is unlikely to explain an 
increase in cold allodynia.  Furthermore, oxaliplatin induced changes in cold responses are 
evident in large, not small diameter neurons (212).  It is plausible that the subtle changes in 
cold sensitivity of C fibres after exposure to Cn2 observed in this study reflects the differential 
expression of ion channel isoforms at the C fibre distal segment.  Depending on the repertoire 
of ion channels expressed in this subset of fibres, a small influx of sodium caused by Cn2 
might drive the membrane potential to values more or less favourable for other NaV channel 
isoforms.  This includes the TTX-R NaV1.9 that has a depolarised V1/2 of activation and has 
been implicated in aberrant cold sensing (187).  The NaV1.9 channel, an isoform completely 
restricted to small diameter C fibres, is also important for excitability in the distal terminals in 
the skin (306).  Moreover, TTX-R NaV1.8 channels are enriched at the distal terminals and are 
responsible for the action potential conduction in C fibres (279).  In line with this, the selective 
NaV1.8 antagonist A803467 significantly reduced action potential firing in C fibres caused by 
P-CTX-1.  Furthermore, dermal C fibres from NaV1.8
-/- mice have a considerably attenuated 
response to P-CTX-1.  In Chapter 5, the contribution of NaV subtypes to P-CTX-1 induced 
spontaneous pain is investigated in vivo.  Finally, in the study of selective NaV1.6 activation, 
no cold sensitive A fibres were found in control conditions.  However, whether Cn2 leads to 
non-sensitive fibres shifting to a cold sensitive state remains unknown.  Exploring the role of 
NaV1.6 in these fibres types is warranted given their importance in pathological pains states 
(212).   
Intriguingly, data (not included in this thesis) suggests the NaV1.6 isoform is important for 
excitability of peripheral neurons innervating the gut.  Visceral afferents are solely comprised 
of small diameter thinly myelinated Aδ and non-myelinated C fibres (307-310).  However, 
single-cell RT-PCR data show that 62.5% of colon-innervating thoracolumbar DRG neurons 
express NaV1.6 channels (243).  Indeed, selective antagonism of NaV1.6 channels in low-
threshold colorectal afferents reduced tonic spiking in response to stretch (311).  Evidence 
from the application of Cn2 to the colonic mucosal surface (not shown) supports this finding.  
This evidence extends it to high-threshold nociceptors, and suggests that mechanosensitive C 
fibres in the gut express NaV1.6 channels and activation of this isoform leads to increased 
mechano-sensitivity.  It should be noted that the concentrations used to elicit the increase in 
response to mechanical stimulus in colonic neurons was considerably higher (100 fold) than 
that tested in the skin.  In vitro assessment of Cn2 (Chapter 1, Figure 1) suggest that Cn2 
remains selective at this concentration.  However, testing this concentration in the skin is 
115 
 
technically challenging due to confounding A fibre hyperexcitability discussed below.  Many 
of the studies of ion channels in the distal terminals utilize conditional and global knock-out 
animals, an approach difficult for the study of NaV1.6 channels due to lethality of null 
mutations.  Thus, it is likely that the mélange of different NaV isoforms in the distal terminals 
of C fibres in the skin allows redundancy and even compensation that may explain the subtle 
changes (to temperature and mechanical stimulus) observed.  This aspect could be further 
explored with the use of selective molecules in conjunction with knock-out animals.  
P-CTX-1 induced spontaneous firing in A fibres is blocked by NaV1.7 or NaV1.6 highlighting 
their importance in these fibres types.  NaV1.6 activation dramatically altered the excitability 
of large diameter DRG soma (Figure 3.2).  Projections from these large DRG soma are 
myelinated Aδ and Aβ fibres in the dermis.  Accordingly, NaV1.6 activation by Cn2 
preferentially enhanced the response to mechanical stimulus in these fibre types ex vivo.  
Primarily, this confirms the crucial role for NaV1.6 channels in A fibres and the importance of 
these fibres in mechanosensation (218, 280, 312).  What effect (if any) this enhanced A fibre 
excitability has on nociceptive behaviours is explored in Chapter 5.  The conduction velocity 
of the two groups of A fibres identified were not significantly different.  However 
mechanically sensitive fibres tended towards faster conduction velocities suggesting that they 
were more heavily myelinated Aβ fibres. Bursting A fibres were often identified after 
receptive fields were treated with Cn2 making reliable measurement of the conduction 
velocity of these fibres difficult.  Indeed, the recruitment of these A fibres at low 
concentrations of Cn2 made signal filtering of other fibres challenging.  
Some parallels can be drawn between the effect of Cn2 at the distal terminal and those from 
current clamp experiment in Chapter 3 (Figure 3.6).  Large diameter neurons did not 
spontaneous fire during or after addition of Cn2, accordingly A fibres did not spontaneously 
fire after application of Cn2 to the receptive field.  In both, a stimulus (in this case 
mechanical) was required to elicit the Cn2 induced NaV1.6 response consistent with toxin 
binding to the voltage sensor in the activated position.  It is plausible in this experimental 
design that this initial depolarising step that is evoked by current injection in vitro may be 
arrived at ex vivo by mechanical stimulation with von Frey hair.  Furthermore, the lack of 
spontaneous activity in the absence of a mechanical stimulus in A fibres treated with Cn2 
confirms that this isoform is not important in action potential initiation (149).  This is in 
contrast to NaV1.7 channels which display ramp currents (147, 148) and are important for 
setting the threshold for action potential generation (313). 
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In conclusion, use of Cn2 has identified two populations of A fibres in the skin previously 
indistinguishable by conduction velocity or adaption – highlighting a need to use 
pharmacological approaches.  What differences drive the discrete responses to NaV1.6 channel 
activation in these A fibres and whether they are relevant in non-pathological circumstances 
remains to be seen. The two groups identified might simply have unique ion channel profiles 
outside NaV1.6 or differing spatial expression of ion channels.  Furthermore, NaV1.6 activation 
in the distal terminals of C fibres leads to slightly altered firing patterns.  
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Chapter 5 – Pharmacological approaches to isolating NaV1.6 expressing 
neurons in vivo  
 
 
5.1 Foreword 
 
This chapter describes the contribution of NaV1.6 to pain pathways in vivo using 
pharmacological approaches.  This includes using the NaV1.6 selective peptide Cn2 and the 
analogue Cn2[E15R]. The contribution of NaV1.6 to pathological pain is probed using murine 
models including P-CTX-1 and formalin.  This chapter contains results published in papers 
that appeared in Journal of Medicinal Chemistry (227) and Scientific Reports (243). To fit 
with the style of the thesis, the data has been presented in a different manner with the inclusion 
of previously unpublished data.  
 
 
5.2 Introduction  
 
The contribution of different ion channels to the pain pathway can be aided by the study of 
animal models of nociception. This includes models of acute, chronic and neuropathic pain. 
Animal models of nociception can involve the introduction of injury such as those seen in the 
clinic, to reproduce neuropathic pain.  This includes surgeries such as complete axotomy, 
spared nerve injury, chronic constriction injury and spinal nerve ligation (314-316).  Models 
such as bone cancer pain and post-herpetic neuralgia involve injection of cancerous cells or 
virus directly into rodents (317, 318).  Alternatively, nociceptive behaviours may be induced 
pharmacologically by injecting anti-cancer agents or toxins (213, 224).  A range of methods 
are then used to assess “pain-like” behaviours and these are most commonly quantified by 
using an animal’s withdrawal from nociceptive stimulus.  Behavioural methods to assess 
nociception are divided into stimulus-evoked and non-stimulus-evoked, the former being 
subdivided by the type of the stimulus; mechanical, heat or cold.  Commonly used tools for 
stimulus-evoked nociception include von Frey hairs and hot/cold plates or temperature probes 
(319).  
NaV channel knock-out animals have been used to elucidate various isoforms’ specific 
contributions to pain pathways.  For example, the symptoms of congenital insensitivity to pain 
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(CIP) that is caused by loss-of-function mutations of SCN9A, were successfully recapitulated 
in global NaV1.7 null mice (155).  Patients with CIP are unable to sense painfully high 
temperatures (150) accordingly, animals with a particular loss-of-function mutation in SCN9A 
also do not withdraw when challenged with noxious heat (155).  
Evidence for the involvement of NaV1.6 in pain pathways is emerging, although the 
contribution of this isoform to excitability of sensory neurons remains unclear.  In humans, a 
gain-of-function mutation in NaV1.6 contributes to hyperexcitability in a case of trigeminal 
neuralgia (201). Increased channel availability and increased resurgent current were found in 
ND7/23 cells transfected with mutant NaV1.6 channels (201).  The effect of this mutation on 
different fibre types has not been assessed to date.  It should be noted that the proportion of 
unmyelinated fibres in the trigeminal root is distinctly less than that of the dorsal root of 
primates (320).  Human loss-of-function mutations have also been described, although these 
patients typically present with CNS/intellectual disabilities and the effect, if any, of these 
mutations on sensory neuron function have not been described.  Unfortunately, the juvenile 
lethality of global NaV1.6
-/- mice has significantly impeded the study of this isoform in 
peripheral sensory pathways (204).  Nonetheless, there is evidence that NaV1.6 is a significant 
contributor to hyperexcitability in several animal models of pain (211-213, 219, 220).  In a 
model of type 2 diabetes associated with persistent mechanical allodynia, NaV1.6 mRNA and 
protein expression is significantly increased in DRG neurons (211).  Knockdown of NaV1.6 by 
siRNA reduces hyperexcitability in DRG neurons and pain behaviours caused by spinal nerve 
ligation (219).  Additionally, conditional knock-out of NaV1.6 in NaV1.8-expressing neurons 
reduces pain behaviours associated with spinal nerve injury (220). 
NaV1.6 is critical for chemotherapy-induced peripheral neuropathy (212, 213).  Currents in 
large diameter neurons that are carried by the NaV1.6 isoform underlie the hyperexcitability 
that is associated with cooling (212).  Specifically, oxaliplatin enhances resurgent and 
persistent currents in large diameter DRG neurons, an effect that is reduced in NaV1.6
-/- 
neurons.  Interestingly, these currents are both enhanced by Cn2 (Chapter 3) which when 
injected alone fails to cause cold allodynia (213).  Finally, blocking NaV1.6 (with the µ-
conotoxin GIIIA) in vivo reduces pain behaviours associated with ciguatoxin and oxaliplatin 
induced cold allodynia (213, 214). 
However, despite this emerging evidence, the contribution of NaV1.6 to physiological and 
pathological pain is not well defined.  One highly successful approach to circumnavigating 
genetic approaches of delineating the contribution of specific ion channel isoforms to pain 
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pathways has been the use of subtype-selective venom peptides.  These pharmacological 
agents have been useful in delineating the effect of ion channels in pain sensing due to their 
high potency and selectivity.  For example, the NaV1.7 α-scorpion toxin OD1 causes robust 
spontaneous pain behaviours when injected intra-plantar, providing a rapid, target-specific 
assay for in vivo efficacy of NaV1.7 blockers (303).  Similarly, the δ-theraphotoxin-Hm1a, 
derived from tarantula venom, revealed a previously underappreciated role for NaV1.1 in 
mechano-sensitive Aδ fibres (104) 
Therefore, this study aimed to explore the role of NaV1.6 in nociception in vivo using the 
selective tools synthesized and characterised in Chapters 2 - 4.  This encompasses the effect of 
NaV1.6 agonists and antagonists on basal levels of stimulus-evoked nociceptive behaviours 
and the effect of NaV1.6 blockers in models of pathological pain.  NaV1.6 activation by Cn2 
caused mechanical allodynia when injected locally into the plantar hind paw. This chapter 
therefore builds on ex vivo evidence presented in Chapter 4 that showed a crucial role for 
NaV1.6 channels in mechanosensing fibres, and links behavioural responses to these 
pharmacological effects.  NaV1.6 antagonist did not significantly increase paw withdrawal to 
mechanical stimulus.  Cn2[E15R] reduced pain behaviours in NaV1.6 but not NaV1.7 specific 
pain models and was anti-nociceptive in P-CTX-1 and formalin induced non-stimulus evoked 
pain.  Thus, the novel NaV1.6 antagonist Cn2[E15R] emerges as a promising tool for 
elucidating the role of NaV1.6 in peripheral sensory neurons.  
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5.3 Methods 
 
5.3.1 Materials 
All materials were obtained from Sigma-Aldrich (Australia) unless otherwise stated.  Cn2 and 
Cn2[E15R] were synthesized as per Chapter 2.  OD1 was synthesized by Thomas Durek 
(Institute for Molecular Biosciences, University of Queensland) as previously described (242).  
GIIIA, TIIIA and Pn3a was synthesized by Zoltan Dekan (Institute for Molecular Biosciences, 
University of Queensland) as previously described Deuis et al (160). P-CTX-1 was isolated 
and purified from moray eel viscera as previously described by Lewis et al (301).  
5.3.2 General housing  
All animal experiments were approved by local ethics committees at the University of 
Queensland and the University of Erlangen and were conducted in accordance with the 
NHMRC code for use of animals (2013 Edition) and International Association for the Study of 
Pain Guidelines for the Use of Animals in Research.  All experiments performed conformed to 
the relevant regulatory standards and the ARRIVE guidelines (321).  C57BL/6 mice were 
housed in the University of Queensland School of Pharmacy (PACE) specific animal care 
facilities.  Mice were housed in individually ventilated cages (≤ 5 animals per cage) with corn 
cob bedding or aspen wood chip bedding. Cage racks were in temperature-controlled rooms 
(22oC) and exposed to 12 hr light / 12 hr dark cycle.  Animals were given access to standard 
rodent chow and water ad libitum and supplied with a red polycarbonate Mouse House 
(Techniplast, Italy) and shredded paper for nesting and enrichment.  All animals were 
acclimatised (for 1 hr) in the behavioural room prior to behavioural experiments.  
5.3.3 Murine model of nociception and behavioural analysis  
All animal behavioural experiments utilized male C57BL/6 mice, 6-8 weeks, approximately 
20-25g.  After experimentation all animals were sacrificed by CO2 inhalation. To assess the 
effect of NaV1.6 channel activation in vivo, a previously described model of toxin-evoked 
nociception was utilized (213). Under brief isoflurane (3%) anaesthesia, a single dose of Cn2 
(10 nM), OD1 (300 nM), P-CTX-1 (10 nM) or formalin (1%, w/v) were diluted in sterile PBS 
containing 0.1% BSA (Cn2, OD1 and P-CTX-1) and administered via shallow subcutaneous 
injection to the hind paw (intraplantar i.pl., 40 µL).  Mice were allowed to recover in clear 
polyvinyl boxes and recorded for one hour post injection.  Following this, nocifensive 
behaviours including flinches, lifts and shakes were counted at 5-minute intervals from a video 
recording by a blinded observer. Following cessation of spontaneous pain behaviours, 
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mechanical allodynia was tested using the MouseMetTM electronic von Frey.  Briefly, the von 
Frey probe was placed on the dorsal hindpaw plantar surface.  By rotating the device, the 
pressure was increased by 1 g/sec until withdrawal of dorsal hindpaw.  The paw withdrawal 
threshold was recorded by the MouseMet software with the final score being an average from 
three stimulus over the space of 10 minutes.  Thermal thresholds were assessed with the 
MouseMetTM thermal probe.  Like the electronic von Frey apparatus, the thermal probe, pre-
heated to 37oC, was placed on the plantar surface.  The probe heats at a rate of 2.5oC/sec and 
cuts off at 60oC.  The paw withdrawal temperature was recorded by the software and an 
average of three withdrawals were tested by a blinded observer.  Experiments on NaV1.3 and 
NaV1.7 knock-out animals were undertaken at University of Erlangen, recorded and counted 
by a blinded observer.  
All pharmacological modulators were co-injected with Cn2 (10 nM), OD1 (300 nM), P-CTX-
1 (10 nM) and formalin (1%, w/v) in order to assess their effect on nocifensive behaviours.  
The only exception was in the QX-314/flagellin experiment outlined below.  This includes; 
Cn2[E15R] (0.2 µM, 2 µM, 10 µM), GIIIA (10 µM), A803467 (10 µM), TTX, (1 µM), Pn3a 
(1 µM) and TIIIA (10 µM).  
In order to elucidate whether NaV1.6 spontaneous pain and mechanical allodynia were 
mediated by particular A fibre types, a method for selective block of Aβ fibres was used as 
previously described (282).  Flagellin (0.9 µg), QX-314 (5 mM), QX-314 + flagellin were 
injected intraplantar (20 µL) in naïve mice and allowed to recover for 30 minutes before paw 
withdrawal threshold was measured using the MouseMetTM electronic von Frey.  Following 
this, Cn2 (10 nM; 20 µL) was injected into the same paw and the animals were recorded for 10 
minutes in clear Perspex boxes. Nocifensive behaviours were counted by a blinded observer.  
Animals were then acclimatised into cages for von Frey testing.  
5.3.4 Data and statistical analysis 
Data was collected and plotted using GraphPad Prism (Version 7.00, San Diego, California). 
The experimenter was blinded to the experimental conditions in all in vivo work.  Statistical 
significance (p <0.05) was tested using both paired and unpaired Students’ t-tests.  Data is 
presented as mean ± SEM unless otherwise stated. 
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5.4 Results 
 
5.4.1 NaV1.6 activation causes mechanical allodynia but not thermal allodynia 
Consistent with bursting phenotype observed in a subset of A fibres, as well as previous 
reports (213), Cn2 caused non-stimulus evoked pain when administered by the intra-plantar 
route (Figure 5.1 A).  NaV1.6 activation led to mechanical hypersensitivity in A fibres 
(Chapter 4), therefore I sought to test whether this extended to in vivo mechanical thresholds.  
Indeed, intraplantar injection of Cn2 (10 nM) decreases paw withdrawal threshold to 
mechanical stimulus (Figure 5.1 B). Consistent with the limited effects observed in C fibres in 
ex vivo recordings (Chapter 4, Figure 4.3), Cn2 alone does not affect behavioural responses to 
cold stimuli (213).  In addition, the heat withdrawal threshold remained unchanged between 
control and Cn2 treated animals (Figure 5.1 C). 
In Chapter 4, the two groups of A fibres identified by Cn2 were not distinguished by 
conduction velocity. However, those which responded to von Frey stimulus with a recoverable 
increase in the number of action potentials and peak firing frequency tended to having higher 
conduction velocities.  In order to explore the A fibre type responsible for in vivo non-stimulus 
and stimulus evoked pain I utilised the method described by Xu et al., (282).  The authors 
propose that by using the toll-like receptor 5 (TLR5) ligand, and flagellin, in conjunction with 
the quaternary lignocaine QX-314 (non-selective membrane impermeable NaV blocker), 
selective blockade of Aβ fibres is achieved (282). 
Flagellin alone had no effect on Cn2-induced nocifensive behaviours, however flagellin co-
administered with QX-314 abolished all flinches caused by NaV1.6 activation.  Intriguingly, 
QX-314 alone also blocked all non-stimulus evoked pain (Figure 5.1 D).  Furthermore, QX-
314 alone does not change the mechanical threshold in naïve animals but reversed the NaV1.6 
mediated mechanical allodynia (Figure 5.1 E). 
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Figure 5.1 NaV1.6 expressing peripheral sensory neurons in the skin crucial for 
mechanosensation.  
A) Intra-plantar injection of Cn2 (10 nM) causes spontaneous pain (control 0.6 ± 0.3 and Cn2 
72.7 ± 10.1 behaviours, n = 5 - 8) and B) at the same concentration reduces paw withdrawal 
threshold to von Frey filament, control 2.3 ± 0.3 (n = 13) and Cn2 1.0 ± 0.2 (n = 8) p < 0.05 
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unpaired t-test. C) Cn2 does not affect noxious temperature sensing. Paw withdrawal 
temperature Control: 50.6 ± 0.9 oC and Cn2: 50.5 ± 1.3 oC. D) Flagellin (0.9 µg) does not 
decrease spontaneous pain (73.3 ± 2.8 pain behaviours, n = 4), QX-314 (5 mM) and QX-314 + 
flagellin (0.4 ± 0.4 and 1.75 ± 0.9 behaviours respectively, n = 4) both significantly reduce 
nocifensive behaviours associated with NaV1.6 activation. E) QX-314 (5 mM) alone abolishes 
mechanical allodynia caused by Cn2 (QX-314 before Cn2 1.5 ± 0.2 and after Cn2 1.6 ± 0.3 g; 
Control before Cn2 1.7 ± 0.1 and after Cn2 0.4 ± 0.3, n = 4 p < 0.05, paired Student t-test) 
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5.4.2 The effect of NaV1.6 blockers on mechanical and thermal thresholds 
In Chapter 2, in vitro evidence showed that the analog Cn2[E15R] had retained the depressant 
β-scorpion activity in the absence of excitatory early channel opening.  Given that Cn2[E15R] 
only retains NaV1.6 depressant activity, I hypothesized that it would show anti-nociceptive 
properties in the NaV1.6 mediated spontaneous pain assay.  Intraplantar injection of up to10 
μM Cn2[E15R] failed to cause spontaneous pain behaviours when administered alone (Figure 
5.2 A). Co-administration of Cn2 with Cn2[E15R] concentration-dependently reduced 
spontaneous pain behaviours evoked by Cn2 (Figure 5.2 B) suggesting that Cn2 and 
Cn2[E15R] compete for the same NaV1.6 binding site in vivo.  To further test on-target 
activity in vivo, I used the NaV1.7 specific scorpion toxin OD1 which causes robust induction 
of nocifensive behaviours (303). Cn2[E15R] did not reduce flinches caused by NaV1.7 
activation (Figure 5.2 C).  Although, blocking NaV1.6 in vivo with GIIIA 10 μM caused 
increase in the paw withdrawal threshold compared to control, this effect did not reach 
statistical significance.  In contrast, 2μM Cn2[E15R] did not affect mechanical threshold in 
vivo (Figure 5.2 D).  Finally, the NaV1.6 modulators GIIIA and Cn2[E15R] did not change the 
threshold for withdrawal to noxious heat (Figure 5.2 E).  
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Figure 5.2 Cn2[E15R] ablates NaV1.6 specific pain but does not significantly change 
mechanical threshold 
A) Unlike Cn2 (10 nM), Cn2[E15R] (10 µM) does not cause spontaneous pain when injected 
intraplantar. B) Cn2[E15R] concentration dependently decreases (0.2 µM; 51.7 ± 10.7, p > 
0.05 and 2 µM; 1.0 ± 1.0 p < 0.05, n = 3) the nocifensive behaviours associated with NaV1.6 
activation by Cn2. C) Cn2[E15R] does not reduce nocifensive behaviours caused by NaV1.7 
activation by OD1 (OD1 300 nM ; 82 ± 6 and Cn2E15R 2 µM; 92.3 ± 8.0, p > 0.05, n = 5). 
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D) NaV1.6 antagonists do not significantly change threshold of paw withdrawal to mechanical 
stimulus (Vehicle Control; 2.3 ± 0.3g, GIIIA 10 µM; 3.2 ± 0.5g, Cn2[E15R] 2 µM; 2.4 ± 0.4g, 
p > 0.05) or change threshold of paw withdrawal to heat stimulus (Control; 50.6 ± 0.9 oC, 
GIIIA 10 µM; 50.2 ± 1.3 oC, Cn2[E15R] 2 µM; ± 0.6 oC, p > 0.05) (n = 9 – 12). 
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5.4.3 NaV1.6 contributes to pathological pain states: ciguatoxin-induced pain  
Spontaneous firing in C and A fibres caused by P-CTX-1 is mediated by both TTX-R and 
TTX-S isoforms respectively (Chapter 4, (105)).  In order to test the hypothesis that both 
TTX-S and TTX-R isoforms are responsible for spontaneous pain symptoms we assessed 
selective NaV antagonists in vivo.  A murine model of ciguatera was established based on 
shallow intra-plantar injection of P-CTX-1 (214).  P-CTX-1 spontaneous pain and anti-
nociception is time dependent and spontaneous pain-like behaviours can be observed up to 40 
minutes after administration (Figure 5.3 B, D).  To assess whether P-CTX-1 induced 
spontaneous pain is TTX sensitive we co-administered P-CTX-1 (5 nM) with 1 µM TTX 
intra-plantar (40 µL) and pain behaviours were recorded by a blinded observer.  TTX 
abolishes spontaneous pain associated with P-CTX-1 (Figure 5.3 A, B).  Given this I sought to 
test the effect of NaV subtype selective antagonists.  Unsurprisingly, given the sensitive to 
TTX, co-administration of P-CTX with NaV1.8 antagonist A803467 (10 µM) does not alter 
spontaneous pain behaviours.  
I then sought to systematically test the contribution of TTX-S NaV isoforms to P-CTX-1 
induced pain.  The NaV1.1/1.2 antagonist TIIIA also had no effect on P-CTX-1 induced 
spontaneous pain.  Accordingly, NaV1.3 knock-out animals did not have reduced pain 
behaviours (Figure 5.3 C).  Conversely, intra-plantar administration of the NaV1.6 inhibitor 
GIIIA (10 µM; 19.0 ± 10.1 behaviours/5 min) or NaV1.7 inhibitor Pn3a (3 µM; 7.7 ± 5.7 pain 
behaviours/5 min) abolished pain behaviours associated with P-CTX-1 (p < 0.01).  The 
importance of NaV1.7 in P-CTX-1 pain was confirmed using NaV1.7 knock-out animals.  
Interestingly, the putative NaV1.6 selective channel modulator Cn2[E15R] (10 µM) also 
ablated P-CTX-1 effects in vivo, supporting the crucial role of NaV1.6 in spontaneous pain 
generation in this model (Figure 5.3 E).  
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Figure 5.3 The development of ciguatoxin-induced spontaneous pain is mediated by 
NaV1.6 and NaV1.7 
A) Flinches at (T=10) caused by co-administration (i pl) of P-CTX-1 and NaV blockers. 
Selective NaV1.8 A803487 (10 µM) does not reduce P-CTX-1 induced spontaneous pain 
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(Control; 97.4 ± 9.4, A8043467; 105.7 ± 9.4 pain behaviours). TTX (1 µM) abolishes 
nocifensive behaviours caused by P-CTX-1 (TTX; 7.1 ± 1.3 pain behaviours). B, F) Time 
course of P-CTX-1 induced spontaneous pain shows nocifensive behaviours persist for up to 
45 minutes after injection and that block of TTX-S channels provides long term analgesia. 
C) Selective NaV1.1/1.2 antagonist TIIIA (10 µM) does not block spontaneous pain 
behaviours associated with P-CTX-1 administration (125.7 ± 31.1 pain behaviours). Mice 
lacking NaV1.3 develop P-CTX-1 induced pain (103.3 ± 20.4). D) The NaV1.6/1.1 antagonist 
GIIIA (10 µM) significantly reduces P-CTX-1 induced spontaneous pain (19.8 ± 10.1). 
NaV1.7 null mice also have significantly reduced pain behaviours (20.7 ± 10.7). Selective 
NaV1.7 blocker Pn3a (1 µM) is also effective (16.7 ± 8.2). E) The novel NaV1.6 selective 
antagonist Cn2[E15R] also significantly blocks total nocifensive behaviours caused by P-
CTX-1 (Control; 306 ± 29.3 , Cn2[E15R];63 ± 13.7 ). (n = 3 - 5 animals per treatment) 
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5.4.4 NaV1.6 contributes to pathological pain states: formalin-induced pain  
Cn2 [E15R] is analgesic in NaV1.6 specific pain (Figure 5.1 B) but not NaV1.7 specific pain 
(Figure 5.1 C).  Therefore, I examined the effect of Cn2[E15R] in a generalised assay of 
nociception.  The formalin mouse model is a well-established model of pain in which phase I 
is caused by direct activation of nociceptors and phase II is caused by inflammatory 
sensitization.  Cn2[E15R] significantly reduced flinching associated with phase II (pain 
behaviours: control 232 ± 18, Cn2[E15R] (10 µM) 138 ± 15; p < 0.05 two-way ANOVA) 
(Figure 5.4 A, B).  Thus, Cn2[E15R] not only competes with Cn2, but is a functional inhibitor 
of NaV1.6 in vivo in its own right.  
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Figure 5.4 Novel NaV1.6 antagonist Cn2[E15R] reduces formalin induced pain  
A) Time course of the effect of Cn2[E15R] (10 μM) formalin induced pain behaviours. 
B) Phase II, but not phase I, total pain behaviours were significantly reduced with intraplantar 
injection of 10 μM Cn2[E15R] (control 232 ± 18, Cn2[E15R] 138 ± 15*= p ≤ 0.05, unpaired t 
test, n = 3 - 13). 
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5.5 Discussion 
  
Voltage-gated sodium channels (NaV) are crucial for the excitability of peripheral sensory 
neurons.  Of the nine known isoforms, only a subset are expressed in peripheral sensory 
neurons including the TTX-S NaV1.1, 1.6, 1.7 and the TTX-R isoforms NaV1.8 and NaV1.9.  
In the present study, I explored the role of the NaV1.6 in these neurons using pharmacological 
probes.  For the first time, the effect of pharmacological activation and inhibition of NaV1.6 in 
vivo was systematically assessed.  The contribution of NaV1.6 to pathological pain states was 
highlighted using two models of non-stimulus evoked nociception. 
5.5.1 Effects of selective NaV1.6 agonist and antagonists  
NaV1.6 activation by Cn2 caused non-stimulus and stimulus (mechanical) evoked pain when 
injected intraplantar.  Unlike the native toxin, Cn2[E15R] did not cause spontaneous pain or 
mechanical allodynia.  This goes some way to confirming that the enhanced excitability is 
indeed a direct result of the early channel opening/voltage-sensor trapping mechanism 
proposed by Cestele et al. and reduced in the E15R mutant (322).  Cn2[E15R] blocks Cn2 
induced spontaneous pain behaviour confirming on target activity in vivo.  Furthermore, the 
inability for Cn2[E15R] to reduce pain behaviours in a model of NaV1.7 specific pain suggests 
in vivo on target specificity.  Significantly, Cn2[E15R] reduced nocifensive behaviour in the 
second phase of the formalin model of nociception.  This suggests that Cn2[E15R] is a 
modulator of NaV1.6 in vivo in its own right.  Transient receptor potential ankyrin 1 (TRPA1) 
expressing neurons, the majority of which are C fibres, have been implicated in formalin (1% 
w/v) induced nocifensive behaviour (323).  Contrastingly, formalin (2% w/v) caused robust 
pain behaviours even after genetic ablation of a large proportion of C fibres, indicating a 
significant contribution by myelinated A fibres (324).  Indeed, single fibre recordings from 
afferents in the skin suggest that phase II of formalin evoked activity is dependent on both Aδ 
and C fibres (325).  Given the evidence from the native toxin (Chapters 3 and 4), I hypothesize 
that these medium and large diameter myelinated fibres are the target for Cn2[E15R].  The 
partial effect of Cn2[E15R] in this model might be attributed to ongoing activity of C fibres.  
Assessing the effect of Cn2[E15R] on peripheral sensory neurons in vitro and ex vivo might 
confirm this hypothesis. 
While NaV1.6 activation by Cn2 caused robust mechanical allodynia; blocking NaV1.6 with 
Cn2[E15R] failed to lead to hypoalgesia.  Interestingly, the mu-conotoxin GIIIA increased the 
paw withdrawal threshold by 40%, although this did not reach statistical significance.  GIIIA 
is a mixed 1.6/1.1 antagonist, and binds to site one of the NaV channel physically occluding 
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the ion conducting pore (326).  Contrastingly, Cn2[E15R] is a gating modifier toxin (Chapter 
2), depolarising the voltage dependence of inactivation and decreasing peak current by 
approximately 50%.  The subtle difference in mechanism of action may explain why 
Cn2[E15R] does not increase paw withdrawal threshold.  The effect of selective 
pharmacological inhibition of NaV channels in naïve animals is rarely reported.  However, 
small molecules such as lignocaine that block the pores of NaV channels cause robust 
mechanical hypoalgesia (327).  The effect of gating modifier toxins on NaV channels might 
not be sufficient for generating hypoalgesia.  Furthermore, NaV1.1 has been implicated in 
mechano-sensitive Aδ fibres (104), therefore the compound effect of NaV1.1 and NaV1.6 
blockade by GIIIA might also contribute to the slight hypoalgesia.  The lack of abnormalities 
in noxious heat sensing after NaV1.6 modulation by GIIIA, Cn2 and Cn2[E15R], taken 
together with the absence of any kinetic changes in small diameter neurons (Chapter 3) 
suggests a minor role for NaV1.6 in small diameter heat sensitive C fibres.  Not assessed in 
this study was behavioural changes in sensitivity to cold.  Cn2 alone does not change 
behavioural responses on noxious cold (213).  However, co-administration of Cn2 with the KV 
blocker 4-AP causes cold allodynia (213).  Furthermore, enhanced persistent and resurgent 
current in large diameter neurons (such as those seen in response to Cn2) mediates the 
enhanced responses to cold and chemotherapy agents (212).  This indicates that NaV1.6 
expressing neurons are important in pathological cold sensing; however which sensory 
neuronal populations are involved remains to be seen.  Single fibre data (Chapter 4) showed a 
decreased response to cold in C fibres, however cold sensitivity in A fibres was not tested.  I 
hypothesize that the addition of 4-AP with Cn2 could drive cold-insensitive A fibres to 
respond to cooling ramps.  
5.5.2 QX-314 is analgesic alone in model of NaV1.6 induced pain  
QX-314 is a membrane impermeable lignocaine derivative (328). In order to bind and block 
NaV channels, QX-314 must be located on the intracellular side (329). This fact has been 
exploited to generate specific blockade of different sensory neuron subtypes in vitro and in 
vivo (282, 330).  For example, when applied externally in conjunction with the TRPV1 agonist 
capsaicin, selective inhibition of TRPV1 expressing neurons is achieved (330).  Recently, the 
same method was used to selectively block Aβ fibres (282).  TLR5 is expressed only in 
neurofilament positive neurons, corresponding to large myelinated A fibres (133, 282).  Using 
the TLR5 agonist co-administered with QX-314 a selective block of only large diameter 
neurons was reported.  However, in my study QX-314 alone completely abolished both 
NaV1.6 – specific spontaneous pain and mechanical allodynia.  Therefore, which A fibre group 
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identified in Chapter 4 is responsible for in vivo nocifensive behaviours remains unknown.  
However, due to the trend towards increased conduction velocity in the fibres that responded 
with enhanced mechanical sensitivity; I hypothesize that Aβ fibres are responsible for the 
mechanical allodynia observed in vivo. 
Cn2 induces repetitive firing in large diameter neurons in vitro and ex vivo, however, whether 
this alone is enough to allow QX-314 to enter the cells and subsequently block NaV channels 
remains unclear.  However, the rapid onset of reduced pain behaviours would suggest a direct 
effect of QX-314 on the channel.  The molecular determinants of this unexpected finding 
warrant further study.  Optogenetic approaches have been successfully used in recent years to 
silence (or stimulate) specific sensory fibres in vivo (331, 332).  The use of an inhibitory 
channel rhodopsin on Aβ fibres to selectively block their excitability could assist in 
determining the relative effect of each fibre type to isoform specific nociception.  
5.5.3 P-CTX-1 induced spontaneous pain is mediated by NaV1.6 and NaV1.7 expressing 
neurons 
Parathesiae associated with ciguatera fish poisoning include itching, tingling and cold 
allodynia (294).  Only 50% of A fibres responded to P-CTX-1 with sustained action potential 
firing (Figure 4.2), those that did were blocked by either NaV1.6 or NaV1.7.  All C fibres 
responded and were only significantly blocked by A803467, a NaV1.8 selective molecule.  
A803467 did not reduce spontaneous pain behaviours in vivo.  Contrastingly, selective NaV1.6 
or NaV1.7 antagonists significantly blocked P-CTX-1 induced non-stimulus evoked pain.  It 
follows that P-CTX-1 induced spontaneous dermal pain is mediated by A fibres that express 
both NaV1.6 and NaV1.7.  P-CTX-1 binds to site 5 of the NaV channel which is located within 
domain IS6 and domain IVS5 (92, 106).  Evidence from Chapter 2 submits that Cn2[E15R] is 
binding to a region other than site 4 (domain II S1-S2, S3-S4) and domain III SS2-S6 has been 
implicated in β-scorpion toxin interactions (102, 333, 334).  Therefore, it is unlikely that 
Cn2[E15R] binding site overlaps with P-CTX-1.  Thus, the efficacy of Cn2[E15R] in this 
model (and formalin) suggests that the delay in inactivation of NaV1.6 caused by Cn2[E15R], 
rather than competitive binding, is leading to reduction in pain behaviours.  
5.5.4 Conclusions and future directions  
The expression of NaV1.6 on motor neurons makes clinically targeting the isoform for the 
treatment of pain challenging.  Systemic administration of selective NaV1.6 blockers would 
likely lead to loss of muscle innervation and ultimately respiratory depression (cf. NaV1.6 
global knock-out animals).  However, the non-selective NaV pore blocker TTX is currently in 
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phase II clinical trials for chemotherapy induced neuropathy (335).  Given that NaV1.6 is 
sensitive to TTX, the outcome of the aforementioned clinical trial could set a positive 
precedent for pursing selective drug leads for this isoform.  Alternatively, NaV1.6 specific 
molecules could be delivered topically to reduce the systemic effects.  This route of 
administration has been somewhat effective for capsaicin and lignocaine in chronic 
neuropathic pain states (336, 337).  This includes patients with post-herpetic neuralgia and 
diabetes induced neuropathy, in which NaV1.6 has been implicated in preclinical studies (211, 
215).   
In conclusion, activating NaV1.6 in vivo leads to sensitivity to mechanical but not heat and 
cold (213) stimulus. Taken together with the findings from Chapters 3 - 4 this highlights the 
importance of the isoform in large diameter A fibres that are mechano-sensitive and an under-
appreciated role for these fibres in pain sensing.  The novel NaV1.6 selective inhibitor reduces 
pain behaviours in preclinical studies of pathological pain and is a promising therapeutic lead.  
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Chapter 6 - Overall Discussion and Conclusions  
 
 
Voltage-gated sodium channels (NaV) are crucial for the function of neurons in the central and 
peripheral nervous system.  Peripheral sensory neurons express only a subset of the nine NaV 
channel isoforms identified.  The aetiology of some heritable pain disorders has been found to 
be mutations in NaV isoforms of the peripheral neurons.  Therefore, the contribution of some 
individual NaV subtypes to pain has been broadly studied (134, 338).  Study of one isoform, 
NaV1.6, in the peripheral sensory nervous system has been neglected due in part to its 
expression centrally.  
The aim of this thesis was to assess the functional contribution of NaV1.6 in peripheral sensory 
neurons using pharmacological approaches.  In order to address this aim, subtype selective 
pharmacological probes were required.  The natural world has engineered a wealth of highly 
selective, potent bioactive molecules including peptidic neurotoxins from animal venoms.  
This includes the NaV1.6 selective β-scorpion toxin initially described by Possani et al (339) 
and further characterized by Schiavon et al (112).  The discovery of this toxin laid the 
groundwork for this thesis; however using Cn2 to isolate NaV1.6 in peripheral sensory neurons 
was in its infancy and had previously only been utilized in vivo (213).  Indeed, the use of 
venom-derived toxins in large scale pharmacological experiments is hampered by low yields 
when isolating from the crude venom. 
Thus, I began this thesis (Chapter 2) with a method for generating multi-milligram amounts of 
Cn2.  Not only does this method generate sufficient material for the experiments that followed 
(Chapters 3 - 5) it permits the design of an analog (Cn2[E15R]) selective for the NaV1.6 
isoform to further understand NaV1.6-toxin interactions.  Crucially the synthetic Cn2 toxin 
retains the selectivity and potency of the native toxin.  The generation of the analog 
Cn2[E15R], which displays selective antagonism of NaV1.6 in vitro (Chapter 2) and is 
analgesic in murine models of pathological pain (Chapter 5) is a step towards a truly potent, 
selective full NaV1.6 antagonist.  This is timely as NaV1.6 antagonists previously reported fail 
to selectively block the isoform in our (Chapter 2) and other’s hands (236).  The practicality of 
peptides as therapeutics agents is limited by their scarce oral bioavailability and short duration 
of action (340).  The viability of a NaV1.6 selective antagonist is further disadvantaged due to 
the channels expression on motor neurons (204).  However, novel routes of administration 
have been applied to improve availability of peptide therapeutics and could also be used to 
physically isolate NaV1.6 blockers to their target neurons (341).  Finally, with the generation 
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of Cn2[E15R], I add to the body of evidence demonstrating that the residue at this position is 
critical for NaV voltage-sensor trapping by β-scorpion toxins (102, 114, 232, 233).  Some 
questions remain regarding the voltage-dependence of Cn2 – NaV1.6 interaction, for example, 
does the pre-pulse potential value change the effect on activation kinetics? And, what is the 
molecular basis for the decrease in peak current during the pre-pulse? Finally, any interplay 
between NaVβ subunits and the toxin-NaV complex remains unknown and should be clarified 
in future experiments. Despite these outstanding points, the utility of venom-derived toxins 
has once again been proven, specifically in elucidating the molecular details of ion channel 
function.   
The NaV1.6 selective probe is then used to address the major question of this thesis, beginning 
with in vitro isolation of NaV1.6 in cultured peripheral sensory neurons.  Prior to this study, 
the effect of selective activation of NaV1.6 in peripheral sensory was unknown.  In Chapter 3, I 
describe Cn2 causing a profound effect on the Na+ current in large diameter but not small 
diameter peripheral sensory neurons.  This data suggests that NaV1.6 plays a minor role in 
small diameter neurons.  Indeed, the lack of changes to Na+ current by Cn2 in small diameter 
neurons is mirrored in large diameter neurons from NaV1.6 knock-out animals.  This confirms 
the selectivity of the peptide for NaV1.6, however what underlies this selectivity is unknown.  
Any future discovery of the crystal structures for each mammalian NaV channel isoform will 
undoubtedly aid in determining toxin interaction points that are the basis for selective action.  
The projections of small diameter cell bodies in the DRG are canonical nociceptive C fibres 
that terminate in the skin and viscera.  Findings from this thesis suggest that NaV1.6 activation 
in C fibre terminals in the skin does not substantively alter responses to heat stimulus (Chapter 
4).  Coinciding with this, no changes were observed in response to noxious heat in vivo.   
I confirm that the sodium current through NaV1.6 does not significantly contribute to the 
maintenance of the resting membrane potential or activation threshold in large diameter 
neurons.  In spite of this, NaV1.6 activation by Cn2 dramatically increases the excitability of 
large diameter neurons.  Correspondingly, A fibres that terminate in the skin are most affected 
by NaV1.6 activation.  I show for the first time that modulating NaV1.6 profoundly changes 
responses to mechanical stimulus in A fibres alone (Chapter 4).  The same NaV1.6 selective 
probe enhances responses to mechanical stimulus in vivo (Chapter 5).  Preceding work on 
chemotherapy induced pain states, implicated NaV1.6 and indeed large diameter sensory 
neurons in mechanical and cold-induced pain (212, 213).  Based on the results from thesis, I 
conclude that NaV1.6 expressing A fibres (corresponding to large diameter DRG neurons in 
vitro) are critical for mechano-sensation.  Future studies should use Cn2 to interrogate the role 
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of these NaV1.6 expressing A fibres in cold sensing.  P-CTX-1 causes robust spontaneous 
firing in both A and C fibres, which could be a reflection of its non-selective activation of NaV 
channels.  However, Cn2 failed to cause spontaneous firing in ex vivo skin saphenous nerve 
recordings.  Promiscuous activity of P-CTX-1 at KV channels might cause this difference.  
Indeed, Cn2 is unable to cause cold allodynia in its own right and requires the addition of a KV 
channel blocker highlighting the importance of these ion channels (213).  
During the completion of this work, several studies on NaV1.6 in peripheral sensory neurons 
were published and it is worth including their findings in the overall discussion of the results 
presented.  Firstly, the discovery of a novel NaV1.6 gain-of-function mutation in a patient with 
trigeminal neuralgia that contributes to hyperexcitability of trigeminal neurons in vitro (201).  
This finding represents the first NaV1.6 mutation associated with pain and highlights the need 
for further study of the isoform in peripheral sensory neurons.  Results presented in Chapters 3 
and 4 would suggest that enhancing NaV1.6 isoform channel opening probability close to 
resting membrane potential does not lead to spontaneous action potential firing in sensory 
neurons.  Small diameter trigeminal neurons transfected with the NaV1.6 mutant identified 
behave in a similar fashion to those exposed to Cn2; with increases in excitability often only 
observed after current injection.  How this finding translates to symptoms such as those seen 
in trigeminal neuralgia is unclear.  Secondly, the question of NaV1.6 function in small 
diameter neuron was assessed using a conditional knock-out approach (220).  In this method, 
NaV1.6 was knocked out in NaV1.8 expressing neurons (both small and large diameter) and the 
Na+ current of small diameter DRG neurons was reduced by 30%.  In this thesis, activation of 
NaV1.6 in small diameter neurons did not change overall Na
+ current or kinetics.  This 
discrepancy warrants further attention.   
This study utilized in vitro, ex vivo and in vivo (murine) techniques to assess the role of 
NaV1.6 in peripheral sensory neurons. This design has limitations with respect to translation of 
the finding into the clinic. The study of cultured DRG neurons isolated post mortem from 
humans has yielded some interesting findings with respect to NaV channel isoforms important 
in excitability (342). These results are often in direct opposition to previous work on rodent 
DRG neurons, for example the generally accepted notion that NaV1.7 channels conduct the 
majority of the TTX-S current has been challenged by evidence from human DRG neurons 
(342). The use of humanized iPSC sensory neurons has allowed for the study of human 
sensory neurons from patients “in a dish” without the need for post mortem tissue (161).  To 
address the problem of translation, future experiments might include using selective 
pharmacological probes (such as Cn2) to activate NaV1.6 in these cultures. This would 
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inevitably lead to a better understanding of the contribution of this isoform to sensory neuron 
excitability in humans. It should be noted that NaV1.6 is highly expressed in motor neurons 
and neurons of the brain and spinal cord. In general, this would preclude the use of orally 
bioavailable NaV1.6 antagonists in the clinic. However, a NaV1.6 mutation has been associated 
with increased excitability in trigeminal neuralgia (201). This suggests that targeting the 
isoform in the clinic should not be discounted entirely. 
In conclusion, this thesis highlights a previously underappreciated role for NaV1.6 in 
peripheral sensory neurons.  The systematic pharmacological assessment of NaV1.6 function in 
peripheral sensory neurons confirms functional expression of the isoform, particularly in large 
diameter A fibres.   
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Appendix 1 – List of Materials   
 
Name Source Catalogue # 
A-803467 Sigma-Aldrich, Castle Hill, New South A3109-10MG 
 Wales, Australia  
Acetonitrile VWR International, Tingalpa, Queensland, 34851 
 Australia  
α-Cyano-4- Sigma-Aldrich, Castle Hill, New South C2020 
hydroxycinnamic Wales, Australia  
acid (CHCA)   
Adobe Illustrator® Adobe, San Jose, CA, USA  
C56, version 16.0.3   
Amitriptylline Sigma-Aldrich, Castle Hill, New South A8404-25G 
 Wales, Australia  
Allyl isothiocyanate Sigma-Aldrich, Castle Hill, New South 36682 
 Wales, Australia  
AVPR1B (human) OriGene Technologies, MD, USA RG210436 
plasmid DNA   
β-mercaptoethanol Sigma-Aldrich, Castle Hill, New South M3148-25ml 
 Wales, Australia  
Blasticidin Life Technologies, Mulgrave, Victoria, A11139-03 
 Australia  
Bovine serum Bio-scientific, Kirrawee, New South Wales, J64944.18 (ALF) - 50g 
albumin (BSA) Australia  
CatWalk XT Noldus, Wageningen, The Netherlands  
Capsaicin Sigma-Aldrich, Castle Hill, New South 12084-10MG-F 
 Wales, Australia  
Calcium 4 No-Wash Molecular Devices, Sunnyvale, CA, USA R8123 
dye   
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CHO cells ChanTest, Cleveland, OH, USA CT4011 
expressing human   
NaV1.8   
Chromeleon HPLC Dionex, Brendale, Queensland, Australia  
software   
Collagenase Sigma-Aldrich, Castle Hill, New South C7657-500MG 
 Wales, Australia  
Conical tube - VWR International, Tingalpa, Queensland, BDAA352070 
Falcon Australia  
Corning® 384-well Sigma-Aldrich, Castle Hill, New South CLS3657-100EA 
plates Wales, Australia  
Corning® 384-well Sigma-Aldrich, Castle Hill, New South CLS3683-50EA 
plates - CellBIND Wales, Australia  
Coverslips 13mm Thermo Fisher Scientific, Brendale, MENCSC131GP 
round Queensland, Australia  
Crude venom Dr. Volker Herzig, Institute for Molecular  
samples Bioscience, University of Queensland  
Cryostat Leica Biosystems, New South Wales, Leica CM3050 S 
 Australia  
DAPI (4',6- Sigma-Aldrich, Castle Hill, New South D9542 
diamidino-2- Wales, Australia  
phenylindole)   
Deltamethrin Sapphire Bioscience, Redfern, New South BML-PR101-0050 
 Wales, Australia  
Dimethyl dulfoxide Sigma-Aldrich, Castle Hill, New South 700590 
 Wales, Australia  
Donkey- Anti- Abcam, Melbourne, Victoria, Australia Ab150073 
Rabbit IgG Alexa   
Fluor® 488   
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Donkey serum Sigma-Aldrich, Castle Hill, New South D9663-10ML 
 Wales, Australia  
Dulbecco’s Life Technologies, Mulgrave, Victoria, 14190-144 
Phosphate Buffered Australia  
Saline (DPBS)   
Dulbecco’s Life Technologies, Mulgrave, Victoria, 21068-028 
modified eagle Australia  
medium (DMEM)   
Ethanol Chem-Supply, Gillman, South Australia, EA043-2.5L-P 
 Australia  
F-11 cells Sigma-Aldrich, Castle Hill, New South 08062601 
 Wales, Australia  
F-12 nutrient Life Technologies, Mulgrave, Victoria, 11765062 
mixture medium Australia  
Fluorescent Olympus, NY, USA BX51P 
microscope   
Olympus BX-51   
Fluorescent Dako, North Sydney, New South Wales, S3023 
mounting media Australia  
Foetal bovine serum Life Technologies, Mulgrave, Victoria, 26140-079 
(FBS) Australia  
Formaldehyde (16% Thermo Fisher Scientific, Brendale, PIE28906 
methanol-free) Queensland, Australia  
Formic acid VWR International, Tingalpa, Queensland, VWRC20318.297 
 Australia  
Gabapentin Sigma-Aldrich, Castle Hill, New South G154-10MG 
 Wales, Australia  
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Geneticin Sigma-Aldrich, Castle Hill, New South G8168-100ML 
 Wales, Australia  
GIIIA Mr. Zoltan Dekan, , Institute for Molecular  
 Bioscience, University of Queensland  
Glass slides Menzel-Glaser, Braunschweig, Germany MENSF21202 
(Superfrost)   
Glass slides – Menzel-Glaser, Braunschweig, Germany SF41296SP 
positively-charged   
(Superfrost Plus)   
GlutaMAX™ Life Technologies, Mulgrave, Victoria, 35050061 
Supplement Australia  
GraphPad Prism
TM
, GraphPad Software, La Jolla, CA, USA  
version 6.00   
Hargreave’s Plantar IITC Life Science, Woodland Hills, CA, USA 390G 
Analgesia Meter   
HEK cells In Vitro Technologies, Noble Park North, ATCCRL1573 
 Victoria, Australia  
HEK cells Scottish Biomedical, Glasgow, UK  
expressing human   
NaV1.1-1.8   
HPLC – Ascentis Sigma-Aldrich, Castle Hill, New South 53307-U 
column Wales, Australia  
HPLC – Vydac Alltech Associates, Eagle Farm, Queensland, 218TP54 
column Australia  
Hybri-MaxTM Sigma-Aldrich, Castle Hill, New South H0262 
HAT Media Wales, Australia  
Supplement (50x)   
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Hygromycin Life Technologies, Mulgrave, Victoria, 10987-010 
 Australia  
ICA-121431 Sigma-Aldrich, Castle Hill, New South SML1035-5MG 
 Wales, Australia  
Immersion oil (Carl Carl Zeiss, New South Wales, Australia 444960 
Zeiss Immersol
TM
)   
Isoflurane Provet Queensland, Queensland, Australia ISOF 04 
Lipofectamine
TM 
Life Technologies, Mulgrave, Victoria, 11668-019 
2000 Australia  
MALDI 4700 AB Sciex Australia, Mulgrave, Victoria,  
MALDI-TOF Australia  
system   
MALDI-TOP 192- Applied Biosystems, Mulgrave, Victoria,  
well sample plate Australia  
Membrane potential Bio-strategy Distribution, Campbellfield, R8123 
FLIPR red dye Victoria, Australia  
Meloxicam Abcam, Melbourne, Victoria, Australia) Ab141955 
Menthol Sigma-Aldrich, Castle Hill, New South M2258 
 Wales, Australia  
Mice (Wild-type University of Queensland Biological  
C57BL/6) Resources, St Lucia, Queensland, Australia  
Minimum Essential Sigma-Aldrich, Castle Hill, New South M5650-500ML 
Media (MEM) Wales, Australia  
MouseMet TopCat Metrology, Cambridgeshire, United  
electronic von Frey Kingdom  
Mouse house Tecnoplast, Buguggiate, Italy  
NaV1.6 antibody Sapphire Bioscience, Redfern, New South Ab65166 
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(Abcam) Wales, Australia  
NaV1.6 antibody Jomar Life Research, Scoresby, Victoria, ASC-009 
(Alomone) Australia  
NanoDrop NanoDrop, DE, USA  
spectrophotometer   
(ND-1000)   
ND7/23 cells Sigma-Aldrich, Castle Hill, New South 92090903 
 Wales, Australia  
Oxycodone Mundipharma, Sydney, New South Wales,  
 Australia  
Oxytocin Professor Paul Alewood, Institute for OxyNorm Oral Liquid 
 Molecular Bioscience, University of  
 Queensland  
Oxytocin receptor OriGene Technologies, MD, USA RC211797 
(human) plasmid   
DNA   
PAP-Pen ProSciTech, Queensland, Australia ID310 
Parafilm Labtek, Brendale, Queensland, Australia PM996 
Parallel Rod Floor Stoelting Co., Wood Dale, IL, USA 61000 
Apparatus with   
ANY-Maze   
Software   
Peltier plate Ugo Basile, Varese, Italy 35150 
PCR tubes Point-of-care diagnostics, Artarmon, New 0030 124 359 
 South Wales, Australia  
PDL-coated PerkinElmer, Melbourne, Victoria, Australia 6007710 
ViewPlate 384-well   
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plates   
Petri dish - Tissue Thermo Fisher Scientific, Brendale, NUN153066 
Culture Dish Queensland, Australia  
35x10mm   
Pn3a Mr. Zoltan Dekan, , Institute for Molecular  
 Bioscience, University of Queensland  
Poly-D-lysine Sigma-Aldrich, Castle Hill, New South P6407-5MG 
hydrobromide Wales, Australia  
Proglumide Sigma-Aldrich, Castle Hill, New South M006-100MG 
 Wales, Australia  
Protease Sigma-Aldrich, Castle Hill, New South P8811-1G 
 Wales, Australia  
RNALater Sigma-Aldrich, Castle Hill, New South R0901-500ML 
 Wales, Australia  
RNeasy Mini Kit Qiagen, Melbourne, Victoria, Australia 74104 
Roswell Park Life Technologies, Mulgrave, Victoria, 21870-092 
Memorial Institute Australia  
medium (RPMI)   
ScreenWorks, Molecular Devices, CA, USA  
version 3.2   
SH-SY5Y cells Sigma-Aldrich, Castle Hill, New South 94030304-1VL 
 Wales, Australia  
Sucrose Chem-supply, South Australia, Australia SA030-500G 
T75 flasks - Sigma-Aldrich, Castle Hill, New South CLS430641-100EA 
Corning® Wales, Australia  
T75 flasks – Sigma-Aldrich, Castle Hill, New South CLS3290-100EA 
Corning® Wales, Australia  
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CellBIND   
T75 flasks - Nunc Thermo Fisher Scientific, Brendale, NUN156499 
 Queensland, Australia  
Tetracycline Sigma-Aldrich, Castle Hill, New South 7660-5G 
 Wales, Australia  
Tetrodotoxin Sapphire Bioscience, Redfern, New South AB120055 
 Wales, Australia  
Thermal threshold TopCat Metrology, Cambridgeshire, United  
probe (MouseMet Kingdom  
Thermal)   
TIIIA Mr. Zoltan Dekan, , Institute for Molecular  
 Bioscience, University of Queensland  
Tissue-Tek® O.C.T. ProSciTech, Townsville. Queensland, IA018 
media Australia  
Tissue culture 24- Thermo Fisher Scientific, Brendale, NUN142475 
well plate Queensland, Australia  
Trifluoroacetic acid Sigma-Aldrich, Castle Hill, New South T6508-100ML 
 Wales, Australia  
Triton
TM
 X-100 Sigma-Aldrich, Castle Hill, New South X100-500ML 
 Wales, Australia  
Trypsin/EDTA Life Technologies, Mulgrave, Victoria, 25200-072 
(0.25% trypsin with Australia  
EDTA)   
UltiMate 3000 Dionex, Brendale, Queensland, Australia  
HPLC machine   
Veratridine Sapphire Bioscience, Redfern, New South AB120279 
 Wales, Australia  
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Appendix 2 - Buffer Composition 
 
2.1 Phosphate Buffered Saline (PBS) 
Composition:  
137 mM NaCl, 
2.7 mM KCl, 
10 mM NaH2PO4 (sodium phosphate, dibasic), 
1.8 mM KH2PO4 (potassium phosphate, dibasic); pH 7.4 
 
2.2 Trypsin-EDTA (Invitrogen)  
Composition: 
0.11 mM Trypsin, 
0.91 mM EDTA, 
0.03 mM Phenol Red, 
5.6 mM glucose, 
5.3 mM KCl, 
0.44 mM KH2PO4 (potassium phosphate, dibasic), 
4.2 mM NaHCO3 (sodium bicarbonate), 
138 mM NaCl, 
0.34 mM NaH2PO4 (sodium phosphate, dibasic) 
 
2.3 Extracellular Solution - QPatch 
Composition: 
140 mM or 30 mM NaCl, 
4 mM KCl, 
165 
 
2 mM CaCl2,  
1 mM MgCl2,  
10 mM HEPES, 
0.1 mM CdCl2,  
10 mM glucose; 315 mOsm, pH 7.4 
 
2.4 Intracellular Solution - QPacth 
Composition: 
140 mM CsF, 
1 mM EGTA,  
5 mM CsOH, 
10 mM HEPES, 
10 mM NaCl; 320 mOsm, pH 7.4  
 
2.5 Minimum Essential Medium Eagle (MEM)  
Composition undisclosed by manufacturer (Sigma Aldrich; M5650), containing Earle’s salts, 
non-essential amino acids and sodium bicarbonate.  
2.6 Dulbecco’s Modified Eagle’s Medium (DMEM)  
 
Composition undisclosed by manufacturer (Sigma Aldrich; D6429), containing 4500 mg/L 
glucose, L-glutamine, sodium pyruvate and pyridoxine.  
 
2.7 Ex-cell ACF CHO Medium 
 
Composition undisclosed by manufacturer (Sigma Aldrich, C5467), containing inorganic 
salts, HEPES, sodium bicarbonate, essential and non-essential amino acids, vitamins, insulin 
and plant hydrolysates.  
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Appendix 3 – Supplementary Data  
 
 
 
 
 
Figure S1: uHPLC of Cn2[1−28]  
uHPLC (@214 nm) and ESI-MS analysis of purified Cn2[1−28]-α-thioester 
(KEGYLVDKNTGCKYECLKLGDNDYCLRE-[COS]F). 
  
500 750 1000 1250 1500 m/z
0.0
1.0
2.0
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Figure S2: uHPLC of Cn2[29-66] 
uHPLC (@214 nm) and ESI-MS analysis of purified Cn2[29-66] 
(CKQQYGKGAGGYCYAFACWCTHLYEQAIVWPLPNKRCS-NH2). 
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0.0
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Figure S3: uHPLC of Cn2 polypeptide  
uHPLC (@214 nm) and ESI-MS analysis of fully reduced Cn2 [1-66] polypeptide after 
ligation of the two peptides segments and purification.  
 
 
Figure S4: uHPLC Cn2[29-45]-α-thioester 
uHPLC and ESI-MS analysis of Cn2[29-45]-α-thioester (CKQQYGKGAGGYCYAFA-
[COS]G). 
500 750 1000 1250 1500 m/z
0.0
1.0
2.0
3.0
Inten.(x1,000,000)
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691.70 1245.20
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Figure S5: uHPLC Cn2[46-66, Q54Pra]-NH2 
uHPLC and ESI-MS analysis of Cn2[46-66, Q54Pra]-NH2 (CWCTHLYE-Pra-
AIVWPLPNKRCS-NH2). 
 
Figure S6: uHPLC of Cn2(29-66, Q54PRa) and fully reduced Cn2(1-66, Q54PRa) 
A) uHPLC and ESI-MS analysis of Cn2(29-66, Q54PRa). B) uHPLC and ESI-MS analysis of 
fully reduced Cn2(1-66, Q54PRa).  
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Figure S7: uHPLC and ESI-MS analysis of folded Cn2 (Q54Pra). 
 
 
Figure S8: uHPLC of BODIPY-Cn2 
 A) uHPLC and ESI-MS analysis of folded and BODIPY labeled Cn2 (Q54Pra-BODIPY). 
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Optimization of folding conditions: 
Reduced Cn2 (Figure S3) was dissolved in 6 M GdmHCl (pH ~ 5) to give a final peptide 
concentration of 4 mg/mL. For folding trials, 25 μl of peptide solution was added to 500 μl of 
folding buffer. Oxidation of cysteines and folding was performed at 22°C and monitored by 
uHPLC. The final peptide concentration was 190 μg/mL (25 μM). 
Folding conditions/buffers: 
Buffer A: 100 mM Tris, pH 8.0, 1 mM GSH, 1 mM GSSG 
Buffer B: 100 mM MOPS, pH 7.0, 1mM GSH, 1mM GSSG 
Buffer C: 100 mM MOPS, pH 7.0, 20% (v/v) glycerol, 1 mM GSH, 1 mM GSSG 
Buffer D: 100 mM Tris, pH 8.0, 1 M GdmHCl, 1 mM GSH, 1 mM GSSG 
Buffer E: 100 mM Tris, pH 8.0, 1.5 M GdmHCl, 1mM GSH, 1mM GSSG 
 
Figure S9: Optimization of folding mixtures 
Equal volumes of crude folding mixtures (Buffers A-E) were analysed by uHPLC (@214 
nm) after 24h. Relatively high concentrations (1.0 - 1.5 M) of the denaturant GdmHCl are 
needed to prevent the polypeptide from aggregating. Higher concentrations (>1.5 M) did not 
lead to improved folding yields. 
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Figure S10: ESI-MS spectrum of folded, synthetic wild type Cn2  
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0.0
1.0
2.0
Inten.(x100,000)
1085.00 1265.85
1518.65
1898.00
949.70
1317.30 1667.80844.30 1036.95671.50 1843.00
1990.60
173 
 
 
 
Figure S11: HPLC analysis of synthetic Cn2 and venom-derived Cn2 
A) RP-HPLC on a Zorbax C18 column (9.4×250, 5 μm, 300 Å) at room temperature (23C). 
The two peaks at retention times 20 and 21 min represent two conformers of Cn2 that are in 
slow chemical exchange. B) RP-uHPLC analysis on a Zorbax C18 column (2.1x50, 1.8 μm, 
300 Å) at 50C. 
 
 
Figure S12: Structural superimposition of scorpion β -toxins 
Cn2 (blue, PDB ID: 1CN2) and TS1 (red, PDB ID: 1NPI). Gln54 of Cn2 was chosen as the 
site for introduction of BODIPY labels, as replacement of the structurally equivalent Trp50 in 
Ts1 was previously shown to not affect toxin activity.   
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Figure S13: The effect of Cn2 on the kinetics of hNaV1.4 channels 
A) Current-voltage relationship of hNaV1.4 expressed in HEK293 cells in the presence (red) 
and absence of Cn2 (10 nM). Cn2 does not cause early channel opening at this concentration. 
(n = 4) B) The voltage-dependence of activation and of steady state inactivation of hNaV1.4 
is not altered by Cn2 (10 nM)  
 
Figure S14: Cn2 causes concentration dependent decrease in peak current at hNaV1.6 
Concentration-response curve for Cn2 generated from the decrease in peak current observed 
after Cn2 application (EC50 = 6.1 nM) 
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Figure S15: Cn2-488 (300 nM) causes shift in voltage dependence of activation.  
(Top panel) Current-voltage relationship of hNaV1.6 in the presence (grey) and absence 
(black) of Cn2-488 (300 nM). At higher concentrations Cn2-488 causes early channel 
opening and decreases in peak current (n = 4). Lower panel) Cn2-488 also shifts the voltage 
dependence of activation at this concentration (Control -19.1 ± 0.3 and Cn2-488 -25.01 ± 0.9) 
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Figure S16: Confocal image of Cn2-488 showing NaV1.6 expressed in HEK293 cells  
 
 
Figure S17 Cn2-BODIPY did not robustly stain NaV1.6 in HEK293 cells  
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Figure S18 Examination of resurgent current from mock treatment of large DRG 
neurons 
A) Voltage protocol and representative traces of resurgent current recorded following mock 
treatment and washout in large DRG neurons. B, D) Average peak current amplitudes of 
resurgent current (Control: 3.3 ± 1.3 nA, Mock: 3.2 ± 1.1 nA; Wash: 3.1 ± 1.0 nA). C, E) 
Comparison of peak current - voltage relationship for control, mock and washout periods 
(Control: -31 ± 3 mV, Mock: -32 ± 2 mV, Wash: -34 ± 3.0 mV). p > 0.05, paired sample t-
test, n = 4. 
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S1 Table 1: Effect of Cn2 and buffer on action potential parameters in med and WT DRG neurons 
 
  Ampl2[A] 
 Baseline 
[mV] 
 AP_ampl 
[mV] 
 
time_to_
max[ms] 
 
repol_ampl[m
V] 
 
time_to_min[
ms] 
 
rise_time
[ms] 
 up_slope 
[mV/ms] 
 rt_delay 
[ms] 
 
decay_ti
me[ms] 
 
down_slope[
mV/ms] 
 dt_delay 
[ms] 
Control 
(med) 
 
-65.4 +- 1.9 112.7 ± 6.0 4.2 ± 0.5 -12.5 ± 1 213.4 ± 1.6 2.4 ± 0.2 29.7 ± 3.4 1.6 ± 0.5 1.2 ± 0.2 -60.1 ± 5.2 4.6 ± 0.4 
 
Buffer control -68.1 +- 1.4 118.3 ± 4.1 4.1 ± 0.4 -12.3 ± 1.1 211.8 ± 3.8 1.8 ± 0.2 42.4 ± 6.8 2.1 ± 0.6 1.1 ± 0.1 -69.2 ± 11.6 4.6 ± 0.3 n=5 
              
Control 
(med) -64.5 ± 2 118.8 ± 1.5 4.6 ± 0.2 -12 ± 0.6 197.3 ± 18.5 2.7 ± 0.3 1.7 ± 0.4 29.3 ± 4.2 1 ± 0.2 -79.1 ±  9.8 5.0 ± 0.2 
 
Cn2 
(50nM) 
 
-66.5 ± 1.7 121.5 ± 3.0 4.9 ± 0.5 -12.7 ± 0.8 159.4 ± 38.3 2.5 ± 0.5 2.1 ± 0.3 34.4 ± 5.6 1.1 ± 0.2 -73.8 ± 9.5 5.3 ± 0.5 n=6 
              
Control (WT) -67.7 ± 0.9 115.5 ± 2.7 4.2 ± 0.2 -11.25 ± 0.9 213.3 ± 2.6 2.5 ± 0.2 1.4 ± 0.2 1.1 ± 0.2 -74.4 ± 11.1 4.6 ± 0.2 
 
Cn2 
(50nM) 
 
-67.2 ± 1.3 111.8 ± 4.1 5.1 ± 0.8 -12.1 ± 1.6 202 ± 12.1 2.1 ± 0.1 1.4 ± 0.2 1.2 ± 0.2 -64.9 ± 7.0 5.5 ± 0.8 n=10 
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Figure S19: The effect of Cn2 on CMCH fibre 
In a polymodal C fibre that responds to both cold and heat stimulus, Cn2 application leads to 
slight decrease in frequency in response to cold and increase in the firing frequency in 
response to heat stimulus.   
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Appendix 4 – Animal Ethics Approval  
 
